Common use of Additional Definitions Clause in Contracts

Additional Definitions. The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: ACA 1.45(f) Additional Approval Condition 3.4(bCompound Designation Period 3.7(c) Additional Studies 3.8 Agreement Preamble Alternative Acquisition Agreement 5.4(aAstellas Preamble Astellas Collaboration IP 10.1(c) AntiAstellas Collaboration IP Patent Rights 10.4(d)(i) Astellas Indemnitees 13.1 Bankruptcy Code 7.5 Biologic Exclusivity 1.64 CMO 8.7(c) CMO IP 8.7(c) Collaboration Recitals Combination Product 1.45 Competing Product 9.3 CPI 1.28 Development Plan 4.2 Disclosing Party 11.1(a) Dispute 15.6(a) Effective Date Preamble GLP-Bribery Laws 3.22(cTox Milestone 8.3(a)(ii) Articles of Merger 2.4(aICC 15.6(b)(ii) Certificates 2.9(c)(iICH 1.30 Indemnified Party 13.3 Indemnifying Party 13.3 Infringement 10.5(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Initial Inventory 3.8(c) Initial Pandion Technology 3.8(a) Joint Collaboration IP 10.1(d) Joint Collaboration IP Patent Rights 10.4(c)(i) JSC 2.1(a) JSC Co-Chair 2.1(e) Milestone Event 8.3(a) Milestone Payment 8.3(a) Offset Floor 8.7(d) Out-of-Pocket Costs Invoice 8.2(b) Pandion Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bPandion Acquirer 9.3 Pandion Collaboration IP 10.1(b) Company Leased Real Property 3.15(bPandion Collaboration IP Patent Rights 10.4(b)(i) Company Option 2.8(c)(iPandion Indemnitees 13.2 Pandion Research FTEs 3.3 Pandion Updates 2.4 Parameters 3.7 Party Preamble Prior CDA 1.14 Product Marks 10.7 Receiving Party 11.1(a) Company Owned Real Property 3.15(aRelated IP 1.15 Remainder 10.5(e) Company PSU 2.10(c)(iResearch Advance Invoice 8.2(a) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities Research Budget 3.3 Research Plan Costs 3.6 Research Program 3.1 Research Term 3.2 Research Term Designation Period 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(aResearch True-Up Report 8.2(a)(ii) Converted PSU Award 2.10(c)(iiSEC 11.5(b) Converted Restricted Share Award 2.10(bSubsequent Inventory 3.8(c) Converted RSU Award 2.10(a)(iiSubsequent Pandion Technology 3.8(a) Copyrights 1.1(kkkTerm 14.1 Tether Targets 1.71 Third Party License 8.7(c) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Transition Plan 1.74

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Amgen 2.5.2 Amgen Agreement 5.4(a2.5.2 Annual [***] 3.3.2 Assigned Kiniksa Agreements 8.3(e)(ii) Anti-Bribery Laws 3.22(cAssumed Liabilities 2.3 ATCC Agreement Schedule E Bioequivalence 5.3.2(c) Articles Bioequivalent 5.3.2(c) Biogen Preamble Biogen Indemnified Parties 9.2 Biogen Product 8.3(e)(iv) CDA Effective Date CDA definition Change of Merger 2.4(aControl Transaction 3.4.2 Claims 9.2 Competing Drug 5.3.2(c) Certificates 2.9(c)(iConfidential Information 7.1 CTA IND definition Data Package 3.4.1(b) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xDiligence Period 3.4.1(c) Effective Time 2.4(bDate Preamble Exchange Act 3.4.2 Excluded Assets 2.2 Excluded Liabilities 2.4 Exclusivity Period 2.7 Exclusivity Term 3.4.1(d) Electronic Delivery 9.13 Enforcement Expenses 8.3(dExempt Transaction 3.4.3 Gross Sales Definition of Net Sales ICH 3.2 Infringement 4.2.1 Infringement Notice 4.2.1 Infringement Response 4.2.2 Issuing Party 7.5.2 Kiniksa Preamble Kiniksa Election Notice 8.4 Kiniksa Indemnified Parties 9.3 Kiniksa Supply Agreement 8.3(e)(vi) ExLosses 9.2 Negotiation Notice 3.4.1(b) Non-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Assignable Kiniksa Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a8.3(e)(ii) Notice Review Period 5.4(d)(ii)(33.4.1(b) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Party/Parties Preamble Patents 1.1(kkkPatent Assignment Agreement 2.6.2 Purchased Assets 2.1 Recovery 4.2.5 Release 7.5.2 Report 3.3.1 Retained Contract Payments 5.4 Reviewing Party 7.5.2 Right of First Negotiation 3.4 ROFN Transaction 3.4.1(a) Payment Agent 2.9(aSales Returns and Allowances Definition of Net Sales Sigma Agreement Schedule E Technology Transfer Fees 5.1.2 Term 8.1 Transfer Taxes 5.8.2 Trigger Notice 3.4.1(a) Per Share Price 2.9(a)(iiiUnsolicited Offer 3.4.1(b) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Upfront Fee 5.1.1

Additional Definitions. The Each of the following capitalized terms have definitions is set forth on the respective meanings given to them in the respective Sections page of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Development Data 18 [*] [*] Adverse Events 39 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti1 Aptalis 1 Aptalis Inventions 29 Aptalis Know-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) How 43 Aptalis Patents 31 Aptalis Press Release 28 Assignment 36 Bankruptcy Event 48 Breaching Party 42 Clinical Studies 40 Confidential Information 26 Controlled 1 Controlling Party 35 Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) License 16 Debtor Party 48 [*] [*] Designated Senior Officer 15 Development Data 16 Development Plan 16 Disclosing Party 26 Dispute 48 [*] [*] [*] [*] Force Majeure Event 51 Greater Affiliate [*] [*] [*] ICC 48 Indemnification Claim Notice 45 Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice 45 Indemnifying Party 45 Indemnitee 45 Indemnitees 45 Interim Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 36 Joint Inventions 29 Joint Patents 30 Launch Plan Summary 21 Milestone 23 [*] [*] Non-Debtor Party or 48 OC 13 [*] [*] Parties Preamble 1 Party 1 Patent Challenge 42 Person 1 Product Claim 47 ▇▇▇▇▇▇▇▇▇▇ ▇ ▇▇▇▇▇▇▇▇ ▇▇ Receiving Party 26 [*] [*] Sales Milestone Payment 23 Sales Reports 24 [*] [*] Signing Date 1 Strakan 1 Strakan Inventions 29 Strakan Patents 1.1(kkk) 32 Strakan Press Release 28 Subject Documentation 39 [*] [*] [*] [*] Term 41 [*] [*] Third Party Claim 44 [*] [*] Third-Party License 35 Third-Party Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)35 Title 11 48 USPTO 36 Withholding Taxes 24 * Confidential treatment requested.

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: . Accounting Firm 6.4.2(a) Additional Approval Condition 3.4(bAntibody Research 4.6 Additional Investment Amount 5.1(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aPayments 6.3 Approved Zymeworks Sequences 3.1.5 Authorized Expenses 4.6 Available Development Funds 5.1(b) Anti-Bribery Laws 3.22(cChallenge Countries 10.3 Claims 13.1 Code 11.4 Collaboration Exclusivity Period 3.5.2 Commercialization Milestone Event 5.5 Commercialization Milestone Payment 5.5 Confidentiality Agreement 15.13 Controlling Party 7.3.4 Current Assets 5.1(b) Articles of Merger 2.4(aCurrent Liabilities 5.1(b) Certificates 2.9(c)(iDevelopment Funds 5.1(b) Charter Amendment Development Milestone Event 5.4 Development Milestone Payment 5.4 Dispute 15.5.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Excluded Claim 15.5.5 Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b5.2 Expenses and Payments 6.4.2 FTE Costs 5.2.1 Gatekeeping Default 3.1.2(b) Indemnified Party Proceeding 6.9(b13.3.1 Indemnifying Party 13.3.1 Infringement 7.3.1 Intitial Development Funds 5.1(a) Initial Investment 5.1(a) Initial License Fee 5.3 JSC 4.3 Law Firm 3.1.2(e) License 2.1.2 Lilly Challenged Zymeworks Patent Rights 10.3 Lilly Indemnified Persons 6.9(aParty 13.1 ▇▇▇▇▇ ▇▇ Termination Decision 10.2.1 Lilly Sequences 3.1.5 Lilly Target Pair 3.1.2(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(aLosses 13.1 Minimum Working Capital Amount 5.1(b) Notice Period 5.4(d)(ii)(3of Dispute 15.5.1 Outstanding Program 5.1(b) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Party Preamble Party or Parties Preamble Patents 1.1(kkk[... ***...] 3.1.2 Project Leader 4.1 prosecution 7.2.1 Qualifying Exchange 5.1(b) Payment Agent 2.9(aResearch Plan 3.1.4 Research Program 3.1.1 Research Program Term 3.1.3 Research Program Work Product 3.1.7(b) Per Share Royalty 5.6.1 Royalty Term 5.6.2 RP Default 10.4 Shortfall Investment Amount 5.1(b) Shortfall Investment Price 2.9(a)(iii5.1(b) Proxy Holder Recitals Proxy Statement 6.3(aSubscription Agreement 5.1(a) Required Permits 3.20(cTarget Pair 3.1.2 Target Pair Selection Notice 3.1.2 Target Pair Unavailable Notice 3.1.2(b)(i) Restraint 7.1(bTaxes 6.3 Term 10.1 Terminated Target Pairs 11.1.2 Third Party Expenses 5.2.2 Unavailable Target Pair 3.1.2(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aUnrestricted Working Capital 5.1(b) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Zymeworks Preamble Zymeworks Indemnified Party 13.2 Zymeworks Sequences 3.1.5

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections of this Agreement set forth opposite each section of the capitalized terms Agreement indicated below: Additional Approval Condition 3.4(bAgreement Recitals Alliance Managers 3.1(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aApplicant 7.5(b) AntiApplicant Response 7.5(c)(ii) Baseline Net Sales 1.41 Biosimilar Application 7.5(a) BPCIA 7.5(a) Challenge Jurisdiction 5.3(e) Challenged Patent Rights 5.3(e) Challenge-Bribery Laws 3.22(cRelated Royalty Increase 5.3(e) Articles of Merger 2.4(aClawback Amount 5.3(e) Certificates 2.9(c)(iCombination 1.48 Covered Results 6.3 Covers 5.3(c)(iii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company [***] [***] Disclosing Party 1.12 Disclosure Letter 1.4 Company Intellectual Property 3.17(b9.1(c) Company Leased Real Property 3.15(bDispute 11.12 Effective Date Recitals Immediate Patent Infringement Action 7.5(c)(v) Company Option 2.8(c)(iImmunoGen Recitals ImmunoGen Indemnitees 10.1(a) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) ImmunoGen Proprietary Antibody 1.25 Indemnified Party Proceeding 6.9(b10.2 Indemnifying Party 10.2 Infringed Patent List 7.5(c)(v) Indemnified Persons 6.9(aInfringement 7.4(a) Labor Agreements 3.20(aInfringement Notice 7.4(a) Leased Real Property Leases 3.15(bJDC 3.2(a) Marks 1.1(kkkLilly Recitals Lilly Indemnitees 10.1(b) Maximum Premium 6.9(bLilly Response 7.5(c)(iii) Merger Losses 10.1(a) Material Breach 8.2(b) Monies 7.4(g) Negotiation Period 7.5(c)(v) Patent Committee 7.2(c)(i) Patent List 1.33 Party/Parties Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iPermitted Third Party Service Providers 2.1(a) New Plans 6.9(aPost-Royalty Term Issued Patents 5.5(b) Pre-Market Notice 7.5(d)(ii) Proposed Biosimilar Product 7.5(a) Proposed Patent List 7.5(c)(i) Receiving Party 1.12 Reinstated License 5.5(b) Reinstated Royalty Term 5.5(b) Representatives 1.12 Royalty Restoration Date 5.5(b) Royalty Term 5.5 Safety Data Exchange Agreement 3.4 [***] [***] Term 8.1(a) Third Party Claims 10.1(a) Third Party Payments 5.3(b) Upfront Fee 5.1 Wind-Down Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i8.3(a)

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: . 120 Day Period 11.1.1 AAA 15.6.1 Accounting Firm 7.5.2 Additional Approval Condition 3.4(b) Selected Scaffold 3.2.5 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Payments 7.4 Allowed Target Pair 5.3 Allowed Target Pairs Experiments 5.3.1 Antibody Development Work Plan 3.1 Challenge Countries 2.5 Claims 14.1 Code 12.6 Confidentiality Agreement 15.14 Controlling Party 8.3.4 Dispute 15.6.1 Early Selection Criteria 3.2.2 Effective Date Preamble Excluded Claim 15.6.7 Expenses and Payments 7.5.2 First Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b14.3.1 Indemnifying Party 14.3.1 Infringement 8.3.1 Initial Selected Scaffold 3.2.2 Initial Target 4.2.1 Initial Target Sequence Pair 4.2.2 Losses 14.1 Merck Preamble Merck Challenged Zymeworks Patent Rights 2.5 Merck Indemnified Party 14.1 Merck RP Termination Decision 11.2.1(c) Indemnified Persons 6.9(aMerck Selection Criteria 3.2.3 Merck Sequence Pair 4.1 Merck Target Pair 4.1 Milestone Event 6.2 Milestone Payment 6.2 Notice of Dispute 15.6.1 Officials 3.1.1(d) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Original Agreement Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Other Targets 4.2.1 Party Preamble Party or Parties Preamble Patents 1.1(kkkPayment 3.1.1(d) Payment Agent 2.9(aProduct No. 1 6.2.7(a) Per Share Price 2.9(a)(iiiProduct No. 2 6.2.7(a) Proxy Holder Recitals Proxy Statement 6.3(aProduct No. 3 6.2.7(b) Required Permits 3.20(cProsecution 8.2.1 [... ***...] 3.4 Relationship Liaison 3.11 Research Program 3.1 Research Program Term 3.1 Restatement Effective Date Preamble Royalty 6.3.1 Royalty Term 7.2 Sale 15.21 [... ***...] 3.4 SCC 3.12 Second Amendment Preamble Selected Scaffold 3.2.5 Sequence 4.1 Sequence Pair 4.1 Surviving License 12.3.2 Suspended Product 6.2.7 Taxes 7.4 Term 11.1.1 Validation Phase 3.2.4 [... ***...] 5.1 [... ***...] 3.2.4 Work Plan 3.1 Zymeworks Preamble Zymeworks Change of Control Notice 15.1.1 Zymeworks Indemnified Party 14.2 Zymeworks [... ***...] Scaffolds 3.3.3 Zymeworks Sequence Pair 4.3.1(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)In this Agreement, unless the context requires otherwise:

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b. Acquisition 2.7(a)(i) Antitrust Authority 2.9(a) Agreement Preamble Alternative Acquisition Bankruptcy Laws 2.5 cGMP Initial Supply 5.6 Claim 11.1 Clinical Supply Agreement 5.4(a5.1 Commercial Milestone 6.6 Commercial Milestone Payment 6.6 Commercial Supply Agreement 5.1 Competing Product 2.6 Competitive Infringement 7.4(b) Anti-Bribery Laws 3.22(cCure Period 9.2(b)(i) Articles of Merger 2.4(aDeclaratory Judgment Action 7.4(a) Certificates 2.9(c)(iDevelopment Milestone Payment 6.4 Development Plan 3.3 Diligence Cure Period 9.2(b)(iii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bDiligence Obligations 9.2(b)(iii) Company Leased Real Property 3.15(b[***] 2.2(c) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xDSMB 3.7(a) Effective Time 2.4(bDate Preamble Enforcement Action 7.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d[***] 6.12 Force Majeure 13.4 Indemnitee 11.3 Infringement Claim 7.3 IP Working Group 7.6(a) ExLicensed Particle Dispute 3.7(a) Losses 11.1 LSA 10.1(d) Next Generation Particle 2.11 Non-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(acGMP Initial Supply 5.6 Notice of Dispute 12.1(a) Notice Period 5.4(d)(ii)(39.2(a) Old Plans 6.9(aOption 2.2(a) Owned Company Shares 2.9(a)(iiOption Exercise Payment 6.2 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions Party(ies) Parent Preamble Party or Parties Payment Cure Period 9.2(b)(ii) Project Coordinator 3.1 Proposed Future In-License Agreement 2.10 Quality Agreement 5.1 Regulatory Milestone Payment 6.5 Royalty Tier 6.10(a) SAB 3.7(a) Scheduled Payment 6.1 Securities Laws 8.2(b) Selecta Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Selecta Indemnitee 11.2

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bDefined Term Section Audited Party §8.16(a) Agreement Auditing Party §8.16(a) AVEO Preamble Alternative Acquisition Agreement 5.4(aAVEO Control Assumption Date §14.6(a) AntiAVEO Indemnities §12.1 AVEO Group §3.2(b) Bankruptcy Code §13.3 Biogen Idec Preamble Biogen Idec Control Assumption Date §14.6(b) Biogen Idec ▇▇▇▇▇▇▇▇▇▇▇ §▇▇.▇ Breached Licensed Product §14.5(a) [**] §8.3(b) Collaboration Manager §4.5 Commercially Viable Indication §5.12(a) Competing Acquiror §13.1 Defined Term Section Competitive Infringement §9.6(a) Contract Manufacturer Notice §7.2 Control Assumption Option §13.1 Cost Payment §5.5 Cure Plan §14.3(b) Delivered Initial Development Plan §2.9 Development Plan Guidelines §4.8(a) Divestiture Period §13.1 Effective Date Preamble Event Milestone §8.4 Event Milestone Payment §8.4 Force Majeure Event §16.2 Funding Party §5.11(a) [**] §8.3(c) Indication Specific Royalty §5.13(a) ▇▇▇▇▇▇▇▇▇▇ §▇▇.▇ Initial Development Plan §2.9 Initial Release §10.3 Insolvency Control Assumption Option §13.3 Insolvency Event §13.3 JCT §6.2(a) JCT Chairperson §6.2(b) JDC §4.1 JDC Chairperson §4.2 M&A Control Assumption Option §13.1 M&A Event §3.9 Manufacturing Party §14.7 New Indication Existing Licensed Product §5.12(a) New Indication Funding Party §5.12(a) New Licensed Product §5.11(a) Non-Bribery Laws 3.22(cManufacturing Party §14.7 Non-performing Manufacturing Party §7.6 Notified Party §14.3(b) Articles of Merger 2.4(aNotifying Party §14.3(b) Certificates 2.9(c)(iOpt-in Indication §5.13(a) Charter Amendment Opt-in Effective Time Date §5.13(a) Opt-in New Indication Existing Licensed Product §5.13(a) Opt-in Notice §5.13(a) Opt-in Notice Date §5.13(a) Opting-out Party §5.11 Option §2.1 Option Exercise Date §2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses Exercise Fee §8.3(d) Ex-Im Laws 3.22(cOption Exercise Notice §2.3 Option Exercise Period §2.2 Defined Term Section Panel Identification §8.3(a) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Parties Preamble Party or Parties Preamble Patents 1.1(kkkPatent Expenses §9.5 Pre-Exercise Milestone §8.3 Pre-Exercise Milestone Payment §8.3 Product Opt-out Effective Date §5.11 Product Trademarks §9.9(b) Payment Agent 2.9(aPromotional Materials §6.4 Quarterly Cost Notice §5.5 Royalty Term §8.8 Royalty-paying Party §8.10 Section 5.11 Opt-out Effective Date §5.11(a) Per Share Price 2.9(a)(iiiSection 5.12 Opt-out Effective Date §5.12(a) Proxy Holder Recitals Proxy Statement 6.3(aSenior Representative §4.1 Supplemental Information §2.2 Supply Agreement §7.7 Tax/Taxes §8.11 Third Party Technology §3.6(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iThird Party Technology Agreements §3.6(a)

Additional Definitions. The In addition to the terms set forth in Section 1.1, the following capitalized terms have the respective meanings given to them are defined in the respective Sections text of this Agreement set forth opposite each of in the capitalized terms locations specified below: Additional Approval Condition 3.4(b2012 Bonuses 13.5.1 Acquisition Litigation 14.2.2(d) Agreement Preamble Alternative Archstone Indemnitee 13.14.1 Asset Acquisition Statement 13.9 Asset Transfer Documents 2.6.1 Asset Transfer Restriction Order 2.5.1 Audit Inquiry Letter 13.12.4 AVB Preamble AVB Cash Purchase Price Portion 2.2.1 AVB Common Shares 8.4.1 AVB Debt Commitment Letter 8.7.2 AVB Debt Financing 8.7.2 AVB Lenders 8.7.2 AVB Preferred Shares 8.4.1 AVB SEC Documents 8.5.1 AVB Shares 8.4.1 Bills of Sale 10.1.6(d) Buyer Cure Period 15.1.3(b) Buyer Group 12.2.1 Buyer Party Recitals Buyer Indemnified Parties 14.2.2 Cash Purchase Price 2.2.1 Claim Notice 14.3.1 Continuing Employees 13.15.1 Debt Commitment Letters 8.7.2 Debt Financing 8.7.2 Deferred Closing Assets 2.5.1 Designated Properties 12.3 Entity Level Transaction 13.10.1(e) EQR Preamble EQR Common Shares 7.4.1 EQR Preferred Shares 7.4.1 EQR Reimbursement Agreement 5.4(a13.12 EQR SEC Documents 7.5.1 EQR Shares 7.4.1 Equity Residential Parties Preamble ERPOP Preamble ERPOP Cash Purchase Price Portion 2.2.1 ERPOP Debt Commitment Letter 7.7.2 ERPOP Debt Financing 7.7.2 ERPOP Lenders 7.7.2 Escrow Agent 2.5.2(b)(i) Anti-Bribery Laws 3.22(cEscrowed Deferred Closing Asset Transfer Documents 2.5.2(b)(iii) Articles of Merger 2.4(aEvent 2.3.1(c) Certificates 2.9(c)(iEscrowed Deferred Stock Consideration 2.5.2(b)(i) Charter Amendment Effective Time 2.3 Existing Proceedings 14.5 Expenses Amount 15.3.2 Extension Closing 2.5 2.5.1 Extension Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b2.5.1 Extension Notice 2.5.2(g)(i) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Financial Statements 5.6.1 First Extension Notice 2.4 Indemnified Claim 14.3.1 Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger 14.3.1 Indemnifying Party 14.3.1 Indemnity Agreement 13.1.4 Indemnity Obligations 13.14.5 Initial Closing 2.4 LBHI Preamble ▇▇▇▇▇▇ Entities Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Non-Controlled Subsidiary 6.3.2 Non-Party Affiliates 16.17 Ordinary Course Bonuses 13.5.1 Other Bonuses 13.5.1 Outside Closing Date 2.4 Parties Preamble Party or Preamble Reimbursement Agreements 13.12 Requested Transactions 2.6.3 Retained Deferred Closing Asset 2.5.2(g) Retained Escrowed Documents 2.5.2(g)(ii) Retention Agreements 13.5.2 Second Extension Notice 2.4 Seller Preamble Seller Cure Period 15.1.3(a) Seller Indemnified Parties Preamble Patents 1.1(kkk14.2.1 Severance Obligations 13.5.1 Subsidiary Interests 6.3.2 Tax Protection Agreement 6.7.3 Tenant Purchase Option Laws 13.1.5(b) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Third Party Claim 14.3.2 Voting Interest Parties 2.1.2

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definition is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) AAA 1.70 Advisory Period 3.1.2 Agreement Preamble Alternative Acquisition Alliance Manager 4.5 Arbitration Request 13.2 Bankruptcy Code 5.4 Breaching Party 12.3.1(a) Chairperson 4.1.1 Claims 11.1 Collaboration 2.1 Competitive Infringement 8.5.1 Confidential Information 9.1 Disclosing Party 9.1 Dropped Target(s) 2.2.5 Effective Date Preamble EPIZYME Preamble EPIZYME Patent Challenge 12.4.2(b) Existing Confidentiality Agreement 5.4(a9.4 First Meeting 2.2.3 GAAP 13.15 GLP 1.49 GSK Preamble GSK Patent Challenge 12.4.1(b) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee HMT Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) IFRS 13.15 Indemnified Party Proceeding 6.9(b11.3.1 Indemnifying Party 11.3.1 Initial ROFO Target Selection Period 2.2.4 Joint Project Team (JPT) Indemnified Persons 6.9(a4.3 JSC 4.1 Key Employee 13.13 Know-How Royalty 6.8.2(b) Labor Agreements 3.20(aLosses 11.1 Material Receiving Party 2.7.5(a) Leased Real Property Leases 3.15(bMaterials 2.7.5(a) Marks 1.1(kkkNon-Breaching Party 12.3.1(a) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Oncology-Inflammation Available Target 2.2.3 Party or Parties Preamble Patents 1.1(kkkPassed ROFO Target(s) Payment Agent 2.9(a2.2.4 Passed ROFO Target Selection Blackout Period 2.2.4 Patent Liaison 4.4 Patent Strategy 4.4 Payee 6.11 Payor 6.11 PMA 6.6 publishing Party 9.6.2 Purpose 2.7.5(a) Per Share Price 2.9(a)(iiiQualified Financing 6.3 Receiving Party 9.1 Replacement Target 2.2.6(a) Proxy Holder Recitals Proxy Statement 6.3(aResearch Payments 6.2 Research Term 2.3.1 Reviewing Party 9.6.2 ROFO Package 2.2.4 Royalty-Bearing EPIZYME Product 6.9.1 Royalty Term 6.8.2(a) Required Permits 3.20(cSelected Target(s) Restraint 7.1(b2.2.2 Sensitive Information 7.1.2(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aSubcommittee 4.2 Term 12.1.1 Terminated Dropped Target 12.5.3 Terminated EPIZYME Products 12.5.3 Terminated Products 12.5.1 Terminated Target 12.5.1 Transfer Record 2.7.5(a) Statutory Merger Stockholder Approval 3.4(aTransferring Party 2.7.5(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)US/UK Treaty 6.13.1

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each indicated below: [***] Notice Period 4.10.2 [***] Opportunity Notice 4.10.2 [***]ROFN Notice 4.10.2 ARCHEMIX Change of Control Notice 13.2.1 (a) ARCHEMIX Indemnitees 12.2 Back-up Collaboration Compound 3.8.1 Blocking Third Party Patent 9.4 Claims 12.1 Clinical Candidate 3.7 Co-Development Net Sales 4.12 (b) Co-Development Option 4.11.1 (b) Co-Development Option Notice 4.11.1 (b) Collaboration Manager 2.2.6 Dedicated Equipment 3.3.5 Designated Senior Officers 2.1.5 Disputed Matter 2.1.5 Divestment Opportunity Notice 13.12 Divestment Opportunity Notice Period 13.12 Divestment Opportunity ROFN Notice 13.12 ELAN Change of Control Notice 13.2.2 (a) ELAN Indemnitees 12.1 Filing Party 9.1.4 50/50 Offset 5.4.1 (c) Final Offer 13.11 Gilead Indemnitee 12.5 Indemnified Party 12.5 Indemnifying Party 12.3 Infringement 9.2.1 (a) Infringement Notice 9.2.1 (a) Lead Compound 3.6.2 Losses 12.1 Non-Filing Party 9.1.4 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the capitalized terms below: Additional Approval Condition 3.4(bCommission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. Non-Parenteral Option Exercise Period 4.11.1 (b) Patent Coordinator 8.4 Proprietary Chemistry 5.4.1 (c) Psoriatic Diseases Option Exercise Period 4.11.1 (b) Quarterly Report 4.12 R&D Costs 10.3.6 Recipient Party 3.10 Refunded Products 4.13 Roll-Over Payment 4.11.7 Supply Agreement Preamble Alternative Acquisition Agreement 5.4(a4.5.2 Term 10.1 Third Party License 5.4.1 (c) Anti-Bribery Laws 3.22(cThird Party Payments 5.4.1 (c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Transferring Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)3.10

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bAcquired Party 13.3(b) Acquirer 13.3(b) Acquisition 13.3(b) Administrator 11.3(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aTerm 10.1 AKA 1.3 Bankruptcy Laws 10.5(b) Anti-Bribery Laws 3.22(cBreaching Party 10.3 cGCP 1.3 cGMP 1.3 Claim 12.1 Commercialization Report 5.6 Cooperating Party 8.3(b) Articles of Merger 2.4(aCure Period 10.3 Development Event 6.2(a) Certificates 2.9(c)(iDevelopment Event Payment 6.2(a) Charter Amendment Development Plan 3.1 Development Report 3.5(b) Development Transition Plan 3.6 Disclosing Party 1.18 Event 6.2 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bFCA 1.3 FCPA 1.3 FFDCA 1.3 Inbound License 9.2(g) Company Leased Real Property 3.15(bIndemnifying Party 12.3(a) Company Option 2.8(c)(iIndemnitee 12.3(a) Company Owned Real Property 3.15(aInfringement Recovery 7.5(e) Company PSU 2.10(c)(iInsolvency Event 10.5(a) Company Recommendation 3.3(aJoint Inventions 7.1 Joint Patents 7.3(c) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting Losses 12.1 MacroGenics Preamble MacroGenics Indemnitee 12.1 MacroGenics Platform Inventions 7.1 Manufacturing Technology Transfer 4.1 Manufacturing Transition Plan 4.1 [****] 6.4(a) Converted PSU Award 2.10(c)(ii[****] License 6.4(a) Converted Restricted Share Award 2.10(bOfficials 9.4(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Package 5.3 Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Extension 7.4 Patent Extensions 7.4 Payment 9.4(b) Platform Patent 7.5(d) Platform Patent Extension 7.4 Prior CDA 8.5 Provention Preamble Provention Common Stock 9.3 Provention Indemnitee 12.2 Provention License 2.1 Provention Series A Preferred Stock 9.3 Publishing Party 8.7 Qualified Consideration Agreement 1.71 R&D Technology Transfer 3.6 Receiving Party 1.18 Requesting Party 8.3(b) Reviewing Party 8.7 Rules 11.3(a) Sales Event 6.2(b) Sales Event Payment Agent 2.9(a6.2(b) Per Share Price 2.9(a)(iiiSecurities Act 9.2(k) Proxy Holder Recitals Proxy Statement 6.3(aSole Inventions 7.1 Terminating Party 10.3 Third Party Obligation 6.4(a) Required Permits 3.20(cThird Party Patent Challenge 7.7(b) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Transferred Materials 4.1 Transition Period 3.6 UKBA 1.3 Voluntary Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)10.2 Voting Debt 9.3 Warrant 6.1

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of the Agreement: Alliance Manager 2.1 Astellas Development Activities 4.3(b) Astellas Indemnitees 14.1 Bankruptcy Code 3.8 Commercialization Plan 7.2(a) [*] [*] Cytokinetics Country-Specific Development Activities 4.3(a) Cytokinetics Development Activities 4.3(a) Cytokinetics Global Development Activities 4.3(a) Cytokinetics Indemnitees 14.2 Development Advance Invoice 9.2(a) Development Budget 4.2(a) Development Plan 4.2(a) Development Program 4.2(a) Development Project Team 4.10 Development True-Up Report 9.2(b) Disclosing Party 11.1(a) [*] [*] FCPA 15.7(a) FCPA Covered Person 15.7(a) Federal Arbitration Act 15.6 Global Brand Elements 10.5(b) [*] = Certain confidential information contained in this Agreement set forth opposite each document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles Securities Exchange Act of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) 1934, as amended. Indemnified Party Proceeding 6.9(b14.3 Indemnifying Party 14.3 [*] Rules 15.6 Joint Commercialization Committee or JCC 2.5 Joint Development Committee or JDC 2.3 Joint Manufacturing Committee or JMC 2.4 Joint Medical Affairs Committee or JMAC 2.6 Joint Patent Committee or JPC 2.7 Joint Steering Committee or JSC 2.2 [*] Regulatory Materials 5.2(a) Indemnified Persons 6.9(aMedical Affairs Plan 8.3(a) Labor Agreements 3.20(a[*] [*] Pharmacovigilance Agreement 5.5 Product Infringement 10.4(a) Leased Real Property Leases 3.15(bProduct Marks 10.5(a) Marks 1.1(kkkReceiving Party 11.1(a) Maximum Premium 6.9(b[*] [*] Remainder 10.4(g) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iRemedial Action 5.7 [*] [*] Responsible Committee 11.4 [*] [*] Royalty Term 9.4(d) New Plans 6.9(aSpecific Country Development Cost 3.5(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Term 12.1

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: [***] 9.5(b) Additional Approval Condition 3.4(bActive 1.50 Adjuvant Components 1.1 Adjuvant Price 8.2(m) Adjuvant Rolling Forecast 8.2(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAmendment Effective Date Preamble Amendment Upfront Payment 9.3(c) Anti-Bribery Annual Milestone Payment 9.9(b) Annual Support Payment 9.9(a)(ii) Appeal Recitals Assay 8.1(a) Bankruptcy Laws 3.22(c13.5(b) Articles of Merger Breaching Party 13.3(a) Claim 15.1 Clinical Trial Materials 8.1(b) Committee 2.4(a) Certificates 2.9(c)(iCompetitive Vaccine 3.3(b)(i) Charter Amendment COVID-19 Recitals COVID-19 Effect 16.4(b) CRO 5.3(a) Cure Period 13.3(a) Custom PVS 8.3(a) Development Adjuvant Components 8.2(b) Development Data 5.3(a) DB2/ 50302435.21 Disclosing Party 12.1 Dispute or Disputes 14.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bGOJ Recitals GOJ Funding Recitals ICH 1.31 Initial Order Term 8.2(b) Company Leased Real Property 3.15(bIndemnifying Party 15.3(a) Company Option 2.8(c)(iIndemnitee 15.3(a) Company Owned Real Property 3.15(aInitial Clinical Trial Materials 8.1(c) Company PSU 2.10(c)(iJD&RC 2.3(a) Company Recommendation 3.3(aJMC 2.2(a) Company Recommendation Change 5.4(c)(iJoint Inventions 10.1 JSC 2.1(a) Company RSU 2.10(a)(iLatent Defect 8.2(p)(iii) Company SEC Reports 3.8(dLatent Defect Non-Conformance Notice 8.2(p)(iii) Company Securities 3.7(b[***] 3.5(b)(ii) Company Special Committee Recitals Company Stockholder Meeting 6.4(aLosses 15.1 MHRA 1.67 Minimum Order Quantity 8.2(b) Converted PSU Award 2.10(c)(iiNegotiation Period 3.6(a) Converted Restricted Share Award 2.10(bNon-Breaching Party 13.3(a) Converted RSU Award 2.10(a)(iiNovavax Preamble Novavax Discontinuation Request 13.4 Novavax Indemnitee 15.1 Novavax Inventions 10.1 Overfill 8.2(b) Copyrights 1.1(kkkOverage 8.2(b) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Packaging and Labeling 6.5 Party or Parties Preamble Patents 1.1(kkkPayments 9.6(a) Payment Agent 2.9(aPost-Pandemic Agreement 3.6(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Prior Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aPurchase Order 8.2(i) Statutory Merger Stockholder Approval 3.4(aPVA 6.6 Receiving Party 12.1 Recovery 10.5(c)(iv) Statutory Stockholder Approvals 3.4(aReference Countries 6.4 [***] 9.1 Samples 8.1(a) Support DB2/ 50302435.21 Sole Inventions 10.1 Starting Materials 3.1(b) Takeda Preamble [***] 8.2(f) Takeda Indemnitee 15.2 Takeda Inventions 10.1 Takeda Vaccine 8.2(f) Technology Transfer Plan 4.1 Term 13.1 Upstream Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b3.5(b)(i) Termination Date 8.1(bUseful Development Data 5.3(b) Trade Secrets 1.1(kkkVaccine Trademark 7.5(a) Transaction Matters 9.11(aVisual Non-Conformance Notice 8.2(p)(ii) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Article 2 OVERVIEW; MANAGEMENT

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bAcadia Preamble Acadia Indemnitee 13.1(a) Acadia Patents 14.3(c) Acquired COC Program 2.5(b)(ii) Acquiring Person COC Program 2.5(b)(i) Agreement Preamble Alternative Acquisition Alliance Manager 3.1 Assumed Commercialization Activities 7.3 Assumed Development Activities 6.8 Audited Party 9.8 Auditing Party 9.8 BBA 16.3 Claim 13.1(a) Clinical Candidate 4.6(e) Clinical Candidate Notice 4.6(e) CMO 6.3 Commercialization Activities Cure Period 7.3 Commercialization Cost Report 9.6(b)(ii) Commercialization Opt-Out 8.2(a) Commercialization Opt-Out Date 8.2(a) Commercialization Opt-Out Notice 8.2(a) Commercialization Opt-Out Right 8.2(a) Commercialization Opt-Out Transition Activities 8.2(b) Commercialization Opt-Out Transition Plan 8.2(b) Commercialization Strategy 7.1(d)(i) Committee 3.6 Confidential Information 10.1 Confidentiality Agreement 5.4(a17.12 Continuing Party 15.10(a) AntiCost Reconciliation Report 9.6(b)(iii) Cost Reports 9.6(b)(ii) Critical Success Factors 4.1 Deadlocked Matter 3.7(a) Development Activities Cure Period 6.8 Development Cost Report 9.6(b)(ii) Development Opt-Bribery Laws 3.22(cOut 8.1(a) Articles of Merger 2.4(aDevelopment Opt-Out Date 8.1(a) Certificates 2.9(c)(iDevelopment Opt-Out Notice 8.1(a) Charter Amendment Development Opt-Out Party 8.1(a) Development Opt-Out Right 8.1(a) Development Opt-Out Transition Activities 8.1(b) Development Opt-Out Transition Plan 8.1(b) Development Opt-Out Window 8.1(a) Development Records 5.2(e) Dispute 17.4(a) Divestiture 2.5(b)(ii) Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Excess Commercialization Overage 7.2(b) Excess Development Overage 6.4(b) Excess Research Overage 4.4(c) Excluded Claim 17.4(b) H-W Notice Letter 1.4 Company Intellectual Property 3.17(b14.5 ICC 17.4(a) Company Leased Real Property 3.15(bICC Arbitration Rules 17.4(a) Company Option 2.8(c)(iIndemnitee 13.1(c) Company Owned Real Property 3.15(aIndemnitor 13.1(c) Company PSU 2.10(c)(iInfringement 14.4(a) Company Recommendation 3.3(aInterim Commercialization Cost Report 9.6(b)(i) Company Recommendation Change 5.4(c)(iInterim Cost Reports 9.6(b)(i) Company RSU 2.10(a)(iInterim Development Cost Report 9.6(b)(i) Company SEC Reports 3.8(dInterim Revenue Report 9.6(b)(iv) Company Securities 3.7(bJAMS 17.4(c) Company Special Committee Recitals Company Stockholder Meeting 6.4(aJCC 3.2 JDC 3.2 JSC 3.2 Lead Commercialization Party 7.1(d)(i) Converted PSU Award 2.10(c)(iiLead Development Party 6.1(a) Converted Restricted Share Award 2.10(bLead Regulatory Party 6.9(a) Converted RSU Award 2.10(a)(iiLicensor Party 2.6(a) Copyrights 1.1(kkkLosses 13.1(a) Covenant Exceptions MECP2 Development Plan 5.2(a) MECP2 Development Program 5.2(a) MECP2 Research Budget 4.1 MECP2 Research Plan 4.1 MECP2 Research Program 4.1 MECP2 Royalty Term 9.2(c)(ii) MECP2 Technology Transfer 5.1(a) Data Privacy/Security Requirements 3.17(gMECP2 Third Party License(s) Effect 1.1(x9.2(c)(iii)(C) Effective Time 2.4(bMolecule 4.6(e) Electronic Delivery 9.13 Enforcement Expenses 8.3(d[***] Development Plan 5.2(a) Ex-Im Laws 3.22(c[***] Research Budget 4.1 [***] Research Plan 4.1 [***] Technology Transfer 5.1(b) Exchange Fund 2.9(b[***] Third Party License(s) Excluded Arrangements 6.10(a9.3(c)(iii)(C) FHWA 3.21(bParty Preamble Parties Preamble Patent Term Extensions 14.7 Payee 9.9(b) Financing 6.5(aPaying Party 9.9(b) FMCSA 3.21(bPermitted Commercialization Overage 7.2(b) Indemnified Permitted Development Overage 6.4(b) Permitted Research Overage 4.4(c) Pharmacovigilance Agreement 6.10 Pricing Guidelines 7.4 Promotional Working Group 3.5(b)(v) Public Official 12.3(g)(iv) Publishing Notice 11.1(b)(ii) Publishing Party Proceeding 6.9(b11.1(b)(ii) Indemnified Persons Regulatory Strategy 6.9(a) Labor Agreements 3.20(aResearch Plan Records 4.6(a) Leased Real Property Leases 3.15(bResults 4.6(c) Marks 1.1(kkkRevenue Reconciliation Report 9.6(b)(vi) Maximum Premium 6.9(bRevenue Report 9.6(b)(v) Merger Recitals Merger Sub Securities Regulator 11.2(b) Shared Patent Enforcement Costs 14.4(c)(iii) Stoke Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iStoke Indemnitee 13.1(b) New Plans 6.9(aStoke Patents 14.3(a) SYNGAP1 Co-Co Clinical Supply Agreement 6.3 SYNGAP1 Co-Co Commercial Supply Agreement 7.7 SYNGAP1 Co-Co Technology Transfer Plan 7.7 SYNGAP1 Co-Commercialization Budget 7.1(a) SYNGAP1 Co-Commercialization Plan 7.1(a) SYNGAP1 Co-Development Plan 6.1(a) SYNGAP1 Commercialization Technology Transfer 8.2(c) SYNGAP1 Development Technology Transfer 8.1(c) SYNGAP1 Opt-Out Product 8.1(b) SYNGAP1 Research Budget 4.1 SYNGAP1 Research Plan 4.1 SYNGAP1 Research Program 4.1 SYNGAP1 Royalty Term 9.5(b) SYNGAP1 Terminated Product 15.10(a) SYNGAP1 Third Party License(s) 9.5(c)(iii) Tax Partnership 16.1 Term 15.1 Terminated Party 15.10(a) Terminated Product 15.8(a) Termination Notice Period 5.4(d)(ii)(315.5 Trademark Costs 7.9(d) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Upfront Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)9.1 Working Group 3.6

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of the Agreement: Acquisition Transaction 16.8(b) Alliance Manager 3.7 Allowable Increases 4.5(a) Auditor 9.4 Beneficial Party 8.2(d) Budget Cap 4.5(a) Claim 12.3 Collaborative Work 4.5(a) Collaborator Data 10.1(a) Collaborator Indemnitee 12.1 Collaborator Local Development Work 4.5(c) Commercialization Plan 6.2 Competing Program 2.8(a) Compound Invention 10.1(b)(i) Development Budget 4.2(b) Developing Party 4.3 Disputed Matter 15.2 Divest 2.8(b) (a) Exelixis Entity 16.8(a)(i)(1) Exelixis Indemnitee 12.2 Exelixis Local Development Work 4.5(c) First Full Calendar Year 6.3(b) First Generic Entry 2.8(a) Global Development Plan or GDP 4.2(a) Indemnitee 12.3 Indemnitor 12.3 Independent Work 4.3 Independent Work Cost 8.2(b) Injunctive Relief 15.3(b) Joint Commercialization Committee or JCC 3.3 Joint Development Committee or JDC 3.2 Joint Executive Committee or JEC 3.1 Joint Inventions 10.1(b)(ii) Joint Patents 10.1(b)(ii) Local Regulatory Requirement 3.5(b)(i)(2) Losses 12.1 [ * ] = Certain confidential information contained in this Agreement set forth opposite each document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the capitalized terms below: Additional Approval Condition 3.4(bSecurities Exchange Act of 1934, as amended. Materials 4.14 Minimum Commercial Performance 6.3(b) Minimum Commercial Performance Period 6.3(b) Newly-Proposed Development 4.3 Non-Developing Party 4.3 PV Costs 5.5(c) Pharmacovigilance Agreement Preamble Alternative Acquisition 5.5(a) Previously Achieved Sales Milestone 8.4(a) Product Infringement 10.4(a) Product Marks 10.8(a) Promotional Materials 6.4(c) Proposal 4.3 Quality Agreement 5.4(a7.1 Recall 5.9 Regulatory Meeting 5.3 Remaining Royalty Term 8.5(d) Anti-Bribery Responding Party 13.4(a) Royalty Term 8.5(c) Rules 15.3(a) Sole Inventions 10.1(b)(ii) Standstill Period 16.8(a) Submitting Party 13.4(a) Sunshine Reporting Laws 3.22(c5.10 Supply Agreement 7.1 Supply Contacts 3.8 Term 14.1(a) Articles of Merger 2.4(aUnaffiliated Third Party 2.8(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWithholding Tax Action 9.3(c)

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b1974 Convention 14.4 AbbVie Preamble [**] 8.1.3 AbbVie Indemnified Parties 11.1 AbbVie Sole Inventions 8.1.1 Acquisition Transaction 3.7.3(a) ADR 13.1 Adverse Ruling 12.2.1(a) Agreement Wind-Down Period 12.3.13 Alliance Manager 2.10 Alliance Manager Expenses Financial Exhibit Allowable Expenses Financial Exhibit [**] 4.1.6(c) [**] 4.1.6(c) Bankruptcy Code 3.7.4 Breaching Party 12.2.1 Collaboration Losses Financial Exhibit Combination Study Costs 4.6.1 Commercial FTE Financial Exhibit Commercial FTE Costs Financial Exhibit Competing Product 3.7.3(b) Conducting Party 4.2.3 Deductions 1.108 Development Reconciliation Procedures 4.6.2 Dispute 13.1 Distribution Costs Financial Exhibit Divest 3.7.3(c) DMF 4.4.4 EAP Expenses Financial Exhibit Enrollment Event Schedule 7 EPO 8.2.1 Exchange Act 1.16 Excluded Matters 2.9.3 Execution Date Preamble Alternative Acquisition Existing Patents 10.2.1 FCPA 1.90 FFDCA 1.40 Finance Working Group 2.5 First Approval in an Oncology Indication 1.89 First Year 4.1.5(b) Global Publication Strategy 9.4.1 Headlicense Breach 10.6.5(b) Health Care Reform Fees Financial Exhibit Incomplete Activity 4.1.5(b) Indirect Taxes 7.6.5 Infinity Preamble Infinity Indemnified Parties 11.2 Infinity Sole Inventions 8.1.1 Infringement Claim 8.3.9(a) Intellikine ▇▇▇▇ 8.7.3 IST/IIS Working Group 2.5 IP Working Group 2.5 JAMS 13.1.2 JCC 2.3.1 JDC 2.2.1 JMAC 2.4.1 Joint Inventions 8.1.2 Joint Product Patent Rights 8.2.1(a) JSC 2.1.2 Launched Products 12.3.13 Manufacturing Working Group 2.5 Marketing Expenses Financial Exhibit Marketing Related Materials 12.3.14 Medical Affairs Budget 4.2.2 Medical Affairs Costs 4.2.7 Medical Affairs Plan 4.2.2 Medical Affairs Reconciliation Procedures 4.2.8 Milestone Event Schedule 7 Milestone Payment Schedule 7 Mono Product 1.108 Net Profit or Loss Financial Exhibit Neutral 13.1.3 Non-Breaching Party 12.2.1 Non-Incurred Amount 4.1.5(b) Non-Sponsor 4.3.2(b) On-Going Clinical Study 12.3.12 Other Commercialization Costs Financial Exhibit Other Income Financial Exhibit Owed Party 7.5.3 Owing Party 7.5.3 Paragraph IV Certification 8.3.2 Patent Challenge 12.2.3 Pharmacovigilance Working Group 2.5 Post-Termination Royalty Term 12.3.7(b) Prior CDA Effective Date 1.124 Product Trademark Costs 8.7.2(c)(iii) Profit Reconciliation Procedures 7.2.1 Proposed Publications 9.4.2(b) Proposed Terms 13.13.2 Publishing Party 9.4.2(b) Quality Agreement 5.4(a6.1.3 Recall Expenses Financial Exhibit Reconciliation Procedures 7.2.1 Regulatory Working Group 2.5 Regulatory Maintenance Costs Financial Exhibit Regulatory Owner 4.4.3(a) AntiReimbursable Amounts 7.4.1 Reimbursing Party 4.2.3 Reviewing Party 9.4.2(b) Right of Reference 4.4.4 Royalty Term 7.3.2 Sales Representative 5.7.1 Segregate 3.7.3(d) Selling Expenses Financial Exhibit Severed Clause 14.6 Shared Development Costs 4.6.1 [**] 7.4.2 [**] 8.3.9(b) Shared Overage Costs 4.6.1 [**] 8.3.7 [**] 8.2.4 Shared Product Liability Costs 11.4.3 [**] 7.4.2 Sole Inventions 8.1.1 Sponsor 4.3.2(b) Sublicense 3.6.3 Succeeding Year(s) 4.1.5(b) Supply Agreements 6.1.1 Supply Price Financial Exhibit Support Memorandum 13.13.2 Term 12.1 Termination and Wind-Bribery Laws 3.22(cDown Plan 12.3.1 Third Party Claim 11.3.1 Translational Medicine Working Group 2.5 USPTO 8.2.1(a) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Withholding Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)7.6.2 Working Group 2.5

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Acquiring Party 7.7.1 Additional Approval Condition 3.4(bStudy 2.2.3(c) Agreement Preamble Alternative Acquisition Back-Up Source 6.4 Bankrupt Party 7.4 Bankruptcy Code 7.4 Bulk Drug Product Schedule 6.2 cGMP 6.1 CEO 14.1 Clinical Supply Agreement 5.4(a6.2 Collaboration Manager 5.2 Commercial Supply Agreement 6.2 Competitive Infringement 12.3.1 Contracting Party 5.5 Declined NG Candidate Option 2.3.3(a) AntiDeclined NG Candidate Development Costs 2.3.3(d)(ii) Declined NG Development Candidate 2.3.1 Defense Action 12.3.1 Development Buy-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xIn 2.2.3(d) Effective Time 2.4(bDate Preamble Global Branding Strategy 4.4.1 Indemnitee 11.4 Isis 1.98 Losses 11.1 Manufacturing Arbitration Draft 6.3.1 Neutral Expert 6.3.2 Non-Bankrupt Party 7.4 Non-Proposing Party 2.2.3(c) Electronic Delivery 9.13 Enforcement Expenses 8.3(dOpt-In Study 2.3.3(b) ExOption Commencement Notice 2.3.3(b) Option Exercise Notice 2.3.3(c) Option Period 2.3.3(c) Oxford 1.98 Pharmacovigilance Agreement 3.4 Post-Im Laws 3.22(cDevelopment Buy-In 2.2.3(e) Exchange Fund 2.9(bPromotional Materials 4.4.2 Proposing Party 2.2.3(c) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Safety Termination 13.2.3 Sarepta Preamble Sarepta Indemnitees 11.2 Sarepta Territory Commercialization Plan 4.3.1 Sarepta Trademarks 12.8.2 Second Source 6.4 SPC 12.3.4 Standstill Parties 14.1 Standstill Period 14.1 Summit Preamble Summit Indemnitees 11.1 Summit Trademarks 12.8.2 Supply Agreement 6.2 Technology Transfer 6.5 Territory Expansion Option 4.2 Territory Expansion Option Exercise Date 4.2 Territory Expansion Option Fee 4.2 Term 13.1 Terminated Countries 13.3.2 Terminated Licensed Product 13.3.1 Third Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Collaboration Agreement 5.5 Third Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Partner 5.5

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b18 Competitive Information – Commercially Sensitive Terms. 19 Competitive Information – Commercially Sensitive Terms. Accounting Firm 9.10(b)(i) Agreement Preamble Alternative Acquisition Agreement 5.4(aPayments 9.11(a) Alliance Manager 3.1 Anti-Bribery Corruption Laws 3.22(c12.7(a)(i) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company BeiGene Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions BeiGene Drug 5.1(a) Data Privacy/Security Requirements 3.17(gBeiGene Drug Inventions 14.1(a) Effect 1.1(xBeiGene Inventions 14.1(a) BeiGene Indemnitees 13.2 BeiGene Publication 11.1(b) Breach Notification 15.2(b)(i) Claims 13.1 Clinical Supply Agreement 7.3(a) CMO 7.2 Commercialization Milestone Event 9.3 Commercialization Milestone Payment 9.3 Confidentiality Agreement 16.13 Continuing Technology Transfer 4.1 Development Milestone Event 9.2 Development Milestone Payment 9.2 Disclosing Party 1.18 Dispute 16.5(a) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(bDate Preamble Existing Regulatory Materials 12.2(o) Excluded Arrangements 6.10(aClaim 16.5(e) FHWA 3.21(bExecutive Officers 3.2(f) Financing 6.5(aGlobal Development Plan 5.3(a) FMCSA 3.21(bICC 16.5(a) ICH Guidelines 1.32 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Joint Patent Rights 14.1(c) Indemnified Persons 6.9(aJCC 3.2(g) Labor Agreements 3.20(aJDC 3.2(a) Leased Real Property Leases 3.15(bLeap Preamble Leap Inventions 14.1(a) Marks 1.1(kkkLeap Indemnitee(s) Maximum Premium 6.9(b13.1 Leap Manufacturing IP 7.2 Leap Publication 11.1(c) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iLicense 2.2 Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Notice of Dispute 16.5(a) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Option 2.1 Option Exercise Fee 5.1 Party/Parties Preamble Patents 1.1(kkkPOC Data Package 5.1 Product Infringement 14.3(a) Payment Agent 2.9(aProduct Marks 14.7 Public Official 12.7(d) Per Share Price 2.9(a)(iiiPublication 11.1(c) Proxy Holder Recitals Proxy Statement 6.3(aReceiving Party 1.19 Review Period 11.1(b) Required Permits 3.20(cRoyalty Term 9.5(b) Restraint 7.1(bRules 16.5(a) Rollover Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a6.4 SEC 11.4(c) Statutory Merger Stockholder Approval 3.4(aSecurities Regulators 11.4(c) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters Seller 1.40 Taxes 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each indicated below: Acquired Person 1.15 4[***] For the purposes of the capitalized terms below: Additional Approval Condition 3.4(b) “Target” definition, “[***]” means [***] Active Immunotherapeutic Approaches 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(aCelgene Preamble Celgene Acquired Competing Antibody 4.4.2 Celgene Exclusivity Term 4.4.1 Celgene Indemnitees 9.2 Celgene Proposed Terms 4.2.2 Celgene Share 6.8.2(d) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Celgene Third Party Payments 5.2.4 Clinical Trial Preliminary Activities Outside Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) 10.5 Combination Product 1.52 Competing Antibody 4.4.1 Competing Compound 4.1 Cure Period 11.2.1 Disclosing Party 7.1 Dispute 11.7.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d12.11 Effective Date Preamble EMA 1.69 Excluded Claim 11.7.3(d) ExFDA 1.69 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 Grant Notice 4.2.2 HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.5.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patents 6.6.4 Licensed Program Assets 2.5 Licensed Program Confidential Information 7.11 Licensed Program Know-How 1.46(a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.46(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Licensed Program Specific IP 7.2 Master Collaboration Agreement Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) MHLW Negotiation Period 4.2.2 [***] [***] Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 4.2.2 Ongoing Prothena Development Activities 2.3.3 Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.5.2(b) Payment Agent 2.9(aPaying Party 5.5.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.2.1 Program Recitals Prothena Preamble Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.3 Prothena Reversion Antibodies 10.10.1 Publishing Party 8.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.3.1 Right of First Negotiation 4.2.2 Sales Milestone Payment 5.4.1 SEC 8.4.1(a) Proxy Holder Recitals Proxy Statement 6.3(aSecurities Regulators 7.6 Tax Benefit 5.5.2(c) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Term 10.1.1 Transfer Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i2.2.1(a)

Additional Definitions. The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(bAccelerated Company Option 3.8(a) Accelerated Restricted Stock Award 3.8(a) Accelerated RSU 3.8(c) Acceptance Time 2.1(d) Agreement Preamble Alternative Acquisition Agreement 5.4(a6.4(a) Anti-Bribery Laws 3.22(cArrangements 7.8 Certificates 3.9(c)(i) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 3.3 Closing Date 2.5 3.3 Company Preamble Company Charter Amendment Certificate 2.1 Board Recommendation 4.3(a) Company Board Recommendation Change 6.4(c)(i) Company Compensation Committee 7.8 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bPrivacy Policy 4.16(j) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(iRelated Parties 9.3(e)(ii) Company SEC Reports 3.8(d) 4.9 Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii4.7(c) Copyrights 1.1(kkk1.1(yy) Covenant Exceptions 5.1(aDebt Financing 7.4(a) Data Privacy/Security Requirements 3.17(gDissenting Company Shares 3.7(c)(i) DTC Payment 3.9(d) Effect 1.1(x1.1(u) Effective Time 2.4(b) 3.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c10.12 Enforceability Limitations 4.2 Equity Commitment Letter 5.9 Equity Financing 5.9 ERISA Affiliate 1.1(o) Exchange Fund 2.9(b3.9(b) Excluded Arrangements 6.10(aParty 6.3(a) FHWA 3.21(bGovernment Contract 1.1(eee)(xiv) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(bGroup Welfare Benefits 7.10(c) Indemnified Persons 6.9(a7.9(a) Labor Agreements 3.20(aInternational Employee Plans 4.18(a) IP Contracts 4.16(d) Lease 4.14(b) Leased Real Property Leases 3.15(b4.14(b) Marks 1.1(kkk1.1(yy) Maximum Annual Premium 6.9(b7.9(c) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iMinimum Condition 2.1(a)(i) MRA 1.1(fff) New Plans 6.9(a7.10(d) Notice Period 5.4(d)(ii)(36.4(d)(ii)(C) Offer Recitals Offer Condition 2.1(a)(ii) Offer Documents 2.1(e)(i)(A) Offer to Purchase 2.1(a) Old Plans 6.9(a7.10(d) Owned Company Shares 2.9(a)(ii3.7(a)(ii) Parent Preamble Parent Liability Limitation 9.3(e) Party or Parties Preamble Patents 1.1(kkk1.1(yy) Payment Agent 2.9(a3.9(a) Per Share Price 2.9(a)(iii2.1(a) Proxy Holder Recitals Proxy Statement Prospective Acquirer 6.3(a) Required Permits 3.20(cReimbursement Obligations 7.4(f) Restraint 7.1(bRepresentatives 6.4(a) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aSchedule 14D-9 2.2(b) Statutory Merger Stockholder Approval 3.4(aSchedule TO 2.1(e)(i)(A) Statutory Stockholder Approvals 3.4(aSEC Reports Article IV Sublease 4.14(c) Support Agreement Recitals Surviving Corporation Recitals 3.1 Tail Policy 6.9(b7.9(c) Tender and Support Agreements Recitals Termination Date 9.1(c) Termination Date 8.1(bFee 9.3(b)(i) Trade Control Laws 4.26(a) Trade Secrets 1.1(kkk1.1(yy) Transaction Matters 9.11(aSolicitation Period 6.3(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a3.9(c)(ii) Vested Company PSU 2.10(c)(iOption 3.8(a) Vested Company Option Consideration 3.8(a) Vested Restricted Stock Consideration 3.8(b) Vested RSU 2.10(a)(i3.8(c) Vested RSU Consideration 3.8(c) Willful Breach Requirements 9.3(e)

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Acquired Person 1.14 [***] [***] [***] [***] Acquisition Transaction Active Immunotherapeutic Approaches 11.5.1 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Celgene Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Celgene Acquired Competing Antibody 4.5.2 Celgene Exclusivity Term 4.5.1 Celgene Indemnitees 9.2 [***] [***] [***] [***] Celgene Third Party Payments 5.3.4 Combination Product 1.52 Competing Antibody 4.5.1 Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.8.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.12 Effective Date Preamble CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) ExNOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EMA 1.68 Excluded Claim 11.8.3(d) Existing Regulatory Materials 2.2.1 FDA 1.68 Financial Transparency Laws 11.17 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 [***] [***] HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.6.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patent 6.6.4 Licensed Program Assets 2.4 Licensed Program Confidential Information 7.11 Licensed Program Inventory 2.3.4 Licensed Program Know-How 1.46(a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.46(b) Excluded Arrangements 6.10(aLicensed Program Specific IP 7.2 Licensed Program U.S. License Agreement Recitals Master Collaboration Agreement Recitals MHLW 1.68 [***] [***] [***] [***] [***] [***] Ongoing Clinical Trial 2.1.3(a) FHWA 3.21(bOngoing Prothena Development Activities 2.1.3(c) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.6.2(b) Payment Agent 2.9(aPaying Party 5.6.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.3.1 Program Recitals CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) Proxy Holder Recitals Proxy Statement 6.3(aNOT MATERIAL AND (II) Required Permits 3.20(cIS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Prothena Preamble Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.1.3(d) Restraint 7.1(bProthena Reversion Antibodies 10.8.1 Publishing Party 7.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.4.1 [***] [***] Sales Milestone Payment 5.5.1 SEC 7.4.1(a) Rollover Securities Regulators 7.6 Tax Benefit 5.6.2(c) Term 10.1.1 Transaction Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Transition Plan 11.5.1 2.3.6

Additional Definitions. The following capitalized terms shall have the respective meanings given to them ascribed thereto in the respective Sections sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a6.5(b) AntiAuthorizations 3.9(b) Bankruptcy Exceptions 3.4(d) Book-Bribery Laws 3.22(cEntry Shares 2.1(d) Articles Certificate 2.1(d) Change of Merger 2.4(aControl Obligation 3.11(g)(i) Certificates 2.9(c)(iChange of Recommendation 6.5(d) Charter Amendment Effective Time 2.3 Closing 2.5 1.2 Closing Date 2.5 1.2 Commitment Letters 4.12(a) Commitment Party 4.12(a) Company Preamble Company Charter Amendment Certificate 2.1 Benefit Plans 3.11(a) Company Disclosure Letter 1.4 Preamble to Art. III Company Intellectual Property 3.17(bEmployees 6.6(a) Company Leased Real Property 3.15(bForeign Plan 3.11(a) Company Option 2.8(c)(i2.5(a) Company Owned Real Property 3.15(aReports 3.6(b) Company PSU 2.10(c)(iRestricted Share 2.5(b) Company Recommendation 3.3(aShares 2.1(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a6.3(b) Converted PSU Award 2.10(c)(iiCompany Termination Fee 8.2(a)(i) Converted Restricted Share Award 2.10(bCompany 2011 10-K Preamble to Art. III Confidentiality Agreement 6.2(b) Converted RSU Award 2.10(a)(iiContinuation Period 6.6(a) Copyrights 1.1(kkkDebt Commitment Letters 4.12(a) Covenant Exceptions 5.1(aDebt Financing 4.12(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xDissenting Stockholders 2.1(c) Effective Time 2.4(b1.1(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dEnd Date 8.1(b) Ex-Im Laws 3.22(cEquity Commitment Letters 4.12(a) Equity Financing 4.12(a) ERISA 3.11(a) ERISA Affiliate 3.11(d) Excluded Shares 2.1(c) Exchange Fund 2.9(b2.2(b) Executive Officer 3.15(b) Excluded Arrangements 6.10(aParty 6.5(b) FHWA 3.21(bFairness Opinion 3.19 Financing 4.12(a) Financing 6.5(aParties 4.12(a) FMCSA 3.21(bGAAP 3.6(a) Guarantee Recitals Guarantor Recitals HSR Condition 7.1(c) Indebtedness 3.15(b) Indemnified Party Proceeding 6.9(b6.7(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(aInsolvent 4.11 Intervening Event 6.5(d) Leased Real Property 3.13(b) Leases 3.13(b) Material Contract 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(bMerger 1.1(a) Merger Recitals Consideration 2.1(c) Merger Shares 2.1(d) Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iMultiemployer Plan 3.11(a) Negotiation Period 6.5(d)(ii) New Plans 6.9(a) Notice Period 5.4(d)(ii)(36.6(b) Old Plans 6.9(a6.6(b) Owned Company Shares 2.9(a)(iiPaying Agent 2.2(a) Parent Preamble Party or Parties Parent Board Recitals Parent Disclosure Letter Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iiito Art. IV Parent Termination Fee 8.2(a)(v) Proxy Holder Recitals Statement 3.18 Proxy Statement Clearance Date 6.3(a) Required Permits 3.20(cQualifying Acquisition Proposal 8.2(a)(i) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals Recent SEC Reports Preamble to Art. III Recommendation 3.4(a) Statutory Record Date 6.3(b) Required Approvals 3.5 Requisite Stockholder Vote 3.4(b) Solicitation Period End-Date 6.5(a) SOX 3.6(d) SRO 3.5 Summary Articles of Merger Stockholder Approval 1.1(b) Surviving Corporation 1.1(a) Takeover Laws 3.4(a) Statutory Stockholder Approvals 3.4(aTransaction Obligation 3.15(b) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)WARN Act 3.12

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this the Agreement: Accused Party 9.5 Advaccine Preamble Advaccine Housemarks 9.6(b) Advaccine Indemnitees 11.1 Advaccine Inventions 9.1(d)(ii) Advaccine Product ▇▇▇▇ 9.6(a) Advaccine Sublicense Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b2.1(c) Agreement Preamble Alternative Acquisition Alliance Manager 3.1 Bankruptcy Laws 15.13 Claims 11.1 Clinical Manufacturing Technology Transfer Agreement 5.4(a7.1(c) Anti-Bribery Laws 3.22(cClinical Supply Agreement 7.1(a) Articles of Merger 2.4(aCombination Product 1.62 Commercialization Plan 6.2(a) Certificates 2.9(c)(iConfidentiality Agreement 1.21 Development Plan 4.3 Divestiture 2.5 Effective Date Preamble Enforcing Party 9.4(c) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter Executive Officer 14.1 First Supplemental Development Plan 4.3 GAAP 1.1 Greater China 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) IFRS 1.1 Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Infringement 9.4(a) Indemnified Persons 6.9(aInfringement Action 9.5 Initial Development Plan 4.3 Inovio Preamble Inovio Device Commercial Supply Agreement 7.2(a) Labor Agreements 3.20(aInovio Indemnitees 11.2 Inovio Inventions 9.1(d)(i) Leased Real Property Leases 3.15(bInovio Partner 2.2 Insolvency Event 13.5 Insolvent Party 15.13 Joint Inventions 9.1(d)(iii) Marks 1.1(kkkJoint Steering Committee 3.2(a) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Losses 11.1 Non-Exclusive License Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Non-Insolvent Party 15.13 Other Products 1.62 Party Preamble PDF 15.12 Pharmacovigilance Agreement 5.8 Prior Agreement Recitals Surviving Corporation Prior Effective Date Recitals Tail Policy 6.9(bProduct Materials 4.8 Region 1.4 Remedial Action 5.9 Royalty Term 8.4(b) Termination Date 8.1(bSEC 12.3(c) Trade Secrets 1.1(kkkSecurities Regulators 12.2(c) Transaction Matters 9.11(aSIAC 14.2 SIAC Rules 14.2 Step-In Rights 9.2(d) Uncertificated Shares 2.9(c)(iiTax Withholding 8.9(b) Union 3.20(aTerm 13.1 VAT 8.9(c) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Working Group 3.5

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections of this Agreement set forth opposite each section of the capitalized terms Agreement indicated below: Additional Approval Condition 3.4(bActive Development 3.3(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aRecitals Alliance Manager 3.1(a) AntiApplicant 7.5(a) Applicant Response 7.5(c) Base Conversion Fee 5.1(b)(i) Baseline Net Sales 1.46 Biosimilar Notice 7.5(a) BPCIA 7.5(a) Challenge Jurisdiction 5.3(e) Challenged Patent Rights 5.3(e) Challenge-Bribery Laws 3.22(cRelated Royalty Increase 5.3(e) Articles of Merger 2.4(aClawback Amount 5.3(e) Certificates 2.9(c)(iCombination 1.54 Conversion Fee 5.1(b)(ii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Conversion Request 2.1(a)(ii) Conversion Response 2.1(a)(ii) Disclosing Party 1.14 Disclosure Letter 1.4 Company Intellectual Property 3.17(b9.1(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Dispute 11.12 Effective Date Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b[***] Schedule A [***] Schedule A ImmunoGen Recitals ImmunoGen Indemnitees 10.1(a) Indemnified Party Proceeding 6.9(b10.2 Indemnifying Party 10.2 Infringed Patent List 7.5(e) Indemnified Persons 6.9(aInfringement 7.4(a) Labor Agreements 3.20(aInfringement Notice 7.4(a) Leased Real Property Leases 3.15(bJDC 3.2(a) Marks 1.1(kkkLosses 10.1(a) Maximum Premium 6.9(bMaterial Breach 8.2(b) Merger Negotiation Period 7.5(e) Novartis Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iNovartis Indemnitees 10.1(b) New Plans 6.9(aNovartis Response 7.5(d) Other Required Information 7.5(b) Party/Parties Recitals Permitted Third Party Service Providers 2.1(a) Proposed Biosimilar Product 7.5(a) Proposed Patent List 7.5(b) Proprietary Antibody 1.65 Receiving Party 1.14 Rejection Notice 5.4 Royalty Term 5.5 Term 8.1 Third Party Claims 10.1(a) Third Party Patent Rights 5.3(b) Third Party Payments 5.3(b) Upfront Fee 5.1(a) Wind-Down Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i8.3(a)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each the Agreement: Acquisition Transaction 17.8(b) Alliance Manager 3.8 Allowable Increases 4.5(b) Auditor 10.4 Beneficial Party 9.2(e) Change of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund Control 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent Claim 13.3 Commercialization Plan 6.2 Competing Program 2.9(a) Per Share Price 2.9(a)(iiiCompound Invention 11.1(b)(i) Proxy Holder Recitals Proxy Statement 6.3(aDevelopment Budget 4.2 Disputed Matter 16.2 Divest 2.8(c) Required Permits 3.20(cExcess Funds 4.5(a) Restraint 7.1(bExelixis Data 11.1(a) Rollover Exelixis Entity 17.8(a)(i)(1) Exelixis Indemnitee 13.2 Exelixis Only Development Work 4.5(e) Global Development Plan or GDP 4.2 Indemnitee 13.3 Indemnitor 13.3 Independent Work 4.3 Independent Work Cost 9.2(c) Initial Committed Studies 4.5(a) Injunctive Relief 16.3(b) Licensee Data 11.1(a) Licensee Indemnitee 13.1 Licensee Only Development Work 4.5(e) Joint Commercialization Committee or JDC 3.3 Joint Development Committee or JDC 3.2 Joint Steering Committee or JSC 3.1 Joint Inventions 11.1(b)(ii) Joint Patents 11.1(b)(ii) Losses 13.1 Materials 4.14 PV Costs 5.5 Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a5.6 Product Infringement 11.3(a) Statutory Merger Stockholder Approval 3.4(aProduct Marks 11.7(a) Statutory Stockholder Approvals 3.4(aPromotional Materials 6.4(c) Support Recall 5.10 Regulatory Meeting 5.4 Royalty Term 9.5(c) Sales Forecast 6.3(c) Sobi 5.2 Sobi Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b8.1 Sole Inventions 11.1(b)(ii) Termination Date 8.1(bStandstill Period 17.8(a) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iSunshine Reporting Laws 5.11 Supply Agreement 7.1 Supply Contacts 3.9 Term 15.1 TMC 5.2 Withholding Tax Action 10.3(c)

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given meaning ascribed to them such term in the respective Sections of this Agreement Article or Section set forth opposite each of the capitalized terms belowsuch term: Additional Approval Condition 3.4(bTerm Article/Section 2015 Financial Statements Agreement Arbitration Firm Assumed Contracts 4.4 Preamble 3.3(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a2.1(a)(vi) Anti-Bribery Term Article/Section Assumed Liabilities Basket Amount Bonus Amounts Bulk Sales Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Business Buyer Claim Dispute Notice Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Closing Working Capital Closing Payment Commencement Date Confidentiality Agreement Debt Payoff Amounts Direct Claim Notice Dispute Notice Drop Dead Date Employee Plan Estimated Working Capital Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Assets Excluded Liabilities Final Allocation Final Closing Payment Final Working Capital Financial Statements Fundamental Representations Governmental Authority Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Indemnifying Party Key Employee Latest Balance Sheet Leased Real Property Leases 3.15(b▇▇▇▇▇ Major Client Material Contracts Naficy Organizational Documents OSH Act Partners Party/Parties Permits Permitted Liens Post Closing Consideration Post Closing Period Preliminary Allocation Proposed Final Allocation Purchase Price Purchased Assets 2.2(a) Marks 1.1(kkk10.3(a) Maximum Premium 6.9(b7.5 11.14 Recitals Preamble 10.5 3.1 3.1 3.3(a) Merger Recitals Merger Sub 3.2(a) 7.8 7.2 7.4 10.5 3.4(d) 8.4 4.14(a) 3.2(b) 2.1(b) 2.2(b) 3.5 3.3(d) 3.3(b)(ii) 4.4 10.1 4.2(b) 10.4(a) 10.4(a) 4.13(a) 4.4 4.7 4.7 Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i4.21 4.10(a) New Plans 6.9(aPreamble 2.1(b)(iii) Notice Period 5.4(d)(ii)(34.13(f)(vi) Old Plans 6.9(aPreamble Preamble 4.19(b) Owned Company Shares 2.9(a)(ii4.8(a) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a3.5 3.5 3.2(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b2.1(a) Termination Date 8.1(bTerm Article/Section Seller Seller Intellectual Property Rights Seller Systems Third Party Claim Transferred Employees Transfer Taxes WARN Working Capital Statement Preamble 4.11(a) Trade Secrets 1.1(kkk4.11(e) Transaction Matters 9.11(a10.4(a) Uncertificated Shares 2.9(c)(ii7.8 9.3 4.13(f)(v) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i3.3(a)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each the Agreement: Acquisition Transaction 17.8(b) Alliance Manager 3.8 Allowable Increases 4.5(b) Auditor 10.4 Beneficial Party 9.2(e) Change of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund Control 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent Claim 13.3 Commercialization Plan 6.2 Competing Program 2.9(a) Per Share Price 2.9(a)(iiiCompound Invention 11.1(b)(i) Proxy Holder Recitals Proxy Statement 6.3(aDevelopment Budget 4.2 Disputed Matter 16.2 Divest 2.8(c) Required Permits 3.20(cExcess Funds 4.5(a) (a) Restraint 7.1(bExelixis Entity 17.8(a)(i)(1) Rollover [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Exelixis Indemnitee 13.2 Exelixis Only Development Work 4.5(e) Global Development Plan or GDP 4.2 Indemnitee 13.3 Indemnitor 13.3 Independent Work 4.3 Independent Work Cost 9.2(c) Initial Committed Studies 4.5(a) Injunctive Relief 16.3(b) Licensee Data 11.1(a) Licensee Indemnitee 13.1 Licensee Only Development Work 4.5(e) Joint Commercialization Committee or JDC 3.3 Joint Development Committee or JDC 3.2 Joint Steering Committee or JSC 3.1 Joint Inventions 11.1(b)(ii) Joint Patents 11.1(b)(ii) Losses 13.1 Materials 4.14 PV Costs 5.5 Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a5.6 Product Infringement 11.3(a) Statutory Merger Stockholder Approval 3.4(aProduct Marks 11.7(a) Statutory Stockholder Approvals 3.4(aPromotional Materials 6.4(c) Support Recall 5.10 Regulatory Meeting 5.4 Royalty Term 9.5(c) Sales Forecast 6.3(b) Sobi 5.2 Sobi Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b8.1 Sole Inventions 11.1(b)(ii) Termination Date 8.1(bStandstill Period 17.8(a) Trade Secrets 1.1(kkkSunshine Reporting Laws 5.11 Supply Agreement 7.1 Supply Contacts 3.9 Term 15.1 TMC 5.2 Withholding Tax Action 10.3(c) Transaction Matters 9.11(a[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) Uncertificated Shares 2.9(c)(iinot material and (ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)would be competitively harmful if publicly disclosed.

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) [***] [***] Agreement Preamble Alternative Acquisition Alliance Payments 8.3(a) Alliance Payments Report Exhibit 8.3 Annual Alliance Payment Forecast 8.3(e) Annual Royalty Payment Forecast 8.4(c) API 1.19 API Supply Agreement 5.4(a7.3(b) Anti[***] [***] AstraZeneca-Bribery ICR License Agreement 1.8 AstraZeneca-Sheffield License Agreement 1.8 Bankruptcy Laws 3.22(c12.7(b) Articles of Merger 2.4(aBlocking Intellectual Property 8.9(b) Certificates 2.9(c)(iBreaching Party 12.4(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Clinical Supply Agreement 7.1(a)(ii) Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bCombination Product Net Sales 8.4(a)(iii) Company Leased Real Property 3.15(bDevelopment Plan 4.2(c) Company Option 2.8(c)(iField License Agreement 8.9(b)(i) Company Owned Real Property 3.15(aIndemnitee 14.2 Company Infringement Proceeding 14.1(h) Company PSU 2.10(c)(iProduct Liability Proceeding 14.1(g) Company Recommendation 3.3(aProstate-Approved Single Agent Product Net Sales 8.4(a)(ii) Confidential 19 Combined Worldwide Prostate-Approved Single Agent Product Net Sales 8.4(a)(i) Company Recommendation Change 5.4(c)(iCombination Product Net Sales 8.4(a)(ii) Company RSU 2.10(a)(iProstate-Approved Single Agent Product Net Sales 8.4(a)(iii) Company SEC Reports 3.8(dRegistration Plan 5.2(c) Company Securities 3.7(bRegulatory Documentation 5.6(b) Company Special Trademarks 6.5(a) [***] [***] [***] [***] Compound API 7.3(a) CPR Rules 13.3 Cross-Indication License Agreement 8.9(b)(iii) Cure Period 12.4(a) Deadlocked Committee Recitals Company Stockholder Meeting 6.4(aMatter 2.1(d) Converted PSU Award 2.10(c)(iiDefending Party 14.3(d) Converted Restricted Share Award 2.10(bDevelopment Milestone 8.2(a) Converted RSU Award 2.10(a)(iiDevelopment Milestone Payment 8.2(a) Copyrights 1.1(kkkDevelopment Plans 4.2(c) Covenant Disclosing Party 11.1(a) Dispute(s) 13.1 [***] [***] Equitable Exceptions 5.1(a10.1(b) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xEscalation Procedures 2.1(d)(i) Effective Time 2.4(bDate Preamble FATCA 8.10(a) Electronic Delivery 9.13 Enforcement Expenses 8.3(dFirst Prostate Use Exhibit 8.3 Good Faith Dispute 9.4 ICH 1.57 Incremental Tax Cost 8.10(d) ExIndemnification Notice 14.3(a) Indemnifying Party 14.3(a) Indemnitee 14.3(a) Infringement Claim 9.6(a) Infringement Recovery 9.5(c) Insolvency Event 12.7(a) Insolvent Party 12.7(b) Joint Committee 2.6(a) Joint Inventions 9.1 Confidential 20 Joint Patents 9.3(e) JCC 2.3(a) JDC 2.2(a) JFC 2.5(a) JMC 2.4 JSC 2.1(a) Licensed Patents 10.2(b) Losses 14.1 Merck Milestone 8.2(d) Merck Milestone Payment 8.2(d) [***] [***] Milestone Events 8.2 Milestone Payments 8.2 Monotherapy Registration & Distribution Notice 5.3(b)(iii) [***] [***] Non-Im Laws 3.22(cInsolvent Party 12.7(b) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Non-Paying Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a8.10(d) Notice Period 5.4(d)(ii)(3Indication 4.3(b) Old Plans 6.9(aObjection 4.2(d)(iii) Owned Company Shares 2.9(a)(iiOfficials 10.5(b) Parent Preamble Party or Other Included Countries Exhibit 8.3 Party/Parties Preamble Patents 1.1(kkkPass-through AstraZeneca-ICR Royalty 8.4(b)(i)(2) Pass-through AstraZeneca-Sheffield Royalty 8.4(b)(i)(2) Pass-through Merck Royalty 8.4(b)(i)(1) Patent Extension(s) 9.4 Paying Party 8.10(d) Payment 10.5(b) [***] [***] Potential Recall Notice 5.9(a) Pricing Terms 6.2(d)(i) Prior CDA 1.32 Proceeding 14.1 [***] [***] [***] [***] [***] [***] Promotional Materials 6.8 Prostate-Approved Single Agent 2.9(aProduct 8.4(a)(iv) Per Share Price 2.9(a)(iiiProstate-Approved Single Agent Product Net Sales 8.4(a)(v) Proxy Holder Recitals Proxy Statement 6.3(aConfidential 21 Prostate Sales Allocation Factor Exhibit 8.3 Protocol 13.3(b)(iii) Required Permits 3.20(cPVA 5.7(c) Restraint 7.1(bReceiving Party 11.1(a) Rollover Redactable Information 4.2(f)(ii) Related Indemnitees 14.3(a) Registration Plans 5.2(c) Regulatory Milestone 8.2(b) Regulatory Milestone Payment 8.2(b) Residual Allocation Methodology Exhibit 8.3 Residual Prostate Sales Allocation Factor Exhibit 8.3 Reverted Single Agent Product 12.9(a)(ii) Reviewing Party 4.2(d)(i) [***] [***] [***] [***] Royalty Payment Report 8.7 Royalty Tier 8.4(a)(i) Sales Milestone 8.2(c) Sales Milestone Payment 8.2(c) [***] [***] Shared Third Party Obligations 8.9(e) Single Agent Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a12.9(a)(vi) Statutory Merger Stockholder Single Agent Regulatory Approval 3.4(a12.9(a)(iii) Statutory Stockholder Approvals 3.4(aSingle Agent Technology 12.9(a)(ii) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bSole Inventions 9.1 [***] [***] [***] [***] Term 12.1 Terminating Party 12.4(a) Termination Effective Date 8.1(b12.9 Termination Notice Date 12.9 Territory-Wide Company Combination Product Net Sales 8.4(a)(vi) Trade Secrets 1.1(kkkTerritory-Wide Prostate Net Sales 8.4(a) Transaction Matters 9.11(aTESARO Preamble TESARO Development Plan 4.2(c) Uncertificated Shares 2.9(c)(iiTESARO Field License Agreement 8.9(b)(ii) Union 3.20(aTESARO Incremental Royalty 8.4(b)(ii) Vested Company PSU 2.10(c)(iTESARO Indemnitee 14.1 TESARO Infringement Proceeding 14.2(h) Vested Company RSU 2.10(a)(i)Confidential 22 TESARO Prostate-Approved Single Agent Product Net Sales 8.4(a)(viii) TESARO Registration Plan 5.2(c) TESARO Regulatory Documentation 5.6(a) TESARO Trademarks 6.5(b) Third Party Development Report 4.2(h) Third Party Patent Challenge 9.7(b) [***] [***] [***] [***]

Additional Definitions. The following capitalized terms have the respective meanings given to them are defined in the respective Sections of this Agreement set forth opposite each of across from such term in the capitalized terms belowfollowing table: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAlternate Transaction 8.17 Assumed Liabilities 2.3 Break-Up Fee 8.17 Business Employee 5.11(a) Anti-Bribery Laws 3.22(cBuyer Preamble Buyer Applications 8.9(a) Articles of Merger 2.4(aChosen Courts 12.12 Claim Notice 9.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bPayment 3.2(a)(i) Company Leased Real Property 3.15(bContinuing Employees 8.1(i) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(aCustomer 8.2(b) Data Privacy/Security Requirements 3.17(gConverter 8.3(a) Effect 1.1(xEmployee Data Schedule 5.11(a) Effective Time 2.4(bEmployee Plans 5.11(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(bEnd Date 11.1(e) Excluded Arrangements 6.10(aAssets 2.2 Excluded Contracts 2.2(b) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bExcluded Liabilities 2.4 Expense Reimbursement 8.17 Financial Statements 6.8 IOU Prescriptions 8.4 Incentive Plan 8.1(f) Indemnified Party Proceeding 6.9(bPerson 9.4(a) Indemnified Persons 6.9(aIndemnitor 9.4(a) Labor Agreements 3.20(aIndependent Valuator 3.3 Inventory 2.1(c) Leased Real Inventory Amount 3.3 Inventory Audit 3.3 Landlord Estoppel Certificates 8.14 Negative Inventory Adjustment Amount 3.1 Non-Operate Location Pharmacies Preamble Nyer Preamble Nyer Fundamental Representations 9.2(a) Nyer Parties 8.2(a) Nyer Shareholder Approval 6.4 Operate Location Pharmacies Preamble Operations Data 5.5 Other Financial Data 6.8 Parata Equipment 5.9 Payment Programs 5.14(c)(i) Permits 5.14(a) Personal Property Leases 3.15(b2.1(a) Marks 1.1(kkkPharmacies Preamble PHI 8.3(c) Maximum Premium 6.9(bPower of Attorney 8.9(c) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iPrepaid Rent Amount 3.4 Prorated Charges 12.7 Purchase Price 3.1 Purchased Assets 2.1 Record Data 8.3(a) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iRecords 2.1(b)

Additional Definitions. The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b401(k) Plan 6.10(f) Advisor 3.3(c) Agreement Preamble Alternative Acquisition Agreement 5.4(a5.3(a) Anti-Bribery Laws 3.22(cBuyer Parties Preamble Bylaws 3.1 Capitalization Date 3.7(a) Articles Certificate of Merger 2.4(a) 2.2 Certificates 2.9(c)(i2.9(c) Charter Amendment Effective Time 2.5(a) Chosen Courts 9.10 Closing 2.3 Closing 2.5 Closing Date 2.5 2.3 Collective Bargaining Agreement 3.19(a) Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Board Recommendation 3.3(a) Company Board Recommendation Change 5.4(c)(i5.3(c)(i) Company Disclosure Letter Article III Company Equity Awards 3.18(j)3.7(b) Company Incentive Programs 6.10(f) Company Option Consideration 2.8(e) Company PSA Consideration 2.8(b) Company PSU Consideration 2.8(d) Company RSA Consideration 2.8(a) Company RSU 2.10(a)(iConsideration 2.8(c) Company SEC Reports 3.8(d) 3.9 Company Securities 3.7(b3.7(c) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(iiCompany Termination Fee 8.3(b)(i) Converted Restricted Share Award 2.10(bConfidentiality Agreement 9.4 Consent 3.6 Copyrights 1.1(oo) Converted RSU Award 2.10(a)(iiD&O Insurance 6.9(c) Copyrights 1.1(kkkDCP 6.10(g) Covenant Exceptions 5.1(aDebt Financing 6.5(a) Data Privacy/Security Requirements 3.17(gDebt Offer 6.5(c) DGCL Recitals Discharge 6.5(c) Dissenting Company Shares 2.7(c)(i) DTC 2.9(d) DTC Payment 2.9(d) ▇▇▇▇▇ 3.9 Effect 1.1(x1.1(p) Effective Time 2.4(b) 2.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(dEmployee Plan 3.18(a) Ex-Im Laws 3.22(cEnforceability Limitations 3.2 ePrivacy Directive 1.1(bb) ERISA Affiliate 3.18(a) Exchange Fund 2.9(b) Excluded Arrangements 6.10(aGDPR 1.1(bb) FHWA 3.21(bGo Shop Period 5.3(a) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(bGovernment Closure 6.2(a) Indemnified Persons 6.9(a) Labor Agreements 3.20(aIntervening Event 5.3(d)(i) IP Contracts 3.16(b) Lease 3.14(b) Leased Real Property Leases 3.15(b3.14(b) Marks 1.1(kkk1.1(oo) Material Relationships 1.1(ss)(ii) Maximum Annual Premium 6.9(b6.9(c) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a6.10(d) No Shop Period Start Date 5.3(a) Notice Period 5.4(d)(ii)(35.3(d)(ii)(3) Old Plans 6.9(a6.10(d) Other Required Company Filing 6.3(b) Other Required Parent Filing 6.3(d) Owned Company Shares 2.9(a)(iiShare 2.7(a)(iii) Owned Real Property 3.14(a) Parent Preamble Party or Parties Preamble Patents 1.1(kkkParent 401(k) Payment Agent 2.9(aPlan 6.10(f) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Parent Disclosure Letter Article IV

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) AAA 12.2.3 Agreement Preamble Alternative Acquisition Arbitration Request 12.2.1 Approval Reimbursement Event 3.1.2.(c)(i)(2) Audit Opinion 6.6 Audited Financial Statements 6.6 Breaching Party 11.2 Clinical Site Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x1.3.6 Development Plan 3.1.1 Disclosing Party 1.10 DUO Reimbursement Event 3.1.2.(c)(i)(1) Effective Time 2.4(bDate Preamble Existing Confidentiality Agreement 1.10 Existing IPI-145 Product 6.1.1(d) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bExisting Patents 9.2.4 Headlicense Breach 2.5.5 Holdback Payment 3.1.2(b) Indemnified Party Proceeding 6.9(b10.3 Indemnifying Party 10.3 Independent Auditor 6.6 INFI Preamble INFI Acquirer 12.6.1 INFI Pre-Existing Affiliates 12.6.1 Initiating Party 7.6 INK 1.37 INK ▇▇▇▇ 7.8.1 Infringed Patent Right 6.1.1(d) Indemnified Persons 6.9(aInsurance Period 10.6.1 Joint Know-How 7.2 Joint Patent Rights 7.2 Licensee Preamble Licensee Common Stock 3.1.2(c)(ii) Labor Agreements 3.20(aLicensee Acquirer 12.6.2 Licensee Pre-Existing Affiliates 12.6.2 Losses 10.1 MICL 1.56 MICL Repayment Amount 6.1.3(b)(i) Leased Real Property Leases 3.15(bMICL Royalty Payment 6.1.3(b)(i) Marks 1.1(kkkMICL Trailing Royalty Payment 6.1.3(c) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Non-Breaching Party 11.2 Paragraph IV Certification 7.4 Party or Parties Preamble Patents 1.1(kkkPatent Term Extensions 7.9.1 Product ▇▇▇▇ 2.5.1 Prosecution Patent Rights 7.3.1(a) Purdue 1.56 Purdue Repayment Amount 6.1.3(b)(ii) Purdue Royalty Payment Agent 2.9(a6.1.3(b)(ii) Per Share Price 2.9(a)(iiiReceiving Party 1.11 Registration Statement 3.1.2(c)(iv) Proxy Holder Recitals Proxy Statement 6.3(aReimbursable Amount 3.1.2(c)(i) Required Permits 3.20(cReimbursement Announcement Date 3.1.2(c)(i) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Reimbursement Notice 3.1.2(c)(i) 2.1 Reviewing Party 8.5 Royalty Termination Date 8.1(b6.1.1(b) Trade Secrets 1.1(kkkSEC 3.1.2(c)(iv) Transaction Matters 9.11(aSEC Financial Statements 6.6 Securities Act 3.1.2(c)(ii) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Superseded Agreement Preamble Term 11.1 Third Party Infringement 7.4 Transition Plan 3.2.1 Transition Period 3.2.1 Unaudited Financial Statements 6.6 U.S. GAAP 1.58

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this the Agreement: Alliance Manager 2.1 [*] Indication [*] [*] Advance Invoice 11.3(c)(i) [*] [*] [*] [*] [*] True-Up Report 11.3(c)(ii) [*] Development Work [*] [*] Date [*] [*] Products 14.3(a) Astellas [*] [*] Astellas Co-Promotion Notice 9.6(b)(i) Astellas Indemnitee [*] Astellas [*] [*] Astellas [*] [*] Astellas [*] [*] Bankruptcy Code 3.8 Combination Product 1.68 Commercial Operating Team 9.7 Commercialization Plan 9.3(a) [*] [*] Co-Promotion Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b9.6(g) Agreement Preamble Alternative Acquisition Agreement 5.4(a[*] [*] Co-Promotion Matters 9.6(b)(i) AntiCY 5012 11.5(c)(i) Cytokinetics Co-Bribery Laws 3.22(cFunding Option 4.1(b) Articles of Merger 2.4(aCytokinetics Co-Promotion Effort 9.6(c) Certificates 2.9(c)(iCytokinetics Co-Promotion Recommendation 9.6(b)(ii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bCytokinetics [*] [*] Cytokinetics Indemnitee 16.2 Cytokinetics [*] [*] Cytokinetics [*] [*] Cytokinetics Product Marks 12.5(b) Company Leased Real Property 3.15(bCytokinetics Research FTEs 5.3 Cytokinetics [*] [*] Cytokinetics [*] [*] Development Advance Invoice 11.3(a)(i) Company Option 2.8(c)(iDevelopment Plan 6.2(a) Company Owned Real Property 3.15(aDevelopment Program 6.2(a) Company PSU 2.10(c)(iDevelopment Project Team 6.10 Development True-Up Report 11.3(a)(ii) Company Recommendation 3.3(aDisclosing Party 13.1(a) Company Recommendation Change 5.4(c)(i[*] [*] Earlier Milestone Event 11.5(b)(i) Company RSU 2.10(a)(iEarly Stage Work 6.3(b)(ii) Company SEC Reports 3.8(dEstablished Commercial Infrastructure 9.9 [*] [*] [*] Indication [*] [*] [*] FCPA 17.7(a) Company Securities 3.7(bFCPA Covered Person 17.7(a) Company Special Committee Recitals Company Stockholder Meeting 6.4(aFederal Arbitration Act 17.6(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) [*] [*] Indemnified Party Proceeding 6.9(b16.3 Indemnifying Party 16.3 [*] Rules 17.6(a) Indemnified Persons 6.9(aJCC Determination 9.6(b)(ii) Labor Agreements 3.20(aJoint Commercialization Committee or JCC 2.6 Joint Development Committee or JDC 2.4 Joint Manufacturing Committee or JMC 2.5 Joint Medical Affairs Committee or JMAC 2.7 Joint Patent Committee or JPC 2.8 Joint Research Committee or JRC 2.3 Joint Steering Committee or JSC 2.2 [*] Regulatory Materials 7.2(a) Leased Real Property Leases 3.15(bLater Milestone Event 11.5(b)(i) Lead Compound [*] [*] Lead Compound [*] [*] [*] Products [*] Medical Affairs Plan 10.3 MSL 10.1 [*] [*] Neuromuscular Indications 9.6(a) [*] [*] [*] [*] Pharmacovigilance Agreement 7.5 Phase 1 Work 6.3(b)(i) [*] [*] [*] [*] Product Infringement 12.4(a) Product Marks 1.1(kkk12.5(a) Maximum Premium 6.9(bReceiving Party 13.1(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iRemainder 12.4(f) New Plans 6.9(aRemedial Action 7.7 Research Advance Invoice 11.2(a) Notice Period 5.4(d)(ii)(3Research Budget 5.3 Research Plan 5.3 Research Plan Costs 5.6 Research Program 5.1 Research Project Team 5.9 Research Term 5.2 Research True-Up Report 11.2(b) Old Plans 6.9(aResponsible Committee 13.4 [*] Product [*] [*] [*] Royalty Term 11.7(b) Owned Company Shares 2.9(a)(ii[*] [*] SEC 13.5(b) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Term 14.1

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) AAA 12.2.3 Agreement Preamble Alternative Acquisition Arbitration Request 12.2.1 Approval Reimbursement Event 3.1.2.(c)(i)(2) Audit Opinion 6.6 Audited Financial Statements 6.6 Breaching Party 11.2 Clinical Site Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x1.3.6 Development Plan 3.1.1 Disclosing Party 1.10 DUO Reimbursement Event 3.1.2.(c)(i)(1) Effective Time 2.4(bDate Preamble Existing Confidentiality Agreement 1.10 Existing IPI-145 Product 6.1.1(d) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bExisting Patents 9.2.4 Headlicense Breach 2.5.5 Holdback Payment 3.1.2(b) Indemnified Party Proceeding 6.9(b10.3 Indemnifying Party 10.3 Independent Auditor 6.6 INFI Preamble INFI Acquirer 12.6.1 INFI Pre-Existing Affiliates 12.6.1 Initiating Party 7.6 INK 1.37 INK Mark 7.8.1 Infringed Patent Right 6.1.1(d) Indemnified Persons 6.9(aInsurance Period 10.6.1 Joint Know-How 7.2 Joint Patent Rights 7.2 Licensee Preamble Licensee Common Stock 3.1.2(c)(ii) Labor Agreements 3.20(aLicensee Acquirer 12.6.2 Licensee Pre-Existing Affiliates 12.6.2 Losses 10.1 MICL 1.56 MICL Repayment Amount 6.1.3(b)(i) Leased Real Property Leases 3.15(bMICL Royalty Payment 6.1.3(b)(i) Marks 1.1(kkkMICL Trailing Royalty Payment 6.1.3(c) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Non-Breaching Party 11.2 Paragraph IV Certification 7.4 Party or Parties Preamble Patents 1.1(kkkPatent Term Extensions 7.9.1 Product Mark 2.5.1 Prosecution Patent Rights 7.3.1(a) Purdue 1.56 Purdue Repayment Amount 6.1.3(b)(ii) Purdue Royalty Payment Agent 2.9(a6.1.3(b)(ii) Per Share Price 2.9(a)(iiiReceiving Party 1.11 Registration Statement 3.1.2(c)(iv) Proxy Holder Recitals Proxy Statement 6.3(aReimbursable Amount 3.1.2(c)(i) Required Permits 3.20(cReimbursement Announcement Date 3.1.2(c)(i) Restraint 7.1(bReimbursement Notice 3.1.2(c)(i) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Representatives 8.2.1 Reviewing Party 8.5 Royalty Termination Date 8.1(b6.1.1(b) Trade Secrets 1.1(kkkSEC 3.1.2(c)(iv) Transaction Matters 9.11(aSEC Financial Statements 6.6 Securities Act 3.1.2(c)(ii) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Superseded Agreement Preamble Term 11.1 Third Party Infringement 7.4 Transition Plan 3.2.1 Transition Period 3.2.1 Unaudited Financial Statements 6.6 U.S. GAAP 1.58

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this the Agreement: Acquisition Transaction 16.8(b) Alliance Manager 3.7 Allowable Increases 4.5(a) Auditor 9.4 Beneficial Party 8.2(d) Budget Cap 4.5(a) Claim 12.3 Collaborative Work 4.5(a) Collaborator Data 10.1(a) Collaborator Indemnitee 12.1 Collaborator Local Development Work 4.5(c) Commercialization Plan 6.2 Competing Program 2.8(a) Compound Invention 10.1(b)(i) Development Budget 4.2(b) Developing Party 4.3 Disputed Matter 15.2 Divest 2.8(b) (a) Exelixis Entity 16.8(a)(i)(1) Exelixis Indemnitee 12.2 Exelixis Local Development Work 4.5(c) First Full Calendar Year 6.3(b) First Generic Entry 2.8(a) Global Development Plan or GDP 4.2(a) Indemnitee 12.3 Indemnitor 12.3 Independent Work 4.3 Independent Work Cost 8.2(b) Injunctive Relief 15.3(b) Joint Commercialization Committee or JCC 3.3 Joint Development Committee or JDC 3.2 Joint Executive Committee or JEC 3.1 Joint Inventions 10.1(b)(ii) Joint Patents 10.1(b)(ii) Local Regulatory Requirement 3.5(b)(i)(2) Losses 12.1 Materials 4.14 Minimum Commercial Performance 6.3(b) Minimum Commercial Performance Period 6.3(b) Newly-Proposed Development 4.3 Non-Developing Party 4.3 PV Costs 5.5(c) Pharmacovigilance Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b5.5(a) Previously Achieved Sales Milestone 8.4(a) Product Infringement 10.4(a) Product Marks 10.8(a) Promotional Materials 6.4(c) Proposal 4.3 Quality Agreement Preamble Alternative Acquisition 7.1 Recall 5.9 Regulatory Meeting 5.3 Remaining Royalty Term 8.5(d) Responding Party 13.4(a) Royalty Term 8.5(c) Rules 15.3(a) Sole Inventions 10.1(b)(ii) Standstill Period 16.8(a) Submitting Party 13.4(a) Sunshine Reporting Laws 5.10 Supply Agreement 5.4(a7.1 Supply Contacts 3.8 Term 14.1(a) Anti-Bribery Laws 3.22(cUnaffiliated Third Party 2.8(a) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWithholding Tax Action 9.3(c)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of the Agreement: Acquisition Transaction 16.8(b) Alliance Manager 3.7 Allowable Increases 4.5(a) Auditor 9.4 Beneficial Party 8.2(d) Budget Cap 4.5(a) Claim 12.3 Collaborative Work 4.5(a) Collaborator Data 10.1(a) Collaborator Indemnitee 12.1 Collaborator Local Development Work 4.5(c) Commercialization Plan 6.2 Competing Program 2.8(a) Compound Invention 10.1(b)(i) Development Budget 4.2(b) Developing Party 4.3 Disputed Matter 15.2 Divest 2.8(b) (a) Exelixis Entity 16.8(a)(i)(1) Exelixis Indemnitee 12.2 Exelixis Local Development Work 4.5(c) First Full Calendar Year 6.3(b) First Generic Entry 2.8(a) Global Development Plan or GDP 4.2(a) [ * ] = Certain confidential information contained in this Agreement set forth opposite each document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the capitalized terms below: Additional Approval Condition 3.4(bSecurities Exchange Act of 1934, as amended. Indemnitee 12.3 Indemnitor 12.3 Independent Work 4.3 Independent Work Cost 8.2(b) Injunctive Relief 15.3(b) Joint Commercialization Committee or JCC 3.3 Joint Development Committee or JDC 3.2 Joint Executive Committee or JEC 3.1 Joint Inventions 10.1(b)(ii) Joint Patents 10.1(b)(ii) Local Regulatory Requirement 3.5(b)(i)(2) Losses 12.1 Materials 4.14 Minimum Commercial Performance 6.3(b) Minimum Commercial Performance Period 6.3(b) Newly-Proposed Development 4.3 Non-Developing Party 4.3 PV Costs 5.5(c) Pharmacovigilance Agreement Preamble Alternative Acquisition 5.5(a) Previously Achieved Sales Milestone 8.4(a) Product Infringement 10.4(a) Product Marks 10.8(a) Promotional Materials 6.4(c) Proposal 4.3 Quality Agreement 5.4(a7.1 Recall 5.9 Regulatory Meeting 5.3 Remaining Royalty Term 8.5(d) Anti-Bribery Responding Party 13.4(a) Royalty Term 8.5(c) Rules 15.3(a) Sole Inventions 10.1(b)(ii) Standstill Period 16.8(a) Submitting Party 13.4(a) Sunshine Reporting Laws 3.22(c5.10 Supply Agreement 7.1 Supply Contacts 3.8 Term 14.1(a) Articles Unaffiliated Third Party 2.8(a) Withholding Tax Action 9.3(c) [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company the Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Act of 1934, as amended.

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections of this Agreement set forth opposite each section of the capitalized terms Agreement indicated below: Abbreviated Financial Statements 6.9.1 Active Development 4.1.2 ADC Platform Technology 1.2 Additional Approval Condition 3.4(bDevelopment Activities 6.2.2(a) Additional Development Activities Budget 6.2.2(a) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Recitals Alliance Managers 3.1.1 Anti-Bribery Corruption Laws 3.22(c12.4 Applicant 9.5.2 Applicant Response 9.5.3(b) Articles of Merger 2.4(aArbitration 14.13.2(a) Certificates 2.9(c)(iAudited Party 6.8.2 Base Budget 1.84 Base Development FTE Rate 1.29 Biosimilar Application 9.5.1 BLA Notice 7.1 Burdened Technology Agreement 6.2.3 Burdened Technology Obligations 1.8 Burdened Technology Payments 6.2.3 Challenge Jurisdiction 6.4.6 Challenged Patent Rights 6.4.6 [***] [***] [***] [***] Clinical and Regulatory Transfer Plan 4.6 CMC 1.30(f) Charter Amendment Combination 1.87 Competing Program 2.3.2 Covered Results 8.3 Development Costs Report 6.2.1 Development Plan Budget 1.31 Disclosing Party 1.20 Dispute 14.13.1 Divestiture 2.3.2 DOJ 14.16.1 Exchange Act 6.9.1 Financial Statements 6.9.1 FTC 14.16.1 Immediate Patent Infringement Action 9.5.3(d) ImmunoGen Recitals ImmunoGen Indemnitees 13.1.1 ImmunoGen Product Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) 11.1 ImmunoGen’s Qualified Counsel 9.5.2 ImmunoGen Royalty Term 11.3.1 ImmunoGen Third Party Payments 11.3.2 Improvement 1.2 Indemnified Party Proceeding 6.9(b13.2 Indemnifying Party 13.2 Infringement 9.4.1 Infringement Notice 9.4.1 Infringed Patent List 9.5.3(d) Indemnified Persons 6.9(aInitial Patent List 9.5.3(a) Labor Agreements 3.20(aInspected Party 4.1.5 Inspecting Party 6.8.2 Jazz Recitals Jazz Indemnitees 13.1.2 Jazz Response 9.5.3(c) Leased Real Property Leases 3.15(bJDC 3.3.1 JIPC 3.4 JSC 3.2.1 [***] [***] [***] [***] Losses 13.1.1 Monies 9.4.7 Option Agreement Effective Date 1.16 Party/Parties Recitals Permitted Third Party Service Providers 2.1.4 Premarket Notice 9.5.4(b) Marks 1.1(kkkProduct Patent Claims 1.92 Proposed Biosimilar Product 9.5.1 Proposed Initial Patent List 9.5.3(a) Maximum Premium 6.9(bProposed Jazz Response 9.5.3(c) Merger Receiving Party 1.20 Reference Year 1.84 Representatives 1.20 Royalty Term 6.5 [***] [***] [***] [***] SEC 8.2.3 SEC Documents 6.9.1 Securities Act 6.9.1 Senior Officers 14.13.1 Signing Date Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iTechnology Transfer Plan 5.2 Term 10.1 Third Party Claims 13.1.1 Third Party Payments 6.4.2 Tribunal 14.13.2(a) New Plans 6.9(a) Notice Unauthorized Use 4.5 US GAAP 6.9.1 Wind-Down Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)10.6.2

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b1974 Convention 13.1 AAA 12.3(a) Agreement Preamble Alternative Acquisition Alliance Manager 2.6 * Confidential Treatment Requested. Omitted portions filed with the Commission. Bankruptcy Code 11.2(e) Breaching Party 11.2(b) Challenging Party 11.2(d) Collaborator 2.8 Competitive Infringement 8.4(a) Confidential Information 9.1 Controlling Party 8.3(a) Core Development Plan 4.2(a) Core Dyax Patent Rights 8.3(a) Dyax Preamble Dyax Indemnified Party 10.10(a) Dyax Sole Inventions 8.2(a) Dyax Supply Agreement 5.4(a6.3(a) AntiEffective Date Preamble EU Commercialization Opportunity 3.1(f) Existing Dyax Patent Rights 10.7(b) Fovea Preamble Fovea-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Assigned Intellectual Property 3.17(b8.1 Fovea-Assigned Patent Rights 10.8(a) Company Leased Real Property 3.15(bFovea Indemnified Party 10.10(b) Company Option 2.8(c)(iFovea Sole Inventions 8.2(a) Company Owned Real Property 3.15(aFovea Supply Agreement 6.3(a) Company PSU 2.10(c)(iFovea Trademarks 8.8(b) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bGlobal Trademarks 8.8(b) Indemnified Party Proceeding 6.9(b10.10(c)(i) Indemnified Persons 6.9(aIndemnifying Party 10.10(c)(i) Labor Agreements 3.20(aInitial Enforcement Rights Party 8.4(c) Leased Real Property Leases 3.15(bInitial Finished Product 2.8 Initial Notice 3.1(f) Marks 1.1(kkkJoint Inventions 8.2(b) Maximum Premium 6.9(bJSC 2.1(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iLosses 10.10(a) New Plans 6.9(aNon-Breaching Party 11.2(b) Notice Period 5.4(d)(ii)(3Prosecuting Party 8.3(d) Old Plans 6.9(a[*****] 1.54 Royalty Term 7.1(d) Owned Company Shares 2.9(a)(ii[*****] 4.2(a) Parent Preamble Promotional Materials 5.3 Research and Option Agreement Introduction Secondary Enforcement Rights Party or Parties Preamble Patents 1.1(kkk8.4(c) Payment Agent 2.9(aSevered Clause 13.3 Sole Inventions 8.2(a) Per Share Price 2.9(a)(iiiSpecifications Exhibit E Supplemental Development Plan 4.2(a) Proxy Holder Recitals Proxy Statement Supply Agreement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)* Confidential Treatment Requested. Omitted portions filed with the Commission. Technology 2.8 Term 11.1 Third Party Collaboration Agreements 2.8 Working Group 2.2

Additional Definitions. The following capitalized Capitalized terms used but not otherwise defined in this Agreement or Exhibit 1.13 shall have the respective meanings given meaning ascribed to them in the respective Sections Alliance Agreement, it being agreed that references to a Licensed Product in such definitions shall, for purposes of this Agreement, be deemed to be references to a Co-Co Product, and shall apply to the Parties to this Agreement, mutatis mutandis. Each of the following definitions is set forth in the section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bADB 2.1(a) Administration Costs Exhibit 1.13 Agreement Preamble Alternative Acquisition Allergan Preamble Allergan Indemnitees 9.2 Alliance Agreement 5.4(aRecitals Allocable Manufacturing Overhead Exhibit 1.13 Allowable Expenses Exhibit 1.13 Annual Update 2.2(b)(ii) AntiAPIL Recitals Balancing Statement Exhibit 1.13 Biosimilar Product Exhibit 1.13 Change in Tax Treatment Event 8.4 Claims 9.1(a) Clinical Plan 2.2(b)(i) Clinical Sub-Bribery Laws 3.22(cTeam 2.1(b)(iii) Articles CMC 2.1(b)(ii) Code 8.4 Collaboration Exhibit 1.13 Commercialization Budget 3.2 Commercialization Costs Exhibit 1.13 Core Team 2.1(b)(i) Core Team Chairperson 2.1(b)(ii) Core Team Members 2.1(b)(ii) Cost of Merger 2.4(aGoods Exhibit 1.13 CPI Exhibit 1.13 CWG 3.1 Designated Individual 8.4 Detail Exhibit 1.13 Detail Rate Exhibit 1.13 Development Budget 2.2(b)(i) Certificates 2.9(c)(iDevelopment Costs Exhibit 1.13 Development Labor Costs Exhibit 1.13 Development Plan 2.2(b)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Distribution/Warehousing Costs Exhibit 1.13 Editas Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xEditas Indemnitee 9.1(a) Effective Time 2.4(bDate Preamble Executives 11.2 FTE Exhibit 1.13 FTE Rate Exhibit 1.13 Fully Burdened Manufacturing Costs Exhibit 1.13 IND Transfer 2.1(b)(iv)(7) Electronic Delivery 9.13 Enforcement Expenses 8.3(dIndustry Expert 5.3(c) Ex-Im Laws 3.22(cInitial Development Plan and Budget 2.2(b)(i) Exchange Fund 2.9(bIntended Tax Treatment 8.4 Interim Amendment 2.2(b)(iii) Excluded Arrangements 6.10(aJFT 2.1(b)(iii) FHWA 3.21(bLosses 9.1(a) Financing 6.5(aMarketing Costs Exhibit 1.13 Marketing Labor Costs Exhibit 1.13 NTS 2.1(b)(ii) FMCSA 3.21(bOther Operating Income/Expense Exhibit 1.13 Other Overrun Cost 5.3(b) Indemnified Party Proceeding 6.9(bOverrun Cost 5.3(a) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPartnership Representative 8.4 Party Preamble Profit and Loss Exhibit 1.13 Profit Sharing Date 4.1 Regulatory Plan 2.2(f) Payment Agent 2.9(aRoyalty & Milestone Payments Exhibit 1.13 Sales Exhibit 1.13 Sales Costs Exhibit 1.13 Sales Force Costs Exhibit 1.13 Sub-Teams 2.1(b)(iii) Per Share Price 2.9(a)(iiiSubcontractors 2.2(d) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Successor-in-Interest 12.2 Technology Transfer 4.1 Term 10.1

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Acquired Person 1.19 [***] [***] [***] [***] Acquisition Transaction 11.5.1 Active Immunotherapeutic Approaches 4.2.1 Additional Approval Condition 3.4(bCelgene Data Package 2.1.2(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aEnd of Phase 1 Date 1.35 Assigned Patents 6.6.5(a) AntiCelgene Preamble Celgene Acquired Competing Antibody 4.5.2 (a) Celgene Antibody Patents 1.15(b) Celgene Decision Date 2.1.2(e) Celgene Exclusivity Term 4.5.1 Celgene Indemnitees 9.2 Celgene Phase 1 Know-Bribery Laws 3.22(cHow 2.2.3(d) Articles of Merger 2.4(aCelgene Phase 1 Portion Participation Right 2.2.3(b) Certificates 2.9(c)(i[***] [***] Celgene Research Activities 2.1.2(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bCelgene Research Plan 2.1.2(a) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) [***] [***] Celgene Third Party Payments 5.2.4 Combination Product 1.63 Competing Antibody 4.5.1 Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.8.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.12 Effective Date Preamble EMA 1.81 Excluded Claim 11.8.3(d) Ex-Im Existing Regulatory Materials 2.5.3 FDA 1.81 Financial Transparency Laws 3.22(c11.17 First Sales Milestone Event 5.4.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) Exchange Fund 2.9(bNOT MATERIAL AND (II) Excluded Arrangements 6.10(aIS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. First Subsequent Regulatory Milestone 5.3.1 First Subsequent Sales Milestone 5.4.1 First U.S. Approval Milestone 5.3.1 Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 [***] [***] HIPAA 1.5 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.5.2(b) FHWA 3.21(bInitial Celgene Data Package 2.1.2(a) Financing 6.5(aInsolvency Event 10.4 JDC 2.4.2(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Joint IP 6.6.4

Additional Definitions. The following capitalized terms have the respective meanings given to them set forth in the respective corresponding Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b“Action” 12.2.1 “Acquirer Competing Product” 2.3.1(c) Agreement “Acquiring Third Party” 2.3.1(c) “Agreement” Preamble Alternative Acquisition Agreement 5.4(a) “Anti-Bribery Laws 3.22(cLaws” 11.1.5 [***]Confidential Information, indicated by [***], has been omitted by this filing and filed separately with the Securities and Exchange Commission. “Audited Party” 7.7.2 “Blocking Patent Claims” 8.3.3(b) Articles “Breaching Party” 10.2.1(a) “Co-Chairperson” 4.1.1(b) “Commercialization Plan” 6.3 “Date of Merger 2.4(aNotice” 10.2.1(a) Certificates 2.9(c)(i“Disclosing Party” 9.1 “Divested Product” 2.3.2(b)(1) Charter Amendment “Early Termination” 10.3.1(b) “Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Date” Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b“Efficacy Failure” 10.4.1 “embodiments of intellectual property” 10.5 “Forendo Acquirer” 2.3.2(b) Company Leased Real Property 3.15(b“Forendo Acquirer Generic Competing Product” 2.3.2(b)(2) Company Option 2.8(c)(i“Forendo Acquirer Competing Product” 2.3.2(b) Company Owned Real Property 3.15(a“Forendo Election Deadline” 2.3.2(b)(1) Company PSU 2.10(c)(i“Forendo Indemnitees” 11.5.1 “Forendo” Preamble “Generic Entry” 7.4.2 “Indemnitee” 11.5.3 “Infringement Claim” 8.3.1 [***]Confidential Information, indicated by [***], has been omitted by this filing and filed separately with the Securities and Exchange Commission. “Infringement Defense Costs” 8.3.3(c) Company Recommendation 3.3(a“IP” 10.5 “Joint Collaboration Patents” 8.1.1(b) Company Recommendation Change 5.4(c)(i“Joint Steering Committee” 4.1.1 “JSC” 4.1.1 “Licensee” Preamble “Licensee Election Deadline” 2.3.1(c) Company RSU 2.10(a)(i“Licensee Indemnitees” 11.5.2 “Losses” 11.5.1 “Milestone Event” 7.3 “Milestone Payment” 7.3 “Obligations” 12.18.1 “Orange Book” 1.48 “Party” Preamble “Post-Approval Termination” 10.3.1(c) Company SEC Reports 3.8(d“Product Records” 5.4 “Receiving Party” 9.1 “Safety Failure” 10.4.1 “Term” 10.1 “Transition Assistance” 3.1.2 “Transition Term” 3.1.1 “Upstream License Agreements” 11.2.6(a) Company [***]Confidential Information, indicated by [***], has been omitted by this filing and filed separately with the Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) and Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Commission.

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b) Acquisition 12.8 Agreement Preamble Alternative Acquisition Alliance Manager 3.1 Claims 11.1 Clinical Supply Agreement 5.4(a6.3 CMO 6.1(d) Anti-Bribery Laws 3.22(cCMO Supply Agreement 6.1(d) Articles of Merger CMO Quality Agreement 5.3(c) Committee 3.1 Competing Product 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time Competing Program 2.4(b) Electronic Delivery 9.13 Crinetics Preamble Crinetics Indemnitee(s) 11.1 Development Plan 4.1(a) Development Timeline 4.2(a) Disclosing Party 9.1(a) Dispute 14.1 Effective Date Preamble Enforcement Expenses 8.3(dAction 12.5(b) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bExecutive Officers 14.2 First Party 5.5 Generally Applicable Inventions 12.2 ICC 14.3 IIT Guidelines 3.3(b) Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Initial Term 13.1 Inventory 13.7(b) Indemnified Persons 6.9(aJCC 3.1 JCC Matter(s) Labor Agreements 3.20(a3.4(b) Leased Real Property Leases 3.15(bJDC 3.1 JDC Matter(s) Marks 1.1(kkk3.3(b) Maximum Premium 6.9(bJoint Inventions 12.2 JSC 3.1 JSC Matter(s) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i3.2(b) License 2.1(a) Losses 11.1 Manufacturing and Supply Agreement 6.2(a) New Plans 6.9(aTechnology 12.7(b) Notice Negotiation Period 5.4(d)(ii)(32.4(b) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPMD Act 5.3(c) Payment Agent 2.9(aPrior CDA 1.14 Product Materials 13.7(c)(v) Per Share Price 2.9(a)(iiiProduct-Related Inventions 12.2 Product-Specific Inventions 12.2 Program Interest Notice 2.4(b) Proxy Holder Recitals Proxy Statement 6.3(aProgram Notice 2.4(b) Required Permits 3.20(cProsecution and Maintenance / Prosecute and Maintain 12.4(a) Restraint 7.1(bReceiving Party 9.1(a) Rollover Representatives 9.1(c) Safety Data Exchange and Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a5.7 Selling Party 1.46 SKK Preamble SKK Commercialization Plan 7.1 SKK Indemnitee(s) Statutory Merger Stockholder Approval 3.4(a11.2 SKK Third Party Agreements 13.7(d) Statutory Stockholder Approvals 3.4(aSKK’s Data 4.3(b) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bSKK’s Trademarks 7.4(b) Termination Date 8.1(bSST2 Agonist 2.4(a) Trade Secrets 1.1(kkkTerm 13.1 Third Party Infringement 12.5(a) Transaction Matters 9.11(aVAT 1.61 Wind-Down Period 13.7(c)(iii) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWithholding Tax 8.10(b)

Additional Definitions. The Each of the following capitalized terms definitions shall have the respective meanings given to them defined in the respective Sections corresponding sections of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Defined Term Section Agreement Wind-Down Period 12.9.2 Agreement Preamble Alternative Acquisition Agreement 5.4(aAlliance Manager 2.7 Challenge 12.4 Co‑Chair 2.3 Collaborator Indemnitees 11.5.1 Collaborator Rights 3.1.1 Collaborator Sole Inventions 9.1 Collaborator Sole Patents 9.1 Commercialization Criteria 5.2 Commercialization Plan 5.2 Committee 2.3 Competing Activities 3.5.1 Competing Product Article 1 3.1 Confidential Information 10.1 Control Affiliate 3.5.2(a) Anti-Bribery Laws 3.22(cControl Transaction 3.5.2(a) Articles of Merger 2.4(aControl, Controlled, or Controlling Article 1 Controlled Party 3.5.2(a) Certificates 2.9(c)(iCWG 2.2.3 Defending Party 9.3 Dispute 13.1 Divest 3.5.2(c) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Divestiture 3.5.2(c) DWG 2.2.1 Signature Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Action 9.4.2 Enforcing Party 9.4.4 Ex-Im Laws 3.22(cAgreement Patents 12.9.4 Indemnify 11.5.1 Initial Regulatory Meeting 4.2.1 Investment Agreement Background Joint Inventions 9.1 Joint Patents 9.1 JSC 2.1.1 Losses 11.5.1 Manufacturing Plan 6.1.2 Defined Term Section Manufacturing Technology Transfer Plan 6.1.1 Mesoblast Inc. Preamble Mesoblast Limited Recitals Mesoblast Sàrl Preamble Milestone Event 8.1.2 Milestone Payment 8.1.2 MSB Improvement Patents 9.1 MSB Indemnitees 11.5.2 MSB ▇▇▇▇ 5.5.2(a) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub MSB Rights 3.2.1 MSB Sole Inventions 9.1 MSB Sole Patents 9.1 MSB Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party MWG 2.2.2 Other Dispute 13.3 Party, or Parties Preamble Patents 1.1(kkkPRC Agency 1.3.1 PRC Approvals 1.3.1 Prior Understandings 10.3 Product Marks 5.5.1 Regulatory Materials Transfer Request 12.9.3 Royalty 8.1.3 Royalty Term 8.1.3 SDE Agreement 7.5.1 Senior Executive 2.5 Solicitation Action 10.7 Soliciting Party 10.7 Subject Affiliate 3.5.2(b) Payment Agent 2.9(aSubject Party 3.5.2(b) Per Share Price 2.9(a)(iiiSubject Transaction 3.5.2(b) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Tasly Preamble Taxed Party 8.3.3 Term 12.1 Third Party Project Technology Agreements 11.3.1 Third-Party Claim 11.5.1 Transfer Taxes 8.3.4 Working Group 2.2

Additional Definitions. The Definitions for each of the following capitalized defined terms have the respective meanings given to them are set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: [*] CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION 2Q 6.5.2(b) 2001 Agreement 2.4 4Q 6.5.2(d) Action Party 7.2.7(c) Additional Approval Condition 3.4(bFormulation Option 5.5.1 Agreement Introduction Controlling Third Party Progenics Kow-How Combination Sale Net Sales Commercialization Payments 6.3 Commercialization Plan 3.4.3 Debtor Party 10.5.1 December 31 YTD Royalties 6.5.2(c) Agreement Preamble Alternative Acquisition Agreement 5.4(aDevelopment Milestone 6.2 Development Milestone Payments 6.2 Development Plan 4.1 Disclosing Party 8.1 Effective Date Introduction Exchange Act 13.22.1(a) Anti-Bribery Laws 3.22(c[*] 3.1.3 Full Ono Fiscal Year Royalties 6.5.2(d) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Gross Sales Net Sales Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Inventions 2.4 Liability 11.1 Licensed Progenics Patent Rights 9.2(a) Negotiation Period 5.5.2 Net Combination Sale Amount Net Sales Non-Debtor Party 10.5.1 Ono Introduction Ono Indemnified Persons 6.9(aParty 11.2 Option Period 5.5.1 Owned Progenics Patent Rights 9.2(a) Labor Agreements 3.20(aParty Introduction Parties Introduction Party Vote 3.1.3 Permitted Deductions Net Sales Progenics Introduction Progenics Indemnified Party 11.1 Receiving Party 8.1 Responsible Executive 13.20 [*] Background SEC 13.22.1(b) Leased Real Property Leases 3.15(bSelling Person Net Sales September 30 YTD Royalties 6.5.2(b) Marks 1.1(kkkSPC Patent Term Extension Sued Party 7.2.8(c) Maximum Premium 6.9(bTerm 10.1 Third Party IP Rights 7.2.8(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Third Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover License 6.4.3 Title 11 10.5.2 University 2.4 Working Group 3.5 Wyeth Collaboration Wyeth Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)[*] CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections of this Agreement set forth opposite each section of the capitalized terms Agreement indicated below: Additional Approval Condition 3.4(bAgreement Recitals Alliance Managers 3.1(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aApplicant 7.5(b) AntiApplicant Response 7.5(c)(ii) Base Royalty Term 5.4 Biosimilar Application 7.5(a) ImmunoGen/Millennium Confidential BPCIA 7.5(a) Challenge Jurisdiction 5.3(e) Challenged Patent Rights 5.3(e) Challenge-Bribery Laws 3.22(cRelated Royalty Increase 5.3(e) Articles of Merger 2.4(aClawback Amount 5.3(e) Certificates 2.9(c)(iCombination 1.64 [***] [***] Covers 5.3(c)(iii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosing Party 1.14 Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x9.1 Dispute 11.12(a) Effective Time 2.4(bDate Recitals Extended Royalty Term 5.4 Immediate Patent Infringement Action 7.5(c)(iv) Electronic Delivery 9.13 Enforcement Expenses 8.3(dImmunoGen Recitals ImmunoGen Indemnitees 10.1(a) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) ImmunoGen Proprietary Antibody 1.33 Improvement 1.2 Indemnified Party Proceeding 6.9(b10.2 Indemnifying Party 10.2 Infringed Patent List 7.5(c)(iv) Indemnified Persons 6.9(aImmunoGen/Millennium Confidential Infringement 7.4(a) Labor Agreements 3.20(aInfringement Notice 7.4(a) Leased Real Property Leases 3.15(bInitial Patent List 7.5(c)(i) Marks 1.1(kkkJC 3.2(a) Maximum Premium 6.9(bKnowledge 9.1 Losses 10.1(a) Merger Material Breach 8.2(b) Millennium Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iMillennium Indemnitees 10.1(b) New Plans 6.9(aMillennium Response 7.5(c)(iii) Monies 7.4(i) Negotiation Period 7.5(c)(iv) Panel 11.12(b)(ii) Party/Parties Recitals Patent Committee 7.1(d) Patent-Related Filings 7.2(c) Permitted Third Party Service Providers 2.1(c) Premarket Notice Period 5.4(d)(ii)(37.5(d)(ii) Old Plans 6.9(aProduct Trademarks 7.8 Proposed Biosimilar Product 7.5(a) Owned Company Shares 2.9(a)(iiProposed Initial Patent List 7.5I(i) Parent Preamble ImmunoGen/Millennium Confidential Proposed Millennium Response 7.5(c)(iii) Proposed Sublicensee 2.3 Receiving Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover 1.14 Representatives 1.14 Royalty Term 5.4 Safety Data Exchange Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a[***] [***] Term 8.1 Third Party Claims 10.1(a) Statutory Stockholder Approvals 3.4(aThird Party Payments 5.3(b) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWind-Down Period 8.3(a)

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Definition Section AAA 19.3 AAA Arbitration Rules 19.3 Accounting Period 9.1 Adverse Event 6.3 Alliance Director 4.10 APAC Region 1.55 Arbitration Offer 8.3.5 Arbitration Commencement Date 8.3.5 Average Delivery Time Metric 7.4.2.3 Bankruptcy Code 18 Breaching Party 17.2.1 Chairperson 4.3 Chugai 1.2 Collaboration Agreement Preamble Alternative Acquisition Agreement 5.4(a) AntiWhereas clause Collaboration Products 1.38 Dependent Obligation 7.4.1.5 Disclosing Party 1.12 […***…] 1.55 […***…] 1.55 Expert 8.3.5 F1CDx 1.48 F1CDx Initial Launch Plan 7.3.1 F1CDx Launch Notice 7.3.1 F1CDx Personnel 6.1.2.3 - 10 - ***Confidential Treatment Requested*** Definition Section F1CDx Report 7.7 FACT 1.48 FCPA 19.5 Firewall 6.1.2.3 Firewall Policies 6.1.2.3 FMI Cover page FMI-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Originated Transfer Activities 17.3.4.3 FoundationOne 1.48 FoundationOne CDx 1.48 FoundationOne Product 1.48 Global Cost 8.2.1 Global Test Fixed Fee 8.2.1 Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) 14.3 Indemnifying Party 14.3 Initial Discussion Period 8.3.5 Initial Launch Requirement 7.3.1 Initial Products 1.48 Initial Term 1.4 Investor Rights Agreement Whereas clause […***…] 1.55 JOT 4.9 […***…] 1.55 Local Cost 8.2.1 Local Test Fixed Fee 8.2.1 Master IVD Collaboration Agreement Whereas clause Material Average Delivery Time Failure 7.4.2.3 Members 4.3 Minimum Price 7.5 Minimum Revenue Requirements 7.4.1.2 Minimum Transfer Payment 17.3.4.3 NGS 7.4.2.3 Non-Breaching Party 17.2.2 Non-Regulated Update 7.3.2 […***…] 1.55 Original Agreement Whereas clause Panel 8.3.5 Payment Currency 9.3 Penalty Payment 8.3.6 Peremptory Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 17.2.2 Precedent Obligation 7.4.1.5 Product Documentation Requirements 7.4.1.4 Product Trademarks 12.2 Professional Services 7.7 Publishing Notice 16.4 Publishing Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover 16.4 Qualified Sample 7.4.2.3 Quarterly Average Delivery Time Failure 7.4.2.3 Rebuttal 8.3.5 - 11 - ***Confidential Treatment Requested*** Definition Section Receiving Party 1.12 Regulated Claims 7.7 Regulatory Partner 6.1.2.4 Regulatory Partner Notice 6.1.2.4 Related Agreements Whereas clause Renewal Term 1.4 Restatement Date Cover page Roche Cover page Roche Regulatory Support 6.1.2.4 Roche Transfer Activities 17.3.4.3 ROFN Negotiation Period 3 Royalty Term 8.3.1 Samples 17.3.4.3 Selected Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support 8.3.5 Service Activities 1.15 Supporting Memorandum 8.3.5 Territory Revision Event 1 6.1.2.3 Territory Revision Event 2 6.1.2.4 Territory Revision Event 3 7.3.1 Territory Revision Event 4 7.3.1 Territory Revision Event 5 7.3.2 Territory Revision Event 6 7.4.1.4 Territory Revision Event 7 7.4.1.6 Third Party F1CDx Regulatory Information 6.1.2.3 Third Party Test Fee 8.2.2 Transaction Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Whereas clause Universal CDx Product 2.2 US Cost 8.2.1 US Education Collaboration Agreement Whereas clause Virtual Gross Margin Calculation 8.3.2.1

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each indicated below: Acquirer 1.23 Acquired Third Party 15.3.4 Agreement Preamble Akcea Preamble Akcea Core Technology Patent Rights 10.1.3 Akcea Indemnified Parties 13.1 Akcea Invention 10.1.2 Akcea-Owned Categories 10.1.3 Akcea Proposed Transaction Entity Alliance Manager 7.2.4 5.5 CMO 4.1 Committee 5.2.1 Competitive Infringement 10.3.1 Compulsory Third Party Product 9.5. Confidential Information 11.1 Cross-Territory Sales 3.10.2 Cross-Territory Sales Notice 3.10.2 Cross-Territory Sales Report 3.10.3 Defense Proceeding 10.2.1(a) Disclosing Party 11.1 Dispute 15.2 eCTD 2.5.3 Effective Date Preamble Evaluation Package 7.2.1 Exclusive License 6.1.1 Existing Confidentiality Agreement 11.1.4 Expiration of the capitalized terms below: Additional Approval Condition 3.4(bROFN Right 7.2.1 Final Offer 7.2.3(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) FPL 7.1 GAAP 15.13 ICH 1.41 Inbound Licensor 6.2.1 Incremental Tax Cost 15.3.1 ActiveUS 169009360v.1 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Fee 9.1 Inotersen Buy-Out 7.2.3(a) Indemnified Persons 6.9(aInotersen Buy-Out Option 7.2.3 Inotersen FMV 7.2.3(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Ionis Internal ASO Safety Database 3.9.3 Ionis Pharmaceuticals/Akcea Product Regulatory Strategy 2.4.1 JAMS 15.2 Joint Invention 10.1.2 JSC 5.1.1 JSC Evaluation Presentation 7.2.1 Losses 13.1 Market Share Loss Percentage 9.5 Milestone Payment 9.2 Non-Exclusive License 6.1.2 Parties Preamble Party or Preamble Pre-Existing Affiliates 15.3.3 Product Regulatory Strategy 2.4.2 Product Trademark 3.7.1 Promotional Materials 3.5 Proposed Transaction 7.2.1 PTC Preamble PTC Commercialization Plan 3.2 PTC Commercialization Targets 3.2 PTC Indemnified Parties Preamble Patents 1.1(kkk13.2 PTC Invention 10.1.2 PTC Parent Recitals Receiving Party 11.1 ROFN Right 7.2.1 Royalty Rate 9.3 Royalty Term 9.4 Securities Acts 11.3.3 SDEA 3.9.2 Selected Final Offer 7.2.3(c) Payment Agent 2.9(aSelling Party 1.58 Specific Discounts 1.58.4 Subcommittee 5.2 Sublicense 6.4 Sublicensee 6.4 Supply Agreement 4.1 Term 14.1 Third Party Claims 13.1 ActiveUS 169009360v.1 Valuation Expert 7.2.3(b) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iValuation Notice 7.2.3(b)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bAccounting Firm 9.10(b)(i) Agreement Preamble Alternative Acquisition Agreement 5.4(aPayments 9.11(a) Alliance Manager 3.1 Antibody Component 1.39 Anti-Bribery Corruption Laws 3.22(c12.7(a)(i) Articles of Merger 2.4(aBeiGene Preamble BeiGene Collaboration IP 14.1(a) Certificates 2.9(c)(iBeiGene Collaboration Patent Rights 14.3(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bBeiGene Indemnitees 13.2 BeiGene Publication 11.1(b) Company Leased Real Property 3.15(bBreach Notification 15.2(b)(i) Company Option 2.8(c)(iClaims 13.1 Clinical Supply Agreement 7.3(a) Company Owned Real Property 3.15(aClinical Trial Results 4.1 CMO 7.2 Commercialization Milestone Event 9.3 Commercialization Milestone Payment 9.3 Commercial Supply Agreement 7.3(b) Company PSU 2.10(c)(iCompanion Diagnostics 3.2(b) Company Recommendation 3.3(aCompeting Product 2.6(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xConfidentiality Agreement 16.13 Continuing Technology Transfer 4.1 Development Milestone Event 9.2 Development Milestone Payment 9.2 Disclosing Party 1.19 Dispute 16.5(a) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Date Preamble Ex-Im Laws 3.22(c) Exchange Fund 2.9(bTerritory Infringement 14.3(a) Excluded Arrangements 6.10(aClaim 16.5(e) FHWA 3.21(bExecutive Officers 3.2(f) Financing 6.5(aExisting Regulatory Materials 12.2(o) FMCSA 3.21(bGlobal Brand Elements 8.4(c) Global Development Plan 5.2(a) ICC 16.5(a) ICH Guidelines 1.32 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 JCC 3.2(g) Indemnified Persons 6.9(aJDC 3.2(g) Labor Agreements 3.20(aJoint Collaboration IP 14.1(a) Leased Real Property Leases 3.15(bJoint Patent Rights 14.1(c)(ii) Marks 1.1(kkkJSC 3.2(a) Maximum Premium 6.9(bLicense 2.1 […***…]23 1.39 Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Notice of Dispute 16.5(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Qualifying Audits 7.2 Party/Parties Preamble Patents 1.1(kkkProduct Infringement 14.3(a) Payment Agent 2.9(aProduct Marks 14.7 Public Official 12.7(d) Per Share Price 2.9(a)(iiiPublication 11.1(c) Proxy Holder Recitals Proxy Statement 6.3(aReceiving Party 1.19 Review Period 11.1(b) Required Permits 3.20(cRoyalty Term 9.5(b) Restraint 7.1(bRules 16.5(a) Rollover Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a6.4 SEC 11.4(c) Statutory Merger Stockholder Approval 3.4(aSecurities Regulators 11.4(c) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters Taxes 9.11(a) Uncertificated Shares 2.9(c)(iiTechnology Transfer 4.1 Term 15.1 Territory Development Plan 5.3 Trial Completion Notice 4.1 23 Competitive Information – Technical Information. Upfront Payment 9.1 Working Group 3.2(h) Union 3.20(a[…***…]24 7.3(c) Vested Company PSU 2.10(c)(i[…***…]25 7.3(c) Vested Company RSU 2.10(a)(iZymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Publication 11.1(c)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of the Agreement: Defined Terms Section Acquisition Transaction 17.8(b) Alliance Manager 3.8 Allowable Increases 4.5(b) Auditor 10.4 Beneficial Party 9.2(e) Change of Control 2.9(b) Commercialization Plan 6.2 [ * ] = Certain confidential information contained in this Agreement set forth opposite each document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles Securities Exchange Act of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 1934, as amended. Defined Terms Section Competing Program 2.9(a) Per Share Price 2.9(a)(iiiCompound Invention 11.1(b)(i) Proxy Holder Recitals Proxy Statement 6.3(aDevelopment Budget 4.2 Divest 2.8(c) (a) Required Permits 3.20(cExelixis Data 11.1 (a) Restraint 7.1(bExelixis Entity 17.8(a)(i)(1) Rollover Exelixis Indemnitee 13.2 Exelixis Only Development Work 4.5(e) Global Development Plan or GDP 4.2 Indemnitee 13.3 Indemnitor 13.3 Independent Work Cost 9.2(c) Initial Committed Studies 4.5(a) Injunctive Relief 16.3(b) (a) Licensee Indemnitee 13.1 Licensee Only Development Work 4.5(e) Joint Commercialization Committee or JDC 3.3 Joint Development Committee or JDC 3.2 Joint Steering Committee or JSC 3.1 Joint Inventions 11.1(b)(ii) Joint Patents 11.1(b)(ii) Losses 13.1 Materials 4.14 PV Costs 5.5 Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a5.6 Product Infringement 11.3(a) Statutory Merger Stockholder Approval 3.4(aProduct Marks 11.7(a) Statutory Stockholder Approvals 3.4(aPromotional Materials 6.4(c) Support Recall 5.10 Regulatory Meeting 5.4 Royalty Term 9.5(c) Sales Forecast 6.3(b) Sobi Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b8.1 Sole Inventions 11.1(b)(ii) Termination Date 8.1(bStandstill Period 17.8(a) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iSunshine Reporting Laws 5.11 Supply Agreement 7.1 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Defined Terms Section Supply Contacts 3.9 Term 15.1 TMC 5.2 Withholding Tax Action 10.3(c)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this the Agreement: Achieved Milestone 8.4(b) Additional CAR Antigen Target 3.1(a) Additional CAR Antigen Target Nomination Notice 3.1(a) Additional Option Payment 8.3 Additional PSC Product Type Nomination Notice 3.1(b) Alliance Manager 4.1 Applicable Patent Rights 9.1(h) Assuming Party 9.2(d)(ii) Beam Indemnitees 13.2 [***] Indemnitees 13.3 Beam Withholding Tax Action 8.11(b) [***] Royalty Term 8.7(a) [***] 9.1(c)(ii)(1) Claims 13.3 Commercial Milestone Event 8.5 Confidentiality Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b14.9 CREATE Act 9.1(h) Agreement Preamble Alternative Acquisition Agreement 5.4(aDevelopment Milestone Event 8.4 Disclosed Platform Know-How 9.1(d) AntiDisclosing Party 10.1(a) Dispute 14.6 ACTIVEUS 188080012v.21 Employee-Bribery Laws 3.22(cInitiated Solicitation 14.2 Enforcing Party 9.3(b) Articles of Merger 2.4(aExisting Employer 14.2 [***] 9.1(c)(ii)(2) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Genetic Target Nomination Notice 3.3 Genetic Target Selection Term 3.3 [***] 14.10 Indemnified Party Proceeding 6.9(b13.4 Indemnifying Party 13.4 Initial Technology Transfer Budget 5.1 Initial Technology Transfer Plan 5.1 Joint Inventions 9.1(a) Indemnified Persons 6.9(aJointly-Owned Inventions 9.1(e) Labor Agreements 3.20(aJointly-Owned Patents 9.1(f) Leased Real Property Leases 3.15(bLiabilities 13.1 [***] 6.3 [***] 14.10 New Genetic Target 3.3 Option Maximum 3.1(d) Other Institutions 14.10 Prior MTA 14.9 Product Marks 1.1(kkk9.6 Proposed Genetic Target 3.3 Prosecuting Party 9.2(d)(ii) Maximum Premium 6.9(bProspective Employer 14.2 Receiving Party 10.1(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iRelevant Enforcement Action 9.3(b) New Plans 6.9(aReplacement CAR Antigen Target 3.2 Replacement Genetic Target 3.3 Replacement Nomination Notice 3.2 Replacement PSC Product Type 3.2 Replacement Selection Term 3.2 Royalty Information 8.7(d) Notice Period 5.4(d)(ii)(3Royalty Term 8.7(c) Old Plans 6.9(aSana Indemnitees 13.1 Sana Withholding Tax Action 8.11(c) Owned Company Shares 2.9(a)(iiSEC 10.5(b) Parent Preamble Skipped Milestone 8.4(b) Sole Inventions 9.1(a) ACTIVEUS 188080012v.21 Soliciting Employee 14.2 Technology Transfer Budget 5.1 Technology Transfer Plan 5.1 Term 11.1 Third Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iIn-Licenses 2.4(b)

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Definition: Section: Acquired Person 1.14 Active Immunotherapeutic Approaches 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Celgene Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Celgene Acquired Competing Antibody 4.5.2 Celgene Exclusivity Term 4.5.1 Celgene Indemnitees 9.2 Celgene Proposed Terms 4.2.2 Celgene Share 6.8.4 Celgene Third Party Payments 5.3.4 Combination Product 1.52 Competing Antibody 4.5.1 [***] Certain information in this document has been omitted and filed separately with the Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Definition: Section: Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.7.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.11 Effective Date Preamble EMA 1.68 Excluded Claim 11.7.3(d) ExExisting Regulatory Materials 2.2.1 FDA 1.68 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 Grant Notice 4.2.2 HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.6.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patent 6.6.4 Licensed Program Assets 2.4 Licensed Program Confidential Information 7.11 Licensed Program Inventory 2.3.4 Licensed Program Know-How 1.46(a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.46(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Licensed Program Specific IP 7.2 Licensed Program U.S. License Agreement Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Master Collaboration Agreement Recitals MHLW 1.68 Negotiation Period 4.2.2 [***] [***] Notice Period 5.4(d)(ii)(34.2.2 Ongoing Clinical Trial 2.1.3(a) Old Plans 6.9(aOngoing Prothena Development Activities 2.1.3(c) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.6.2(b) Payment Agent 2.9(aPaying Party 5.6.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.3.1 Program Recitals [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Definition: Section: Prothena Preamble Prothena Acquired Competing Compound 4.4 Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.1.3(d) Proxy Holder Recitals Proxy Statement 6.3(aProthena Reversion Antibodies 10.8.1 Publishing Party 7.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.4.1 Right of First Negotiation 4.2.2 Sales Milestone Payment 5.5.1 SEC 7.4.1(a) Required Permits 3.20(cSecurities Regulators 7.6 Tax Benefit 5.6.2(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Term 10.1.1 Transition Plan 2.3.6

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of the Agreement: Alliance Manager 2.1 [ * ] Advance Invoice 11.3(c)(i) [ * ] Indication Development Budget 6.2(a) [ * ] [ * ] [ * ] True-Up Report 11.3(c)(ii) [ * ] Indication Development Work 6.3(b)(iv) [ * ] Date 9.6(b) Astellas [ * ] [ * ] Astellas Co-Promotion Notice 9.6(b)(i) Astellas Indemnitees 16.1 Astellas [ * ] [ * ] Astellas [ * ] [ * ] Astellas [ * ] [ * ] Bankruptcy Code 3.8 Combination Product 1.65(e) Commercial Operating Team 9.7 Commercialization Plan 9.3(a) [ * ] [ * ] Co-Promotion Agreement 9.6(g) [ * ] [ * ] Co-Promotion Matters 9.6(b)(i) Cytokinetics Co-Funding Option 4.1(b) Cytokinetics Co-Promotion Effort 9.6(c) Cytokinetics Co-Promotion Recommendation 9.6(b)(ii) Cytokinetics [ * ] [ * ] Cytokinetics [ * ] [ * ] Cytokinetics [ * ] [ * ] Cytokinetics Product Marks 12.5(b) Cytokinetics Research FTEs 5.3 Cytokinetics [ * ] [ * ] [ * ] = Certain confidential information contained in this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(bdocument, marked by brackets, has been omitted because it is both (i) Agreement Preamble Alternative Acquisition Agreement 5.4(anot material and (ii) Antiwould likely cause competitive harm if publicly disclosed. Cytokinetics [ * ] [ * ] Development Advance Invoice 11.3(a)(i) Development Plan 6.2(a) Development Program 6.2(a) Development Project Team 6.10 Development True-Bribery Laws 3.22(cUp Report 11.3(a)(ii) Articles of Merger 2.4(aDisclosing Party 13.1(a) Certificates 2.9(c)(i[ * ] [ * ] Earlier Milestone Events 11.5(b) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bEarly Stage Work 6.3(b)(ii) Company Leased Real Property 3.15(bEstablished Commercial Infrastructure 9.9 [ * ] [ * ] [ * ] [ * ] FCPA 17.7(a) Company Option 2.8(c)(iFCPA Covered Person 17.7(a) Company Owned Real Property 3.15(aFederal Arbitration Act 17.6(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) [ * ] [ * ] Indemnified Party Proceeding 6.9(b16.3 Indemnifying Party 16.3 [ * ] Rules 17.6(a) Indemnified Persons 6.9(aJCC Determination 9.6(b)(iii) Labor Agreements 3.20(aJoint Commercialization Committee or JCC 2.6 Joint Development Committee or JDC 2.4 Joint Manufacturing Committee or JMC 2.5 Joint Medical Affairs Committee or JMAC 2.7 Joint Patent Committee or JPC 2.8 Joint Research Committee or JRC 2.3 Joint Steering Committee or JSC 2.2 [ * ] Regulatory Materials 7.2(a) Leased Real Property Leases 3.15(bLater Milestone Events 11.5(b) Medical Affairs Plan 10.3 MSLs 10.1 [ * ] [ * ] Neuromuscular Indications 9.6(a) [ * ] [ * ] [ * ] Indication Development Costs 6.4(b) Pharmacovigilance Agreement 7.5 Phase 1 Work 6.3(b)(i) [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Product Infringement 12.4(a) Product Marks 1.1(kkk12.5(a) Maximum Premium 6.9(bReceiving Party 13.1(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iRemainder 12.4(f) New Plans 6.9(aRemedial Action 7.7 Research Advance Invoice 11.2(a) Notice Period 5.4(d)(ii)(3Research Budget 5.3 Research Plan 5.3 Research Plan Costs 5.6 Research Program 5.1 Research Project Team 5.8 Research Term 5.2 Research True-Up Report 11.2(b) Old Plans 6.9(aResponsible Committee 13.4 [ * ] [ * ] [ * ] [ * ] Royalty Term 11.7(b) Owned Company Shares 2.9(a)(ii[ * ] [ * ] SEC 13.5(b) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)[ * ] Patent Rights 1.81 Term 14.1

Additional Definitions. The Each of the following capitalized terms definitions shall have the respective meanings given to them meaning defined in the respective Sections corresponding sections of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bAdverse Drug Reaction 6.2.4 Adverse Safety/Tox Results 13.2.2 Affected Area 13.4.2 (e)(i) Agreement Preamble Alternative Acquisition Agreement 5.4(aWind-Down Period 13.6.2 Approved Maxygen CMO 6.1.1 (a) AntiApproved Astellas CMO 6.1.5 Astellas Indemnitees 12.5.1 (a) Astellas Independent Inventions 10.2.2 (a) Astellas’ Requirements 6.1.1(a)(iii) Astellas-Bribery Laws 3.22(cSelected New Compounds 13.4.2 (e)(v) Articles of Merger 2.4(aBackup Manufacturer 6.1.6(b)(iv) Certificates 2.9(c)(iBundled Products 5.4 CDI Cessation Notice 13.4.2 (a) Charter Amendment Effective Time Claims 12.5.1 (a) Clinical Candidate Criteria 3.3.1 Co-Chair 2.5.2 Co-Development Activities 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b(b) Company Leased Real Property 3.15(bCo-Development Indication Plan 4.1.2 Maxygen’s Co- 13.4.2 (c) Company Joint Steering Committee or JSC 2.3 JSC Matter 2.7.1 Losses 12.5.1 (a) Manufacturing Costs Fin. Ex. 5.13 Marketing Costs Fin. Ex. 5.14 Marks 10.7 Maxygen Indemnitees 12.5.1 (b) Maxygen Independent Inventions 10.2.2 (a) Maxygen ▇▇▇▇ 5.2.7 Maxygen Opt-Out Right 4.1.4 (b) Maxygen Reverted Compound Activities 13.4.2(e)(vii) Maxygen-Selected New Compounds 13.4.2 (e)(v) Milestone Fin. Ex. 1.1.1 Net Sales Fin. Ex. 5.15 New Manufacturer 6.1.6(a)(iii) New Libraries 13.4.2 (e)(v) No-Fault Cause 6.1.6 (a)(i) Notifying Party 7.2 DevelopmentIndication Costs Combination Product Fin. Ex. 2.1.3(c) Competing Activities 7.1.1 Competing Infringing Activities 10.6 Confidential Information 11.1 Controlling Party 10.3.3 Cooperating Party 11.5.2 Co-Promotion Notice 5.2 Co-Promotion Option 2.8(c)(i5.2 Co-Promotion Percentage 5.2.1 Co-Promotion Plan 5.2.2 (a) Company Owned Real Property 3.15(aCo-Promotion Product 5.2 Core Countries 10.3.1 (a) Company PSU 2.10(c)(iDamages 10.5 Development Costs Fin. Ex. 5.3 Distributable Profits Fin. Ex. 5.4 Divest 7.2.3 Direct Country 9.1.3 (a) Company Recommendation 3.3(aEnforcement Action 10.6 Excluded Compounds 13.4.2(e)(iii) Company Recommendation Change 5.4(c)(iExclusivity Period 7.1.1 Existing Manufacturer 6.1.6(a)(iii) Company RSU 2.10(a)(iExisting Third Party Licenses Fault 12.5.1 (a) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) FTE Fin. Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) . 5.8 Indemnified Party Proceeding 6.9(b12.6 Indemnifying Party 12.6 Initial Preclinical Development Plan 3.2 Joint Inventions 10.2.2 (a) Indemnified Persons 6.9(aJoint Patent 10.3.2 Joint Program Team or JPT 2.4 Opt-Out Notice 4.1.4 (b) Labor Agreements 3.20(aOpt-Out Event 4.1.4 (b) Leased Real Property Leases 3.15(bOther Party 7.2 Permitted Activities 7.1.3 Post-Execution Affiliate 7.2 Preclinical Development Costs Fin. Ex. 5.20 Preclinical Development Program 3.1 Preclinical Development Plan 3.2 Prior CDA 11.3 Prosecution and Maintenance 10.3.5 Publishing Party 11.4.1 Recoveries 10.6.2 Representing Party 12.1 Requesting Party 11.5.2 Responsibility Transfer Plan 6.1.6 (b)(i) Marks 1.1(kkkReverted Compounds 13.4.2(e)(iii) Maximum Premium 6.9(bReviewing Party 11.4.1 Selected Indication 4.1.3 (a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iSelected Indication Notice 4.1.3 (a) New Plans 6.9(aSeparate Program 7.2 Shuffling Improvement 10.2.2 (b) Notice Period 5.4(d)(ii)(3Subcommittee 2.9 Subject Transaction 7.2 Supplies Requirement Plan 6.1.1(a)(iii) Old Plans 6.9(aTarget 11.2 Term 13.1 Third Party License 10.4.2 Third Party Payments Fin. Ex. 2.1.3(a) Owned Company Shares 2.9(a)(iiThird Party Reverted Compound Activities 13.4.2(e)(viii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Walled-Off Programs 11.2

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each indicated below: Acquired Person 1.14 4 [***] For the purposes of the capitalized terms below: Additional Approval Condition 3.4(b) “Target” definition, “[***]” means [***] Active Immunotherapeutic Approaches 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Celgene Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Celgene Acquired Competing Antibody 4.5.2 Celgene Exclusivity Term 4.5.1 Celgene Indemnitees 9.2 Celgene Proposed Terms 4.2.2 Celgene Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) 6.8.4 Celgene Third Party Payments 5.3.4 Combination Product 1.52 Competing Antibody 4.5.1 Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.7.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.11 Effective Date Preamble EMA 1.68 Excluded Claim 11.7.3(d) ExExisting Regulatory Materials 2.2.1 FDA 1.68 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 Grant Notice 4.2.2 HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.6.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patent 6.6.4 Licensed Program Assets 2.4 Licensed Program Confidential Information 7.11 Licensed Program Inventory 2.3.4 Licensed Program Know-How 1.46(a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.46(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Licensed Program Specific IP 7.2 Licensed Program U.S. License Agreement Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Master Collaboration Agreement Recitals MHLW 1.68 Negotiation Period 4.2.2 [***] [***] Notice Period 5.4(d)(ii)(34.2.2 Ongoing Clinical Trial 2.1.3(a) Old Plans 6.9(aOngoing Prothena Development Activities 2.1.3(c) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.6.2(b) Payment Agent 2.9(aPaying Party 5.6.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.3.1 Program Recitals Prothena Preamble Prothena Acquired Competing Compound 4.4 Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.1.3(d) Proxy Holder Recitals Proxy Statement 6.3(aProthena Reversion Antibodies 10.8.1 Publishing Party 7.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.4.1 Right of First Negotiation 4.2.2 Sales Milestone Payment 5.5.1 SEC 7.4.1(a) Required Permits 3.20(cSecurities Regulators 7.6 Tax Benefit 5.6.2(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Term 10.1.1 Transition Plan 2.3.6

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bDefinition Section Accounting Firm 9.10(b)(i) Agreement Preamble Alternative Acquisition Agreement 5.4(aPayments 9.11(a) Alliance Manager 3.1 Anti-Bribery Corruption Laws 3.22(c12.7(a)(i) Articles of Merger 2.4(aBeiGene Preamble BeiGene Collaboration IP 14.1(a) Certificates 2.9(c)(iBeiGene Collaboration Patent Rights 14.3(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bBeiGene Indemnitee(s) Company Leased Real Property 3.15(b13.2 21 Competitive Information – Commercially Sensitive Terms. BeiGene Publication 11.1(b) Company Option 2.8(c)(iBreach Notification 15.2(b)(i) Company Owned Real Property 3.15(aBuyer 1.41 Claims 13.1 Clinical Supply Agreement 7.3(a) Company PSU 2.10(c)(iCMO 7.2 Commercialization Milestone Event 9.3 Commercialization Milestone Payment 9.3 Commercial Supply Agreement 7.3(b) Company Recommendation 3.3(aCompanion Diagnostics 3.2(b) Company Recommendation Change 5.4(c)(iCompeting Product 2.6(a) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xConfidentiality Agreement 16.13 Continuing Technology Transfer 4.1 Development Milestone Event 9.2 Development Milestone Payment 9.2 Disclosing Party 1.18 Dispute 16.5(a) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dDate Preamble Existing Regulatory Materials 12.2(o) Ex-Im Laws 3.22(c) Exchange Fund 2.9(bTerritory Infringement 14.3(a) Excluded Arrangements 6.10(aClaim 16.5(e) FHWA 3.21(bExecutive Officers 3.2(f) Financing 6.5(aGlobal Brand Elements 8.4(c) FMCSA 3.21(bGlobal Development Plan 5.2(a) ICC 16.5(a) ICH Guidelines 1.31 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 JCC 3.2(g) Indemnified Persons 6.9(aJDC 3.2(g) Labor Agreements 3.20(aJoint Collaboration IP 14.1(a) Leased Real Property Leases 3.15(bJoint Patent Rights 14.1(c)(ii) Marks 1.1(kkkJSC 3.2(a) Maximum Premium 6.9(bLicense 2.1 Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Notice of Dispute 16.5(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Qualifying Audits 7.2 Party/Parties Preamble Patents 1.1(kkkProduct Infringement 14.3(a) Payment Agent 2.9(aProduct Marks 14.7 Public Official 12.7(d) Per Share Price 2.9(a)(iiiPublication 11.1(c) Proxy Holder Recitals Proxy Statement 6.3(aReceiving Party 1.18 Review Period 11.1(b) Required Permits 3.20(cRoyalty Floor 9.5(c)(iv) Restraint 7.1(bRoyalty Term 9.5(b) Rollover Rules 16.5(a) Pharmacovigilance Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a6.4 SEC 11.4(c) Statutory Merger Stockholder Approval 3.4(aSecurities Regulators 11.4(c) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters Taxes 9.11(a) Uncertificated Shares 2.9(c)(iiTechnology Transfer 4.1 Term 15.1 Territory Development Plan 5.3 Upfront Payment 9.1 Working Group 3.2(h) Union 3.20(a[…***…]22 7.3(c) Vested Company PSU 2.10(c)(iZymeworks Preamble Zymeworks Collaboration IP 14.1(a) Vested Company RSU 2.10(a)(iZymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Publication 11.1(c)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bAcquired Party 2.4(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aArticles 8.2(c) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions Bankruptcy Code 6.7 BION-1301 Approval Milestone 5.1(a) Data Privacy/Security Requirements 3.17(gCandidate 2.5(a) Effect 1.1(xChinook Preamble Chinook Acquired ROFN Asset 2.5(a) Effective Time 2.4(bChinook Developed ROFN Asset 2.5(a) Electronic Delivery 9.13 Enforcement Expenses 8.3(dChinook ROFN 2.5(a) Ex-Im Laws 3.22(cChinook ROFN Asset 2.5(a) Exchange Fund 2.9(bChinook ROFN Expiration Date 2.5(c) Chinook ROFN Negotiation Period 2.5(b) Chinook ROFN Notice 2.5(b) Chinook ROFN Period 2.5(b) Chinook ROFN Review Period 2.5(b) Chinook Transaction 2.5(a) Combination Product 1.58(f) Competing Asset 2.4 Contract Manufacturing Organization or CMO 4.3(b) Deficient Site 4.4(d)(ii) Dispute 11.8(a) Excluded Arrangements 6.10(aClaim 11.8(f) FHWA 3.21(bExecution Date Preamble Executive Officers 3.4 Global Development Plan 4.4(b)(ii) Financing 6.5(aGlobal Study 4.4(c) FMCSA 3.21(b[***] [***] [***] [***] Global Study Participation Option 4.4(c) ICC Rules 11.8(a) Indemnified Party Proceeding 6.9(b10.3 Indemnifying Party 10.3 Infringement Action 6.4(b) Indemnified Persons 6.9(aJoint Patents 6.3(a) Labor Agreements 3.20(aJoint Steering Committee or JSC 3.1 Licensed Product Marks 6.8(b) Leased Real Property Leases 3.15(bLicensed Trademarks 6.8(a) Marks 1.1(kkkLicensee Preamble Licensee Acquired ROFN Asset 2.6(a) Maximum Premium 6.9(bLicensee Developed ROFN Asset 2.6(a) Merger Recitals Merger Sub Licensee Indemnitees 10.1 Licensee ROFN 2.6(a) Licensee ROFN Asset 2.6(a) Licensee ROFN Expiration Date 2.6(c) Licensee ROFN Negotiation Period 2.6(b) Licensee ROFN Notice 2.6(b) Licensee ROFN Period 2.6(b) Licensee ROFN Review Period 2.6(b) Licensee Transaction 2.6(a) Licensor Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Licensor Indemnitees 10.2 Party or Parties Preamble Patents 1.1(kkkPatent Challenge 8.2(e) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Pharmacovigilance Agreement 4.8 Purchase Agreement Recitals Rollover Remedial Action 4.12 [***] [***] Reversion Product 8.3(a) [***] [***] Securities Regulator 7.3(e) Series A Preferred Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a2.5(c) Statutory Merger Stockholder Approval 3.4(aTechnology Transfer Plan 4.3(b) Statutory Stockholder Approvals 3.4(aTerm 8.1 Territory Infringement 6.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iTerritory-Specific Development Plan 4.4(b)(i)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: 203 Study Schedule 1.80 301 Study Schedule 1.80 Accounting Firm 9.10(b)(i) ADC Infringement 14.4(b)(iii) Additional Approval Condition 3.4(bActive 1.16 Additional Costs 9.2(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Alliance Manager 3.1 Amendment Effective Date Preamble Anti-Bribery Corruption Laws 3.22(c12.7(a)(i) Articles of Merger 2.4(aAudited Party 9.10(b)(i) Certificates 2.9(c)(iAuditing Party 9.10(b)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Breach Notification 15.2(b)(i) Claims 13.1 Clinical Supply Agreement 7.3(c) [*** ***] CMO 7.2 Commercial Supply Agreement 7.3(d) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 Estimated Additional Costs 9.2(b) Excluded Claim 17.5(f) Execution Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bExecutive Officers 17.5(a) Company Leased Real Property 3.15(bExecutive Sponsors 3.2(f) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dExisting Regulatory Materials 12.2(s) Ex-Im Laws 3.22(cTerritory Infringement 14.4(a) Exchange Fund 2.9(bFirst BLA 6.2(b) Excluded Arrangements 6.10(aGlobal Brand Elements 8.3(c) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) ICH Guidelines 1.37 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Indemnified Persons 6.9(aJazz Collaboration Patent Rights 14.3(d) Labor Agreements 3.20(aJazz Competing Product 2.6(a) Leased Real Property Leases 3.15(bJazz Development Plan 5.3 [*** ***] Jazz Indemnitee(s) Marks 1.1(kkk13.2 Jazz Publication 11.1(b) Maximum Premium 6.9(bJazz Study IP 14.1(a) Merger Recitals Merger Sub Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(b) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Original Agreement Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Parties Preamble Party or Parties Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(a) PPQ 7.4(a) Pre-Amendment Period 15.1(c) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Purchase Agreement Preamble Quality Technical Agreement 7.3(e) [*** ***] Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) SDEA Agreement 6.4 SEC 11.3(c) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1(a) Transition Services Agreement Preamble Western Europe 1.59 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.49 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 2.6(b) Zymeworks Development Plan 5.4 Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.1(kkk1.81 Zymeworks Publication 11.1(c) (a) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)ZZI Preamble

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each indicated below: Acceptance Milestone Section 6.3(a)(iii) Acquirer Section 1.20 [ * ] Section 2.5 [ * ] Section 1.62 Adamas Preamble [ * ] Section 6.4(d)(iv) Adamas FDC and ER Patent Rights Schedule 11.6 Adamas FDC Patent Rights Schedule 11.6 Adamas IP Infringement Claim Section 7.4(a) Adamas Manufacturing Know-How Section 3.1(c) Adamas Paragraph IV Claim Section 7.11(a) Adamas Patent Challenge Section 7.3(d)(ii) [ * ] Section 6.4(d)(iv) Agents Section 8.1 Alliance Manager Section 4.2(c) Antitrust Action Section 11.2(c) Antitrust Law Section 11.2(c) Approval Milestone Section 6.3(a)(iv) Arbitrators Section 12.2(b)(i) Assignment and Assumption Agreement Section 2.7 ▇▇▇▇-▇▇▇▇ Act Section 9.1(l) Bioequivalence Milestone Section 6.3(a)(i) Cessation Notice Section 11.2(a) Claim Section 12.2(b)(i) Confidential Information Section 8.2 Confidentiality Agreement Section 8.2 Courts Section 12.1 [ * ] Section 3.3 Effective Date Preamble ER Royalty Term Section 6.4(c)(iii) Existing Supply Agreement Section 3.3 FDC Launch Assumptions Section 5.4 FDC Royalty Term Section 6.4(c)(i) First Sales Year Section 1.81 Forest Preamble Forest Blocking Patent Section 6.4(c)(vii) [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the capitalized terms below: Additional Approval Condition 3.4(bSecurities Act of 1933, as amended. [ * ] Section 9.2(e) Agreement Forest Parent Preamble Alternative Acquisition Agreement 5.4(aForest Parties Section 10.2 Forest Patent Challenge Section 7.3(b) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Forest Reversion Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bSchedule 11.6 Forest Third Party Patent Licenses Section 6.4(c)(vii) Indemnified Party Proceeding 6.9(bSection 10.3(a) Indemnified Persons 6.9(aIndemnifying Party Section 10.3(a) Labor Agreements 3.20(aInitial Development Plan Section 1.25 Invalidity Claim Section 7.5 JAMS Section 12.2(b)(i) Leased Real Property Leases 3.15(bJDC Section 4.1 Joint IP Working Group; JIPWG Section 7.1 Joint Know-How Section 7.2 Joint Manufacture Committee; JMC Section 3.3 Joint Patent Rights Section 7.2 Late Payment Notice Section 6.9 [ * ] Section 5.4 Letter Agreement Section 4.2(a) Marks 1.1(kkk[ * ] Section 6.4(d)(iii) Maximum Premium 6.9(bMilestone Event Section 6.3(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iMilestone Payment Section 6.3(a) New Plans 6.9(a[ * ] Section 1.62 Outside Milestone Date Section 6.3(b) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkParagraph IV Claim Section 7.11(a) Payment Agent 2.9(aDate Section 2.1(b) Per Share Price 2.9(a)(iiiPre-Change of Control Rights Section 1.20 [ * ] Section 2.5 Primary Detail Section 1.23 Product Category Section 1.81 Proprietary Non-Donepezil FDC Product Section 6.4(c)(ii) Proxy Holder Recitals Proxy Statement 6.3(aProprietary Non-Donepezil FDC Royalty Term Section 6.4(c)(ii) Required Permits 3.20(cRegulatory Filings Section 2.6 Regulatory Plan Section 1.80 Regulatory Plan Change Section 4.2(d)(ii) Restraint 7.1(bRelated Adamas Patent Rights Section 1.8 Reverted FDC Products Schedule 11.6 Royalty Commencement Date Section 6.4(c)(iv) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aRules Section 12.2(b)(i) Statutory Merger Stockholder Approval 3.4(aSecondary Detail Section 1.23 Stability Milestone Section 6.3(a)(ii) Statutory Stockholder Approvals 3.4(aTechnology Transfer Plan Section 3.1(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Term Section 11.1 Termination Effective Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Schedule 11.6 Third Party Claims Section 10.1

Additional Definitions. The Each of the following capitalized terms have definitions has the respective meanings given to them defined in the respective Sections corresponding Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Definitions Section Acquiring Entities 1.12 Acquisition Transaction 1.12 Agreement Preamble Alternative Acquisition Trademark 6.2(b)(i) Challenge 12.4 CMC Information 7.3 CMO 7.1(a) CMO Agreement 5.4(a7.1(b) AntiCo‑Chair 2.2 Commercialization Milestone Event Exhibit 1.20 Commercialization Milestone Payment Exhibit 1.20 Commercialization Plan 6.1(d) Competing Activities 3.3 Competing Product 3.3 Confidential Information 10.1 Defending Party 9.4 Deficiencies 4.1(c) Development Milestone Event Exhibit 1.20 Development Milestone Payment Exhibit 1.20 Dispute 13.1 DURECT Preamble DURECT Indemnitees 11.4(b) DURECT Inventions 9.1 DURECT Patents 9.1 DURECT TMs 6.2(c)(i) Enforcement Action 9.5(b) Enforcing Party 9.5(d) Exclusive Negotiation Period 6.3 Execution Date Preamble Generic Product Exhibit 1.20 Definitions Section IFRS 1.1 Indemnify 11.4(a) Infringing Product 9.5(a) Initial Term 12.1 JDC 2.1(a) Losses 11.4(a) Material Contracts 11.2(d) Non-Bribery Laws 3.22(cProduct-Specific Enforcement Action 9.5(c) Articles of Merger 2.4(aOrange Book 5.1(b) Certificates 2.9(c)(iOrthopedic Exclusion Exhibit 1.20 Other Party 5.2(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPre-Launch Plan 6.1(c) Payment Agent 2.9(aPrior CDA 10.3 Product Development Plan or PDP 4.1 Product-Specific Enforcement Action 9.5(b) Per Share Price 2.9(a)(iiiPV Agreement 5.4 Quality Agreement 7.1(c) Proxy Holder Recitals Proxy Statement 6.3(aRenewal Term 12.1 Responsible Party 5.2(a) Required Permits 3.20(cSABER DMF 7.3 SANDOZ Preamble SANDOZ Indemnitees 11.4(a) Restraint Selling Party 1.32 Term 12.1 Third-Party Claim 11.4(a) Three-Way Supply Agreement 7.1(a) Two-Way Supply Agreement 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Upfront Fee 8.2

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: DEFINITION SECTION 2010 Agreement Introduction AAA 15.1(b) Accounting Standards Exhibit E Acquired Party 15.4(b) Acquired Party Activity 15.4(c) Acquired Third Party 15.4(c) Acquirer 15.4(b) Acquisition 15.4(b) Additional Approval Development Activities 3.3 Additional Development Opt-In Date 3.3(e)(i) Additional Development Opt-In Notice 3.3(e) Additional Development Proposal 3.3(a) Additional Development Party 3.3(c) Additional Revenue Exhibit E Advertising and Market Research Expenses Exhibit E AGI-23088 US Agreement Recitals Agios Preamble (a) Agios Commercial-Scale Manufacturing Responsibilities 4.1(a) Agios Guarantor 15.17 Agios Indemnified Parties 13.1(a) DEFINITION SECTION Agios Non-Satisfaction Condition 3.4(b) 15.17 Agios Obligations 15.17 Agios USA Recitals Agreement Preamble Alternative Acquisition Agreement 5.4(aAlliance Manager 2.6 Annual Net Sales Exhibit E Arbitrable Matters 15.1(b) Anti-Bribery Laws 3.22(cAudit Team 9.8(a) Articles of Merger 2.4(aAudit Rights Holder 9.8(f) Certificates 2.9(c)(iAuditee 9.8(f) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bBankruptcy Code 8.8 Breaching Party 14.2(b)(i) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)▇▇ ▇▇▇▇▇ ROW Partnership 15.16

Additional Definitions. The Each of the following capitalized terms shall have the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each indicated below: Agreement Preamble Alliance Manager 3.2 Angioblast Preamble Angioblast Competing Activities 2.4(b) Angioblast Indemnitees 12.1 Angioblast Logos 10.2 BMF 4.6(c) Cephalon Preamble Cephalon Competing Activities 2.4(a) Cephalon Indemnitees 12.2 CMC Information 4.6(c) [**] [**] Commercialization Plan 5.2 Committee 3.3 Competitive Product 2.4(c) Conditional Forecast 4.4(c) Costs 9.4(b) Cover 9.5(c) Defensive Action 9.4(a) Dispute 14.1 Effective Date Preamble Enforcement Action 9.3(b) [**] [**] [**] [**] [**] [**] [**] [**] General Plan 4.2(a) Improvements 9.1(b) Indemnitee 12.3 Indemnitor 12.3 Infringing Product 9.3(b) Inventions 9.1(a) JAMS Rules 14.3(b)(ii) JMC 7.7 Joint Steering Committee 3.1 Joint Defense Agreement 9.4(a) Joint Interest Agreement 9.5(a) Joint Patent 9.2(b) JSC 3.1 Liabilities 12.1 Noticed Party 9.5(a) Noticing Party 9.5(a) Other Dispute 14.3 Other Enforcement Action 9.3(c) Other Infringing Product 9.3(c) Participating Party 4.7 Patent Challenge 13.3(c) Payee 6.6 Payor 6.6 Plan 3.4 Prior Confidentiality Agreement 1.18 Research Plan 4.1 Responsible Party 4.7 [**] [**] SFDA 1.56 Specific Angioblast Patent 9.2(a) ** Portions of the capitalized terms below: Additional Approval Condition 3.4(b) Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. [**] [**] Supply Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles 7.1 Territory 1.60 Third Party Claim 12.1 [**] [**] [**] [**] [**] [**] ** Portions of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company the Exhibit have been omitted and have been filed separately pursuant to an application for confidential treatment filed with the Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) and Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: AAA 14.1.1 Additional Approval Condition 3.4(b) Targets 3.3 Agreement Preamble Alternative Acquisition Agreement 5.4(a) AntiAlliance Manager 2.3.1 ArQule Preamble ArQule Indemnitees 13.2 ArQule Indemnity Claims 13.2 Audited Party 4.8.4 Beryllium Preamble Beryllium Deferred Shared Costs 4.8.3 Beryllium Improvements 1.28 Beryllium Indemnitees 13.1 Beryllium Indemnity Claims 13.1 Collaboration Compound Notice 3.2 Commercialization Report 5.8 Deemed Waived Compound 4.8.3 Deemed Waived Compound Payments 4.8.3 Development Report 4.7 Disclosing Party 1.46 Dispute 14.1.1 Disputed Matter Distributor 2.1.5 Schedule 2 Early Stage Opt-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Out Notice 4.10.1 Early Stage Opt-Out Notice Period 4.10.1 Early Stage Opt-Out Right 4.10.1 Early Stage Separation Date 4.10.1 Early Stage Waived Compound Payments 4.10.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bFiling Party 10.1.4 ICH 3.1.3(b) Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Infringement 10.2.1(a)(i) Indemnified Persons 6.9(aInfringement Notice 10.2.1(a)(i) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iInfringement Response 10.2.1(a)(ii)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b3DMed Preamble Action 6.2(c) Agreement Preamble Alternative Acquisition Alliance Managers 3.7 Back License 2.6 Breaching Party 10.2(a) Cap 5.6(a) Claims 9.1 Commercial Supply Agreement 5.4(a4.10(d) Anti-Bribery Laws 3.22(cCommercial Supply Quality Agreement 4.10(d) Articles of Merger 2.4(aClinical Supply Agreement 4.10(c) Certificates 2.9(c)(iClinical Supply Quality Agreement 4.10(c) Charter Amendment Defending Party 6.3 Development Plan 4.3 Disclosing Party 7.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bExchange Act 8.7(b) Company Leased Real Property 3.15(bExcluded Claim 11.2(f) Company Option 2.8(c)(iForce Majeure 11.5 Global JSC 3.1 HKIAC 11.2 Hong Kong 1.75 Indemnitee 9.3 Infringement 6.2(a) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting Infringement Claims 6.4(a) Converted PSU Award 2.10(c)(iiJoint Decision Matter 3.5 Joint Steering Committee, JSC 3.1 License ‎ 2.1 Losses 9.1 Macau 1.75 Manufacturing Know-How 4.7(c) Converted Restricted Share Award 2.10(bNon-breaching Party 10.2(a) Converted RSU Award 2.10(a)(iiOFAC 8.4(d) Copyrights 1.1(kkkOther Licensed Patents 6.1(b) Covenant Exceptions 5.1(aParty, Parties Preamble Payments 5.6(a) Data Privacy/Security Requirements 3.17(gPharmacovigilance Agreement 4.11 Prior CDA 7.5 Upfront Payment 5.1 Upfront Payment Due Date 5.1 Receiving Party 7.1 Relevant Person 8.4(d) Effect 1.1(xRelevant Region 1.75 Representatives 7.1 [***] [***] [***] [***] [***] [***] [***] [***] Royalty Term 5.3(b) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Securities Regulators 7.6 SELLAS Preamble SELLAS Bermuda Recitals Merger SELLAS Parent Preamble SELLAS Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iSelling Period 10.6(b)(vii) New Plans 6.9(aSupply End Date 4.10(a) Notice Period 5.4(d)(ii)(3Technical Assistance 4.8 Technology Transfer 4.7(c) Old Plans 6.9(aTechnology Transfer Agreements 4.7(c) Owned Company Shares 2.9(a)(iiTechnology Transfer Plan 4.7(c) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Term 10.1 Territory Filings and Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i4.12 VAT 5.6(b)

Additional Definitions. The following capitalized terms have the respective meanings given to them set forth in the respective corresponding Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: ​ ​ ​ AAV Recitals ACTUAL DAMAGES CAP 20.2(g) Actual Passage Bio Receipt 8.2(b) Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Batches 2.5.4(a), Exhibit C Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Approved Production Schedule 2.5.5, Exhibit C Arising IP Patents 15.7 Audit 17.2(b) Auditing Party 11.9 Batch Documentation 9.2(d) Batch Investigation 7.1(c) Batch Processing 7.1(a) Binding Quarter 2.5.2, Exhibit C BQ 2.5.2, Exhibit C BWI Facility Recitals Catalent Preamble Catalent Arising IP 15.4 Catalent Indemnitee 18.7 Catalent Project Manager 9.1(b) Catalent Records 17.1(a) cGMP Manufacturing Runs 4.1(a) CIP 10.1 CMC 11.1 Collaboration Agreement Recitals Confidential Information 14.3 Continuous Improvement Program 10.1(h) Defective Batch 7.1(b) Development Services 4.1(a) Disclosing Party 14.3(a) Disclosure Letter 1.4 Company Intellectual Property 3.17(bAgreement 14.1 Divestee 19.2(c) Company Leased Real Property 3.15(bDivestiture 19.2(c) Company Option 2.8(c)(iDivestiture Event 19.2(c) Company Owned Real Property 3.15(aDivestiture Event A 19.2(c) Company PSU 2.10(c)(iDivestiture Event B 19.2(c) Company Recommendation 3.3(aDivestiture Event C 19.2(c) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xDivestiture Fee 19.2(c) Effective Time 2.4(bDate Recitals Failed Batch Section 7.1(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Force Majeure Event 13.1 Forecast Modification 2.5.4(a), Exhibit C FQ 2.5.1, Exhibit C Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor 18.8 Indemnifying Party 18.8 ​ Letter Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Loss 18.6 NBQ 2.5.2, Exhibit C Original Collaboration Agreement Recitals Original DSCSA Recitals Parties Preamble Party or Parties Preamble Patents 1.1(kkkPassage Bio Preamble Passage Bio Approval 4.6(a) Passage Bio Arising IP 15.5 Passage Bio Indemnitee 18.6 Payment Agent 2.9(aSchedule 4.7(a) Per Share Price 2.9(a)(iiiPPQ 4.1(a) Proxy Holder PPQ Completion Date 4.4 Primary Cause 7.1(c) Prior Agreements Recitals Proxy Statement 6.3(aProcess Performance Qualification 4.1(a) Required Permits 3.20(cProcurement Cost 4.7(c) Restraint 7.1(bProposed Production Schedule 2.5.5, Exhibit C Quality Representative 9.1(a) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aReceiving Party 14.3(a) Statutory Merger Stockholder Approval 3.4(aRepeat Supply Failure 2.5.6, Exhibit C Retained Copies 20.2(i) Statutory Stockholder Approvals 3.4(aRolling Forecast 2.5.1, Exhibit C Scope of Work 4.1(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bSP Credit 2.6.1, Exhibit C Supply Failure 2.5.6, Exhibit C Supply Pricing 1.1, Exhibit C Term 20.1(a) Terminating Event 7.1(a) Termination Date 8.1(b20.2(a) Trade Secrets 1.1(kkk​ ​ ​ ​ ​ ​ ​ This Exhibit C establishes the Parties understanding as to the establishment of procedures for the forecasting (and rolling forecasts) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iof Passage Bio’s ordering of Batches of the Passage Bio Products. 1. 1Batch Pricing Based on Manufacturing Configuration. Each Passage Bio Product being Manufactured by Catalent pursuant to this Agreement may have differing Manufacturing Configurations. In addition, such Manufacturing Configurations may change during the Term for the same Passage Bio Product. Accordingly, pricing for clinical supply of Passage Bio Products will vary depending upon the Manufacturing Configuration utilized in the Manufacture of Batches of such products and shall be set forth in each Scope of Work (the “Supply Pricing”). For the purposes of this Agreement, the Supply Pricing for the Term is based upon a Manufacturing Configuration of [*] and is set forth in Schedule 1.1 of this Exhibit C. For all other clinical supply and any new commercial supply Manufacturing, the applicable Supply Pricing for Batches of Bulk Drug Substance and Drug Product of Passage Bio Products will be agreed to by the Parties and provided in each Scope of Work.

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each indicated below. Acquired Party 14.1(a) Action 9.5(a) Acutus Claims 11.1 Acutus Party Commercialization Liability 1.8(a) Acutus Damages 11.1 Acutus Indemnitees 11.1 Acutus Payment Breach 13.2(a)(iii) Agreed Contingent Accelerated Royalty Payment 14.1(b)(v) Agreed Upfront Accelerated Royalty Payment 14.1(b)(iv) Alliance Manager 3.5(a) Alternative Manufacturer 7.4 Auditor 8.11(b) BIO Parties’ Commercialization Liability 1.2(a) BIO Party Claims 11.2 BIO Party Damages 11.2 BIO Party Indemnitees 11.1 Breaching Party 13.2(a) Cash Technology Transfer Payment 8.2 Change of the capitalized terms below: Additional Approval Condition 3.4(bControl Notice 14.1(a) Code 13.4(a) Commercialization Plan 6.1 Controlling Party 9.5(a) Debarment Laws 10.1(d) Device Reporting 5.3 Disclosing Party 12.1(a) First FS EU Product 4.1(a) First FS US Product 4.1(a) First Products 4.1(a) Force Majeure 15.5 Indemnitee 11.3(a) Indemnitor 11.3(a) Initial Manufacturing Transfer 4.3(a) Initial Other Know-How Transfer 4.3(b) Joint Steering Committee 3.1(a) Manufacture and Supply Agreement Preamble Alternative Acquisition Agreement 5.4(a7.1 Manufacturing License 7.2 Milestone 8.3 Milestone Payment 8.3 Non-Breaching Party 13.2(a) Anti-Bribery Laws 3.22(cPersistent Supply Failure Notice 7.5 Potential FTO Issue 10.5(c) Articles of Merger 2.4(aPublications 12.4(b) Certificates 2.9(c)(iRecipient Party 12.1(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Renewal Term 13.1 Senior Manager 3.4 Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Technology Transfer Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)8.2 Subcommittee 3.2 Term 13.1 Unit Based Royalty Payment 8.4 Unit Based Sales and Royalty Report 8.5

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each indicated below: Annual Reconciliation Statement 6.4.1(b) Additional Research Request 3.9.2(a) ARCHEMIX Change of Control Notice 13.2.1(a) ARCHEMIX Indemnitees 12.2 ARCHEMIX Internal Program Target Notice 3.9.3 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the capitalized terms below: Additional Approval Condition 3.4(bCommission pursuant to to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. Backup Compound Candidate 3.9.1(b) Backup Compound Candidate Evaluation Period 3.9.1(b) Backup Compound Candidate Notice 3.9.1(b) Backup Compound Candidate Option 3.9.1(b) Claims 12.1 Co-Developed Development Candidate 4.10.2(a) Co-Development and Co-Promotion Option 4.10.2(a) Co-Development and Co-Promotion Option Notice 4.10.2(a) Co-Development Option Exercise Period 4.10.2(a) Collaboration Manager 2.4 Competing Aptamer Product 7.10.1(d) Co-Promotion Agreement Preamble Alternative Acquisition Agreement 5.4(a4.10.2(c) AntiCo-Bribery Laws 3.22(cPromotion Option Period 4.11.1 Designated Senior Officers 2.1.6 Designation Notice 7.1.2(c)(i) Articles Dispute 13.1.1 Disputed Matter 2.1.6 Evaluation Period 3.9.1(a) Expert 14.1.2(a) Filing Party 10.1.4 Generic Product 6.6.1(e) Gilead Indemnitee 13.3 Indemnified Party 13.4 Indemnifying Party 13.4 Infringement 10.2.1(a) Infringement Notice 10.2.1(a) IPO Effective Date 5.5.2(c) J▇▇ ▇▇▇▇▇▇▇▇ ▇ ▇▇▇ 2.2.1 JPT Term 2.2.1 JSC Term 2.1.1 Late Stage Development Activities 4.10.6(b) Losses 12.1 MERCK Change of Merger 2.4(aControl Notice 13.2.2(a) Certificates 2.9(c)(iMERCK Contribution 6.4.1(b) Charter Amendment Effective Time 2.3 MERCK Indemnitees 13.1 MERCK Internal Program Target Requests 3.7.2(c) MERCK IPO Shares 5.2.2(b) MERCK IPO Share Amount 5.2.2(c) MERCK Private Placement Shares 5.2.2(c)) MERCK Private Placement Share Amount 5.2.2(b) MTA 3.9.1(a) Net Income Payments 6.7.1 Non-Filing Party 10.1.4 Opting-Out Party 4.10.7(d) Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. Option Fee 6.3 Option Exercise Fee 6.3 Opt-Out Right 4.10.6(d) Opt-Out Right Notice 4.10.6(d) Opt-Out Right Notice Period 4.10.6(d) Patent Coordinator 8.4 Primary Compound Candidate 3.9.1(a) Primary Compound Candidate Notice 3.9.1(a) Primary Compound Candidate Option 3.9.1(a) Private Placement 5.2.1 Private Placement Closing 2.5 5.2.2(d) Private Placement Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b5.2.2(d) Company Leased Real Property 3.15(bPrivate Placement Purchase Price 5.2.2(c) Company Option 2.8(c)(iPurchase Notice 5.2.2(c) Company Owned Real Property 3.15(aQualified IPO Notice 5.2.2(a) Company PSU 2.10(c)(iQualified IPO Purchase Price 5.2.2(c) Company Recommendation 3.3(aRequested ARCHEMIX Activities 3.9.2(a) Company Recommendation Change 5.4(c)(iRequested Chemistry 6.6.1(c) Company RSU 2.10(a)(iRecipient Party 3.13 Roll-Over Payment 4.10.7(c) Company SEC Reports 3.8(dSELEX License 7.1.1(a)(i) Company Securities 3.7(bSeparation Date 4.10.6(d) Company Special Committee Recitals Company Stockholder Meeting 6.4(aSole Developing Party 4.10.6(d) Converted PSU Award 2.10(c)(iiTechnology Transfer Activities 3.2 Technology Transfer Costs 3.2 Technology Transfer Term 3.2 Term 11.1 Third Party Chemistry Payments 6.6.1(c) Converted Restricted Share Award 2.10(bThird Party Costs 7.5.3 Third Party Payments 6.6.1(c) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Transferring Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)3.13

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions are found in the respective Sections body of this Agreement set forth opposite each of the capitalized terms belowas indicated: Additional Approval Condition 3.4(bAffiliate Transferee 4.9(b) Agreed Stamp Duty Assumption(s) 4.4(e)(i) Agreement Preamble Allocation 4.7 Alpha-4 Integrin Product Confidential Information 9.6 Alternative Acquisition Transfer Agreement 5.4(a4.9(e)(i)(A) Anti-Bribery Laws 3.22(cAlternative TYSABRI Transaction 4.9(e) Articles of Merger 2.4(aApplicable Percentage 4.9(a)(i) Certificates 2.9(c)(iAssignment and Assumption Agreement 5.2(c) Charter Amendment Effective Time 2.3 Assumed Liabilities 3.3 BIMA Recitals Biogen Idec Preamble Biogen Idec Disclosure Schedule 7.3 Blocking Prothena IP 3.11(g) Books and Records 3.1(j) Cause 3.10(e) Challenge 4.2(h) Claim 4.4(e)(iii) Clearance Date 2.2(a) Closing 2.5 5.1 Closing Date 2.5 Company 5.1 Closing Date Inventory Value 4.6(b) Closing Date Inventory Value Statement 4.8 Code 4.4(c)(ii) Collaboration Agreement Recitals Contingent Payments 4.2(e) Courts 17.7 Direct Claim 12.4(b)(vi) Direct Claim Offset Amount 12.4(b) Disclosure Information 9.5(a) Distributor 4.9(a)(ii) DOJ 2.2(b) EC 2.2(c) 11 EEA/Switzerland 11.1(a) EEA/Switzerland Alpha-4 Integrin Restricted Period 11.1(b) EEA/Switzerland TYSABRI Restricted Period 11.1(a) Elan Preamble Company Charter Amendment Certificate 2.1 Company Elan Inc. Preamble Elan Disclosure Letter 1.4 Company Intellectual Property 3.17(bSchedule 7.2 ▇▇▇▇ ▇▇▇▇▇ 8.4 Excluded Assets 3.2 Excluded Prothena Licenses 3.11(f) Company Leased Real Property 3.15(bExclusion Notice 3.4(d) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dExecution Date Preamble Existing TYSABRI Distributor 4.10(a)(i) Ex-Im Laws 3.22(cEEA/Switzerland Alpha-4 Integrin Restricted Period 11.2(b) Exchange Fund 2.9(bEx-EEA/Switzerland TYSABRI Restricted Period 11.2(a) Excluded Arrangements 6.10(aFTC 2.2(b) FHWA 3.21(bImproperly Transferred Prothena IP 3.11(f) Financing 6.5(a) FMCSA 3.21(bIndemnifying Party 12.1(b)(i) Indemnified Party Proceeding 6.9(b12.1(b)(i) Indemnified Persons 6.9(aIndemnitees 12.1(a)(i) Labor Agreements 3.20(aIn-License 3.1(g) Leased Real Initial Contingent Payment Period 4.2(a) Instrument 4.4(e)(i) IP Assignments 5.2(b) Irish Stamp Duty Liability 4.4(e)(ii) JCV 1.1(q) LIBOR 12.4(a)(iii) Licensed Transferred Intellectual Property Leases 3.15(b8.1(b) Marks 1.1(kkkLosses 12.1(a)(ii) Maximum Premium 6.9(bMajor Market Countries 4.9(a)(iii) Minor Market Countries 4.9(a)(iv) Material Breach Trigger 12.4(b)(ii) Material Consents 5.2(f) Merger Recitals Control Legislation 2.2(a) Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iControl Legislation Authorities 2.2(a) New Plans 6.9(aNon-Royalty Consideration 4.9(a)(v) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Notifying Party or 7.4 Party/Parties Preamble Patents 1.1(kkkPending Actions 12.2(a) Payment Agent 2.9(aPML 1.1(q) Per Share Price 2.9(a)(iiiPost-Closing Confidential Information 9.4 Potential Indemnified Party 12.2(b) Proxy Holder Recitals Proxy Statement 6.3(aPotential Indemnifying Party 12.2(b) 12 Pre-Closing Confidential Information 9.1 Product Liability Claim 12.1(a)(iii) Rating Trigger 12.4(b)(ii) Regulatory Materials 3.1(f) Required Permits 3.20(cThird Party Consents 3.5 Retained Territory 4.9(a)(vi) Restraint 7.1(bRoyalty Consideration 4.9(a)(vii) Rollover SCA 2.2(a) SDCA 4.4(e)(i) SEC 9.5(a) Shared Pre-Closing Losses 12.1(d) Specified Sections 6.1(a) Standard Distribution Transaction 4.10(a)(i) Stub Period 4.6(a) Term 2.1 Termination Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a2.3 Third Party Claim 12.1(a)(iv) Statutory Merger Stockholder Approval 3.4(aThird Party Claim Offset Amount 12.4(a) Statutory Stockholder Approvals 3.4(aThird Party Infringement Claim 12.1(a)(v) Support Third Party Transferee 4.9(a)(x) Threshold 4.2(d) Threshold Reduction Amount 4.9(a)(viii) Threshold Reduction Fraction 4.9(a)(ix) Transfer Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b4.9(c)(i)(A) Termination Date 8.1(bTransferred Assets 3.1 Transferred Contracts 3.1(h) Trade Secrets 1.1(kkkTransferred Intellectual Property 3.1(e) Transferred Inventory 3.1(i) Transferred License Agreements 3.1(g) TYSABRI Activities 12.1(a)(vi) TYSABRI Employee 2.4(a)(iv) TYSABRI Material Adverse Change 2.6(b) TYSABRI Rights 4.9(a)(x) TYSABRI Transaction Matters 9.11(a4.9(a)(x) Uncertificated Shares 2.9(c)(iiUpfront Payment 4.1 U.S. HSR Act 2.2(a) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iViolation of Law 12.1(a)(vii)

Additional Definitions. The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(bAdvisor 3.3(b) Agreement Preamble Agreement Date Preamble Alternative Acquisition Agreement 5.4(a5.3(a) Anti-Bribery Laws 3.22(cBylaws 3.1 Capitalization Date 3.7(a) Articles Cash Replacement Company RSU Award Amounts 2.11(a)(ii) Cash Replacement Option Amounts 2.11(b)(ii) Certificate of Merger 2.4(a) 2.5 Certificates 2.9(c)(i2.12(c) Charter Amendment Effective Time 2.3 2.8(a) Chosen Courts 9.10(a) Closing 2.5 2.6 Closing Date 2.5 2.6 Collective Bargaining Agreement 3.19(a) Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Board Recommendation 3.3(a) Company Board Recommendation Change 5.4(c)(i5.3(d)(i) Company RSU 2.10(a)(iBreach Notice Period 8.1(d) Company Disclosure Letter Article III Company Equity Awards 1.1(p) Company Liability Limitation 8.3(f)(ii) Company Plans 6.10(b) Company Related Parties 8.3(f)(ii) Company SEC Reports 3.8(d3.9 Company Securities 3.7(c) Company Securities 3.7(bTermination Fee 8.3(b)(i) Comparable Plans 6.10(b) Confidentiality Agreement 9.4 Consent 3.6 Copyrights 1.1(qq) D&O Insurance 6.9(c) Debt Documents 6.5(a)(xii) Debt Financing 6.5(a)(i) DGCL Recitals Dissenting Company Special Committee Recitals Company Stockholder Meeting 6.4(aShares 2.10(c)(i) Converted PSU Award 2.10(c)(iiDTC 2.12(d) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(gDTC Payment 2.12(d) Effect 1.1(x1.1(t) Effective Time 2.4(b) 2.5 Electronic Delivery 9.13 Employee Plans 3.18(a) Enforceability Limitations 3.2 Enforcement Expenses 8.3(d8.3(e) Ex-Im Laws 3.22(cEquity Commitment Letter Recitals Equity Financing 4.11(a) Exchange Fund 2.9(bERISA Affiliate 3.18(a) Excluded Arrangements 6.10(aESPP 2.11(e) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Event Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i5.3(e)(i)(1)

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions are found in the respective Sections body of this Agreement set forth opposite each of the capitalized terms belowas indicated: Acquired Compound Acquired Product Action 2.3.2(b) 2.3.2(b) 7.4.2 Additional Approval Condition 3.4(bNIK Program Information Agreement 3.4.1(c) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Corruption Laws 3.22(c9.5.4 AR Mutant Development Plan 2.2.2(a) Articles of Merger 2.4(aAR Mutant Schedule Information 3.2.1 Audited Site Bankruptcy Code 9.5.5 11.4.2 Breaching Party 11.3.1 CAPA 9.5.5 CPR Mediation Procedure CPR Rules 12.2.1 12.3.1 CREATE Act 7.3.5 Cure Period 11.3.1 Development Program Patent 7.2.1 Development Plan 2.2.2(b) Certificates 2.9(c)(i) Charter Amendment Development Term Acquirer Activities Disclosing Party 2.3.2 8.1.1 Dispute Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company 12.1 Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) ExExisting ▇▇▇▇▇▇▇ Program Know-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) How Existing ▇▇▇▇▇▇▇ Program Patents Force Majeure Event 9.2.49.2.1 13.9 GCP GLP GMP Indemnified Party Proceeding 6.9(b9.5.5 9.5.5 9.5.5 10.2 Indemnifying Party 10.2 Insolvency Event 11.4.1 IRB ▇▇▇▇▇▇▇ 9.5.5 Preamble ▇▇▇▇▇▇▇ Indemnified Party 10.1.1 ▇▇▇▇▇▇▇ ▇▇▇ License Agreement 3.4.1(b) ▇▇▇▇▇▇▇-Owned Development Program Know-How 7.2.1 ▇▇▇▇▇▇▇-Owned Development Program Patent 7.2.1 ▇▇▇▇▇▇▇ Personnel Joint Development Program Patent 9.2 7.2.1 Knowledge 9.2 License Term 4.1 Licensee Preamble Licensee Indemnified Persons 6.9(aParty 10.1.2 Licensee Party 11.4.2 Licensee-Owned Development Program Know-How 7.2.1 Licensee-Owned Development Program Patent 7.2.1 Licensor Party 11.4.2 Losses 10.1.1 Milestone Event 6.1.2 Milestone Payment 6.1.2 Missing Information Notice 3.2.2 NDA 1.32 Negotiation Period 3.4.1(b) Labor Agreements 3.20(aNIK Development Plan 2.2.2(b) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Option Option Exercise Effective Date 3.1 3.3.1 Option Exercise Fee 3.3.1 Option Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or 3.3.1 Other Invention 7.2.2 Other Patent 7.2.2 Party/Parties Preamble Patents 1.1(kkkPatent Representative 7.1 Patent Term Extension 7.6 Permitted Liens 9.2 Permitted Subcontract 2.2.3(e) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination POC Trial Notice Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i3.2.2 Post-Development Term Acquirer Activities 5.5.2 Product Infringement 7.4.2 Program Records 2.2.4(a)

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions are found in the respective Sections body of this Agreement set forth opposite each of the capitalized terms belowas indicated: Additional Approval Condition 3.4(bSection Affiliate Transferee 4.9(b) Agreed Stamp Duty Assumption(s) 4.4(e)(i) Agreement Preamble Allocation 4.7 Alpha-4 Integrin Product Confidential Information 9.6 Alternative Acquisition Transfer Agreement 5.4(a4.9(e)(i)(A) Anti-Bribery Laws 3.22(cAlternative TYSABRI Transaction 4.9(e) Articles of Merger 2.4(aApplicable Percentage 4.9(a)(i) Certificates 2.9(c)(iAssignment and Assumption Agreement 5.2(c) Charter Amendment Effective Time 2.3 Assumed Liabilities 3.3 BIMA Recitals Biogen Idec Preamble Biogen Idec Disclosure Schedule 7.3 Blocking Prothena IP 3.11(g) Books and Records 3.1(j) Cause 3.10(e) Challenge 4.2(h) Claim 4.4(e)(iii) Clearance Date 2.2(a) Closing 2.5 5.1 Closing Date 2.5 Company 5.1 Closing Date Inventory Value 4.6(b) Closing Date Inventory Value Statement 4.8 Code 4.4(c)(ii) Collaboration Agreement Recitals Contingent Payments 4.2(e) Courts 17.7 Direct Claim 12.4(b)(vi) Direct Claim Offset Amount 12.4(b) Disclosure Information 9.5(a) Distributor 4.9(a)(ii) DOJ 2.2(b) EC 2.2(c) EEA/Switzerland 11.1(a) EEA/Switzerland Alpha-4 Integrin Restricted Period 11.1(b) EEA/Switzerland TYSABRI Restricted Period 11.1(a) Elan Preamble Company Charter Amendment Certificate 2.1 Company Elan Inc. Preamble Elan Disclosure Letter 1.4 Company Intellectual Property 3.17(bSchedule 7.2 ▇▇▇▇ ▇▇▇▇▇ 8.4 Excluded Assets 3.2 Excluded Prothena Licenses 3.11(f) Company Leased Real Property 3.15(bExclusion Notice 3.4(d) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dExecution Date Preamble Existing TYSABRI Distributor 4.10(a)(i) Ex-Im Laws 3.22(cEEA/Switzerland Alpha-4 Integrin Restricted Period 11.2(b) Exchange Fund 2.9(bEx-EEA/Switzerland TYSABRI Restricted Period 11.2(a) Excluded Arrangements 6.10(aFTC 2.2(b) FHWA 3.21(bImproperly Transferred Prothena IP 3.11(f) Financing 6.5(a) FMCSA 3.21(bIndemnifying Party 12.1(b)(i) Indemnified Party Proceeding 6.9(b12.1(b)(i) Indemnified Persons 6.9(aIndemnitees 12.1(a)(i) Labor Agreements 3.20(aIn-License 3.1(g) Leased Real Initial Contingent Payment Period 4.2(a) Instrument 4.4(e)(i) IP Assignments 5.2(b) Irish Stamp Duty Liability 4.4(e)(ii) JCV 1.1(q) LIBOR 12.4(a)(iii) Licensed Transferred Intellectual Property Leases 3.15(b8.1(b) Marks 1.1(kkkLosses 12.1(a)(ii) Maximum Premium 6.9(bMajor Market Countries 4.9(a)(iii) Minor Market Countries 4.9(a)(iv) Material Breach Trigger 12.4(b)(ii) Material Consents 5.2(f) Merger Recitals Control Legislation 2.2(a) Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iControl Legislation Authorities 2.2(a) New Plans 6.9(aNon-Royalty Consideration 4.9(a)(v) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Notifying Party or 7.4 Party/Parties Preamble Patents 1.1(kkkPending Actions 12.2(a) Payment Agent 2.9(aPML 1.1(q) Per Share Price 2.9(a)(iiiPost-Closing Confidential Information 9.4 Potential Indemnified Party 12.2(b) Proxy Holder Recitals Proxy Statement 6.3(aPotential Indemnifying Party 12.2(b) Pre-Closing Confidential Information 9.1 Product Liability Claim 12.1(a)(iii) Rating Trigger 12.4(b)(ii) Regulatory Materials 3.1(f) Required Permits 3.20(cThird Party Consents 3.5 Retained Territory 4.9(a)(vi) Restraint 7.1(bRoyalty Consideration 4.9(a)(vii) Rollover SCA 2.2(a) SDCA 4.4(e)(i) SEC 9.5(a) Shared Pre-Closing Losses 12.1(d) Specified Sections 6.1(a) Standard Distribution Transaction 4.10(a)(i) Stub Period 4.6(a) Term 2.1 Termination Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a2.3 Third Party Claim 12.1(a)(iv) Statutory Merger Stockholder Approval 3.4(aThird Party Claim Offset Amount 12.4(a) Statutory Stockholder Approvals 3.4(aThird Party Infringement Claim 12.1(a)(v) Support Third Party Transferee 4.9(a)(x) Threshold 4.2(d) Threshold Reduction Amount 4.9(a)(viii) Threshold Reduction Fraction 4.9(a)(ix) Transfer Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b4.9(c)(i)(A) Termination Date 8.1(bTransferred Assets 3.1 Transferred Contracts 3.1(h) Trade Secrets 1.1(kkkTransferred Intellectual Property 3.1(e) Transferred Inventory 3.1(i) Transferred License Agreements 3.1(g) TYSABRI Activities 12.1(a)(vi) TYSABRI Employee 2.4(a)(iv) TYSABRI Material Adverse Change 2.6(b) TYSABRI Rights 4.9(a)(x) TYSABRI Transaction Matters 9.11(a4.9(a)(x) Uncertificated Shares 2.9(c)(iiUpfront Payment 4.1 U.S. HSR Act 2.2(a) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iViolation of Law 12.1(a)(vii)

Additional Definitions. The following capitalized Additional defined terms have the respective meanings given to them are set forth in the respective following Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b) 2016 Collaboration Agreement Preamble Alternative Acquisition AAA 16.3(a) Acquired Third-Party Program 12.2 Agreement 5.4(aPreamble ALK Waiver Preamble Alleged Breaching Party 11.3(d)(i) AntiAlliance Managers 3.1 Annual Collaboration Fee 5.1 Arbitration Confidential Information 1.24(a)(viii) Burdened Transaction 1.59 [***] 5.2(b)(i)(B)(2) Category 1 Target Diligence Expiration Date 4.1(b)(i) Category 1 Target Payment Expiration Date 4.1(b)(ii) Chemistry Library Source 5.2(b)(i) Co-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Formulated Combination Product 1.16 Co-Packaged Combination Product 1.16 Company Preamble Company Charter Amendment Certificate 2.1 Drug Compound Maximum 1.18 Company Disclosure Letter 1.4 Drug Compounds 1.18 Company Intellectual Property 3.17(bDrug Compound Proposal Notice 1.18 Company Indemnitees 10.1(b) Company Leased Real Property 3.15(bComponent 1.16 Core Compound 1.18 Core Compound Maximum 1.18 CREATE Act 7.5 Decision-Making Representative 3.2(a) Company Option 2.8(c)(iDerivative Compound 1.18 DESRES Preamble DESRES Category 3 Compound Notice 4.5(b) Company Owned Real Property 3.15(aDESRES Indemnitees 10.1(a) Company PSU 2.10(c)(iDisclosing Party 1.24 Effective Date Preamble Freedom to Operate Payment 5.2(b)(iii) Company Recommendation Gross Sales 1.56 Indemnitee 10.1(c) Initial Research Term 1.73 Joint Steering Committee or JSC 3.2(a) JSC Matter 3.3(a) Company Recommendation Change 5.4(c)(iJSC Representatives 3.2(a) Company RSU 2.10(a)(iLibrary 5.2(b)(i) Company SEC Reports 3.8(dNon-Small Molecule Compound 1.18 Other Component 1.16 Other Product 1.16 Paragraph IV Notice 9.5(b) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Parties Preamble Party or Parties Preamble Patents 1.1(kkkProduct Infringement 9.5(a) Payment Agent 2.9(aReceiving Party 1.24 Restatement Date Recitals [***] 5.2(b)(iv) Per Share Price 2.9(a)(iiiSeeker 11.3(d)(i) Proxy Holder Recitals Proxy Statement 6.3(aSoliciting Party 17.9 Stackable Patent 5.2(b)(iii) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iThird Party Infringer 9.5(b)

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Acquired Person 1.15 Active Immunotherapeutic Approaches 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(aCelgene Preamble Celgene Acquired Competing Antibody 4.4.2 Celgene Exclusivity Term 4.4.1 Celgene Indemnitees 9.2 Celgene Proposed Terms 4.2.2 Celgene Share 6.8.2(d) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Celgene Third Party Payments 5.2.4 Clinical Trial Preliminary Activities Outside Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) 10.5 Combination Product 1.52 Competing Antibody 4.4.1 Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.8.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.12 Effective Date Preamble EMA 1.69 Excluded Claim 11.8.3(d) ExFDA 1.69 Financial Transparency Laws 11.17 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 Grant Notice 4.2.2 HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.5.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patents 6.6.4 Licensed Program Assets 2.5 Licensed Program Confidential Information 7.11 (a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.47(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Licensed Program Specific IP 7.2 Master Collaboration Agreement Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) MHLW 1.69 Negotiation Period 4.2.2 [***] [***] Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 4.2.2 Ongoing Prothena Development Activities 2.3.3 Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.5.2(b) Payment Agent 2.9(aPaying Party 5.5.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.2.1 Program Recitals Prothena Preamble Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.3 Prothena Reversion Antibodies 10.10.1 Publishing Party 7.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.3.1 Right of First Negotiation 4.2.2 Sales Milestone Payment 5.4.1 SEC 7.4.1(a) Proxy Holder Recitals Proxy Statement 6.3(aSecurities Regulators 7.6 Tax Benefit 5.5.2(c) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Term 10.1.1 Transfer Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i2.2.1(a)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bAcquisition Affiliate 2.9(a) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Alliance Manager 3.1 Anti-Bribery Corruption Laws 3.22(c11.7(a)(i) Articles of Merger 2.4(aArbitration Notice 15.3(a) Certificates 2.9(c)(iArbitrators 15.3(b) Charter Amendment [***] 2.3 Business Combination Transaction 1.13(b) Buyer 1.53 CFDA Submission Timeline 5.1(c) Combination Product 1.53 Companion Diagnostics 5.10(a) Competing Product 2.8(a) Competing Program 2.9(a) Confidentiality Agreement 16.6 Continuing Technology Transfer 4.1 Deficient Site 5.6(b) (a) Effective Time Date Preamble Ex-Territory Infringement 13.3(a) Examined Party 9.8 Exclusive License 2.1(a) Exclusive Tail Expiration Date 14.1 Executive Officers 3.2(f) Facility-fit Assessment 7.2(b) Five Prime Preamble Five Prime Indemnitee(s) 12.1 Five Prime Specifications 7.2(c) [***] 2.3 Closing 2.5 Closing Date 2.5 Company Global Allocation Cap 5.4 Global Brand Elements 8.4(c) Global Development Plan 5.3 ICH Guidelines 1.38 Indemnified Party 12.3 Indemnifying Party 12.3 Initial Technology Transfer 4.1 CONFIDENTIALEXECUTION Joint Patent 13.1(c)(ii) JPT 3.2(g) JSC 3.2(a) License 2.1(b) [***] 2.3 Losses 12.1 Manufacturing Assumption Notice 7.2(d) Manufacturing Notice 7.2(b) Outstanding Voting Securities 1.13(a) QA 1.36(a) QC 1.36(a) Oversight Plan 6.9 Party/Parties Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bPaying Party 9.9(b) Company Leased Real Property 3.15(bPublic Official 11.7(d) Company Option 2.8(c)(iPublication 10.4 Receiving Party 10.1(a) Company Owned Real Property 3.15(aRecipient 9.9(b) Company PSU 2.10(c)(iReplacement Site 5.6(b) Company Recommendation 3.3(aResearch License 2.1(b) Company Recommendation Change 5.4(c)(iReview Period 10.4 Royalty Term 9.3(b) Company RSU 2.10(a)(iRules 15.3(a) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting Safety Agreement 6.4(a) Converted PSU Award 2.10(c)(iiSEC 10.6(c) Converted Restricted Share Award 2.10(bSeller 1.53 Specified Person 1.13(a) Converted RSU Award 2.10(a)(iiTechnology Transfer 4.1 Term 14.1 Territory Development Plan 5.2 Upstream License Agreements 2.3 Upstream Licensors 2.3 VAT 1.65 VAT Credit 9.10 VAT Withholding 9.10 Working Group 3.2(h) Copyrights 1.1(kkkZai Preamble Zai Indemnitee(s) Covenant Exceptions 5.1(a12.2 Zai Specifications 7.2(c) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)15 CONFIDENTIAL EXECUTION

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each indicated below: Acquirer 1.23 Acquired Third Party 15.3.4 Agreement Preamble Akcea Preamble Akcea Core Technology Patent Rights 10.1.3 Akcea Indemnified Parties 13.1 Akcea Invention 10.1.2 Akcea-Owned Categories 10.1.3 Akcea Proposed Transaction Entity Alliance Manager 7.2.4 5.5 CMO 4.1 Committee 5.2.1 Competitive Infringement 10.3.1 Compulsory Third Party Product 9.5. Confidential Information 11.1 Cross-Territory Sales 3.10.2 Cross-Territory Sales Notice 3.10.2 Cross-Territory Sales Report 3.10.3 Defense Proceeding 10.2.1(a) Disclosing Party 11.1 Dispute 15.2 Distributing Party 3.10.2 eCTD 2.5.3 Effective Date Preamble Evaluation Package 7.2.1 Exclusive License 6.1.1 Existing Confidentiality Agreement 11.1.4 Expiration of the capitalized terms below: Additional Approval Condition 3.4(bROFN Right 7.2.1 Final Offer 7.2.3(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) FPL 7.1 GAAP 15.13 ICH 1.41 Inbound Licensor 6.2.1 Incremental Tax Cost 15.3.1 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Fee 9.1 Inotersen Buy-Out 7.2.3(a) Indemnified Persons 6.9(aInotersen Buy-Out Option 7.2.3 Inotersen FMV 7.2.3(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Ionis Internal ASO Safety Database 3.9.3 Ionis Pharmaceuticals/Akcea Product Regulatory Strategy 2.4.1 JAMS 15.2 Joint Invention 10.1.2 JSC 5.1.1 JSC Evaluation Presentation 7.2.1 Losses 13.1 Market Share Loss Percentage 9.5 Milestone Payment 9.2 Non-Exclusive License 6.1.2 Parties Preamble Party or Preamble Pre-Existing Affiliates 15.3.3 Product Regulatory Strategy 2.4.2 Product Trademark 3.7.1 Promotional Materials 3.5 Proposed Transaction 7.2.1 PTC Preamble PTC Commercialization Plan 3.2 PTC Commercialization Targets 3.2 PTC Indemnified Parties Preamble Patents 1.1(kkk13.2 PTC Invention 10.1.2 PTC Parent Recitals Receiving Party 11.1 ROFN Right 7.2.1 Royalty Rate 9.3 Royalty Term 9.4 Securities Acts 11.3.3 SDEA 3.9.2 Selected Final Offer 7.2.3(c) Payment Agent 2.9(aSelling Party 1.58 Specific Discounts 1.58.4 Subcommittee 5.2 Sublicense 6.4 Sublicensee 6.4 Supply Agreement 4.1 Term 14.1 Third Party Claims 13.1 Valuation Expert 7.2.3(b) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iValuation Notice 7.2.3(b)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bAcquisition Affiliate 2.9(a) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Alliance Manager 3.1 Anti-Bribery Corruption Laws 3.22(c11.7(a)(i) Articles of Merger 2.4(aArbitration Notice 15.3(a) Certificates 2.9(c)(iArbitrators 15.3(b) Charter Amendment [***] 2.3 Business Combination Transaction 1.13(b) Buyer 1.53 CFDA Submission Timeline 5.1(c) Combination Product 1.53 Companion Diagnostics 5.10(a) Competing Product 2.8(a) Competing Program 2.9(a) Confidentiality Agreement 16.6 Continuing Technology Transfer 4.1 Deficient Site 5.6(b) (a) Effective Time Date Preamble Ex-Territory Infringement 13.3(a) Examined Party 9.8 Exclusive License 2.1(a) Exclusive Tail Expiration Date 14.1 Executive Officers 3.2(f) Facility-fit Assessment 7.2(b) Five Prime Preamble Five Prime Indemnitee(s) 12.1 Five Prime Specifications 7.2(c) [***] 2.3 Closing 2.5 Closing Date 2.5 Company Global Allocation Cap 5.4 Global Brand Elements 8.4(c) Global Development Plan 5.3 ICH Guidelines 1.38 Indemnified Party 12.3 Indemnifying Party 12.3 Initial Technology Transfer 4.1 Joint Patent 13.1(c)(ii) JPT 3.2(g) JSC 3.2(a) License 2.1(b) [***] 2.3 Losses 12.1 Manufacturing Assumption Notice 7.2(d) Manufacturing Notice 7.2(b) Outstanding Voting Securities 1.13(a) QA 1.36(a) QC 1.36(a) Oversight Plan 6.9 Party/Parties Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bPaying Party 9.9(b) Company Leased Real Property 3.15(bPublic Official 11.7(d) Company Option 2.8(c)(iPublication 10.4 Receiving Party 10.1(a) Company Owned Real Property 3.15(aRecipient 9.9(b) Company PSU 2.10(c)(iReplacement Site 5.6(b) Company Recommendation 3.3(aResearch License 2.1(b) Company Recommendation Change 5.4(c)(iReview Period 10.4 Royalty Term 9.3(b) Company RSU 2.10(a)(iRules 15.3(a) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting Safety Agreement 6.4(a) Converted PSU Award 2.10(c)(iiSEC 10.6(c) Converted Restricted Share Award 2.10(bSeller 1.53 Specified Person 1.13(a) Converted RSU Award 2.10(a)(iiTechnology Transfer 4.1 Term 14.1 Territory Development Plan 5.2 Upstream License Agreements 2.3 Upstream Licensors 2.3 VAT 1.65 VAT Credit 9.10 VAT Withholding 9.10 Working Group 3.2(h) Copyrights 1.1(kkkZai Preamble Zai Indemnitee(s) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i12.2 Zai Specifications 7.2(c)

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections of this Agreement set forth opposite each section of the capitalized terms Agreement indicated below: Additional Approval Condition 3.4(bAgreement Recitals Alliance Managers 3.1(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aApplicant 7.5(b) AntiApplicant Response 7.5(c)(ii) Baseline Net Sales 1.41 Biosimilar Application 7.5(a) BPCIA 7.5(a) Challenge Jurisdiction 5.3(e) Challenged Patent Rights 5.3(e) Challenge-Bribery Laws 3.22(cRelated Royalty Increase 5.3(e) Articles of Merger 2.4(aClawback Amount 5.3(e) Certificates 2.9(c)(iCombination 1.48 Covered Results 6.3 Covers 5.3(c)(iii) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company [***] [***] Disclosing Party 1.12 Disclosure Letter 1.4 Company Intellectual Property 3.17(b9.1(c) Company Leased Real Property 3.15(bDispute 11.12 Effective Date Recitals Immediate Patent Infringement Action 7.5(c)(v) Company Option 2.8(c)(iImmunoGen Recitals ImmunoGen Indemnitees 10.1(a) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) ImmunoGen Proprietary Antibody 1.25 Indemnified Party Proceeding 6.9(b10.2 Indemnifying Party 10.2 Infringed Patent List 7.5(c)(v) Indemnified Persons 6.9(aInfringement 7.4(a) Labor Agreements 3.20(aInfringement Notice 7.4(a) Leased Real Property Leases 3.15(bJDC 3.2(a) Marks 1.1(kkkLilly Recitals Lilly Indemnitees 10.1(b) Maximum Premium 6.9(bLilly Response 7.5(c)(iii) Merger Losses 10.1(a) Material Breach 8.2(b) Monies 7.4(g) Negotiation Period 7.5(c)(v) Patent Committee 7.2(c)(i) Patent List 1.33 Party/Parties Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iPermitted Third Party Service Providers 2.1(a) New Plans 6.9(aPost-Royalty Term Issued Patents 5.5(b) Pre-Market Notice 7.5(d)(ii) Proposed Biosimilar Product 7.5(a) Proposed Patent List 7.5(c)(i) Receiving Party 1.12 Reinstated License 5.5(b) Reinstated Royalty Term 5.5(b) Representatives 1.12 Royalty Restoration Date 5.5(b) Royalty Term 5.5 Safety Data Exchange Agreement 3.4 [***] [***] Term 8.1(a) Third Party Claims 10.1(a) Third Party Payments 5.3(b) Upfront Fee 5.1 Wind-Down Period 5.4(d)(ii)(38.3(a) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)2. GRANT OF RIGHTS

Additional Definitions. The following capitalized terms shall have the respective meanings given to them ascribed thereto in the respective Sections sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition Affiliate Agreement 6.18 Agere Preamble Agere 2001 Plan 3.4(a)(ii) Agere 401(k) Plans 6.12(a) the Agere Board Recommendation 6.2(a) the Agere Board Recommendation Change 6.2(b) Agere Disclosure Letter Article III Agere Employees 6.13(a) Agere Executive Agreement 6.13(d) Agere In Licenses 3.19(h) Agere Insiders 6.17(c) Agere IP Licenses 3.19(i) (a) Agere Non-Employee Director Plan 3.4(a) Agere Non-U.S. Employee Plans 3.14(k) Agere Out Licenses 3.19(i) Agere Pension Plan 3.14(g) Agere Permits 3.11(b) Agere Qualified Plan 3.14(e) Agere Real Property Leases 3.16 Agere Registered Intellectual Property 3.19(a) Agere Restricted Stock 2.7(d)(ii) Agere SEC Reports 3.7(a) Agere Stock Awards 3.4(c) Agere Stock Option 2.7(d)(i) Agere Stock Plans 3.4(b) Agere Stockholder Meeting 6.3(a) Agere Subordinated Note 3.4(a)(iii) Agere Subsidiary Documents 3.3 Agere Terminating Plans 6.12(b) Agere Voting Proposal 3.5(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aAntitrust Laws 6.6(b) Anti-Bribery Laws 3.22(cAssumed Option 2.7(d)(i) Articles Assumed Unit 2.7(d)(iii) Book Entry Shares 2.8(c) BONY 5.3 Certificate of Merger 2.4(a2.3 Certificates 2.8(c) Certificates 2.9(c)(iTable of Contents Closing 2.2 Closing Date 2.2 Code Preamble Common Stock Consideration 2.7(a)(i) Charter Amendment Confidentiality Agreement 6.7(h) D&O Policy 6.15(c) Delaware Secretary of State 2.3 DGCL Preamble Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(cExchange Agent 2.8(a) Exchange Fund 2.9(b2.8(b) Excluded Arrangements 6.10(aExchange Ratio 2.7(a)(i) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bExtended Termination Date 8.1(c) Indemnified Party Proceeding 6.9(bParties 6.14(b) Indemnified Persons 6.9(aIndenture 5.3 Initial Termination Date 8.1(c) Labor Agreements 3.20(aJoint Proxy Statement/Prospectus 6.4(a) Leased LSI Preamble the LSI Board Recommendation 6.2(a) the LSI Board Recommendation Change 6.2(a) LSI Convertible Notes 4.4(a)(v) LSI Disclosure Letter Article IV LSI ESPP 4.4(a)(iv) LSI In Licenses 4.19(h) LSI IP Licenses 4.19(a) LSI Material Contract 4.13(a) LSI Non-U.S. Employee Plans 4.14(k) LSI Out Licenses 4.19(i) LSI Pension Plan 4.14(g) LSI Permits 4.11(b) LSI Preferred Stock 4.4(a) LSI Qualified Plan 4.14(e) LSI Real Property Leases 3.15(b4.16 LSI Registered Intellectual Property 4.19(a) Marks 1.1(kkkLSI SEC Reports 4.7(a) LSI 2003 Stock Plan 4.4(a)(iii) LSI Stock Plans 4.4(b) LSI Stockholder Meeting 6.3(a) LSI Stockholder Proposal 6.2(a) LSI Subsidiary Documents 4.3 LSI Voting Proposal 4.5(a) Maximum Annual Premium 6.9(b6.14(c) Merger Recitals Preamble Merger Stockholder Meetings 6.3(a) Table of Contents Merger Sub Preamble Merger Sub PBGC 3.14(g) PBGC Claims 3.14(g) Qualifying Amendment 6.4(b) Registration Statement 6.4(a) Regulation M-A Filing 6.4(c) Requisite Agere Stockholder Approval 6.16 Net Debt 5.2(h)(i3.5(b) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Requisite LSI Stockholder Approval 3.4(a4.5(b) Statutory Stockholder Approvals 3.4(aSection 16 Information 6.17(b) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b2.1 Takeover Statute 3.24 Tax Opinions 6.19(b) Termination Date 8.1(bFee Amount 8.3(b)(i) Trade Secrets 1.1(kkkTriggering Event 8.1(f) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWARN Act 3.15(c)

Additional Definitions. The In addition to those terms defined above, definitions for each of the following capitalized terms have the respective meanings given to them are found in the respective Sections body of this Agreement set forth opposite each of the capitalized terms as indicated below: Acquiror 13.3 Additional Approval Condition 3.4(bHITCREATE™ Compounds 2.2(g) Agreement Preamble Alternative Acquisition Alliance Managers 3.1(b) Bankrupt Party 12.4(b) Biocon 2.6 BMS Preamble BMS Alliance Manager 3.1(b) BMS Indemnitees 11.5(b) BMS Royalty-Bearing Patent 6.4(b)(ii) Competitive Infringement 9.1 Confidential Information 10.1(a) Confidentiality Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x10.4 Disclosing Party 10.1(a) Effective Date Preamble Excluded Target 2.2(c)(i) ▇▇▇▇▇-▇▇▇▇▇▇ Time 2.4(bPeriod 9.2(a)(iii) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bIndemnification Claim Notice 11.5(c) Indemnified Party Proceeding 6.9(b11.5(c) Indemnified Persons 6.9(aJoint Research Program IP 7.2(b)(i) Labor Agreements 3.20(aLosses 11.5(a) Leased Real Property Leases 3.15(bMilestone Event 6.3(a) Marks 1.1(kkkMilestone Payment 6.3(a) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Other Patent 8.2 Party or / Parties Preamble Patents 1.1(kkkPhenotype Target Invention 2.2(f) Payment Agent 2.9(aProgram Director(s) Per Share Price 2.9(a)(iii3.1(a) Proxy Holder Recitals Proxy Statement 6.3(aReceiving Party 10.1(a) Required Permits 3.20(cRegulatory Exclusivity 6.4(b)(iii) Restraint 7.1(bRelease 10.3(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aRoyalty Term 6.4(b) Statutory Merger Stockholder Approval 3.4(aScreening Activities 2.2(f) Statutory Stockholder Approvals 3.4(aSole Research Program IP 7.2(b)(i) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bTerm 12.1 Terminated Compounds 12.5(b) Termination Date 8.1(bTerminated Rights 12.5(a) Trade Secrets 1.1(kkkThird Party Claims 11.5(a) Transaction Matters 9.11(aTitle 11 12.4(b) Uncertificated Shares 2.9(c)(iiTranzyme Preamble Tranzyme Alliance Manager 3.1(b) Union 3.20(aTranzyme Indemnitees 11.5(a) Vested Company PSU 2.10(c)(iTranzyme Research Materials 12.6(a) Vested Company RSU 2.10(a)(i)PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS.

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bTax 9.8(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAlliance Manger 3.2 Auditee 9.7(f) AntiAudit Rights Holder 9.7(f) Audit Team 9.7(f) Authorized US Phase II Study 5.3(d) Bankruptcy Code 2.2 Board of Directors 1.18(a) Breaching Party 10.2(b) Calithera Preamble Calithera Combination Study 5.3(e) Calithera In-Bribery Laws 3.22(cLicense Agreements 12.3(k) Articles of Merger 2.4(aCalithera Indemnified Parties 11.1(a) Certificates 2.9(c)(iCalithera Manufacturing Obligation 6.1 Calithera Owned Patent Rights 8.2(b)(i) Charter Amendment Calithera Retained Compound Patent Rights 8.2(b)(ii) CB-1158 1.53 CB-1158-101 Study 5.3(a) Challenged Counter Offer 2.7(i)(ii) Challenging Party 2.7(i)(i) Co-Detailing Right 7.3(a) [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Combination Product 1.62 Commercial Auto Opt-Out Event 9.5(d) Commercial Budget 7.2 Competing Party 2.7(c)(ii) Competing Party Second Offer 2.7(c)(ii) Competing Party Subsequent Offer 2.7(c)(iii) Controlling Party 8.3(c) Defense Action 8.3(a) Detailing Plan 7.3(a) Development Auto Opt-Out Event 5.2(a) Development Budget 5.1(b) Development Plan 5.1(b) Disclosing Party 13.1 Divestiture or Divest 2.6(b) Execution Date Preamble Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b15.16(a) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Election Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i8.2(b)(v)

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bAbandonment Party 8.1.5 Advances 4.2 Alliance Manager 2.5.1 Acquisition 12.10 Appointing Party 2.6.2 Arbitration Matter 12.1 ARIAD Development Cost Cap 4.2 ARIAD Indemnitees 11.2 Assuming Party 8.1.5 Claims 11.1 Clinical Supplies 3.6.3(a) Co-Development Net Sales 4.3.4 Collaborator IP Rights 6.4.3 Combination Product 4.6.1(c) Competing Drug 4.6.1(a)(ii) Co-Promoted Product 3.13.1 Co-Promotion Agreement Preamble Alternative Acquisition 3.13.2(a) Co-Promotion Territory 3.13.1 Co-Promotion Trademarks 8.3.1 Cost Audited Party 3.12.2(b) Cost Auditing Party 3.12.2(b) Date First Learned 3.10.5(a) Development Transfer 3.4(b)(i) Diagnostic Product Agreement 5.4(a3.1.2(d) Anti-Bribery Laws 3.22(cDisputed Matter 2.1.5 Estimate 4.3.2(c) Articles of Merger 2.4(aEstimated Loss 4.3.2(c) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bEstimated Operating Income Payment 4.3.2(c) Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Infringement 8.2.1(a)(i) Indemnified Persons 6.9(aInfringement Notice 8.2.1(a)(i) Labor Agreements 3.20(aLosses 11.1 MERCK Indemnitees 11.1 MERCK Manufacturing Technology and Patent Rights 6.1.2(c) Leased Real Property Leases 3.15(bOperating Income Payments 4.3.1 Opting-Out Party 3.4(a) Marks 1.1(kkkOpt-Out Notice 3.4(a) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Opt-Out Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval Opt-Out Right 3.4(a) Statutory Stockholder Approvals Other Products 4.6.1(c) Patent Coordinator 7.5 Phase 1/2 Clinical Trial 4.5(c) Phase 2/3 Clinical Trial 4.5(d) Program Confidential Information 6.4.4(c) Promissory Note 4.2 Reasonably Estimated Commercial Value 4.6.1(c) Representative Schedule 3 ROW Development Costs 3.12.1 Recipient Party 3.3 Separation Date 3.4(a) Support Supply Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b3.6 Term 9.1(c) Termination Transfer Date 8.1(b3.4(b)(ii) Trade Secrets 1.1(kkkTransferring Party 3.3 U.S. Commercialization Transfer 3.4(b)(ii) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iWeighted Average Sales Price 4.6.1(c)

Additional Definitions. The In addition, each of the following capitalized terms definitions shall have the respective meanings given to them set forth in the respective Sections section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b. Accounting Firm 6.4.2(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aPayments 6.3 Alliance Manager 4.1.2 Audited Party 6.4.2(a) Anti-Bribery Laws 3.22(cAuditing Party 6.4.2(a) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Collaboration Sequence Pair 3.4.2 Commercial License 2.1.2 Commercialization Milestone Event 5.4.3 Commercialization Milestone Payment 5.4.3 Competing Product Infringement 7.3.1 Confidentiality Agreement 14.13 Controlling Party 7.3.4 Designation Notice 3.4.2 Development Milestone Event 5.4.1 Development Milestone Payment 5.4.1 Dispute 14.5.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Claim 14.5.5 First Program [...***...] 29 5.3 [...***...] Milestone Event 30 5.4.2 [...***...] Milestone Payment 31 5.4.2 IND Filing 3.1.1 Identified Sequence Pair 3.4.1 Indemnified Party Proceeding 6.9(b) 13.3.1 ____________________________ 27 Competitive Information – Technical Information. 28 Competitive Information – Technical Information. 29 Competitive Information – Financial Provisions. 30 Competitive Information – Financial Provisions. 31 Competitive Information – Financial Provisions. Indemnifying Party 13.3.1 Joint Publication 9.1.1 JSC 4.2 JSC Chair 4.2 ▇▇▇ Preamble ▇▇▇ Development IP 7.1.2 ▇▇▇ Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Party 13.1 ▇▇▇ ▇▇▇▇▇▇▇ Term 5.6.3 Losses 13.1 Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent of Achievement of Milestone 6.1.1 Notice of Dispute 14.5.1 Parties Preamble Party or Parties Preamble Patents 1.1(kkk) Payee 6.1 Payor 6.1 Product Royalty 5.6.1 Product Royalty Term 5.6.3 [...***...] 32 5.3 Prosecution 7.2.1 Publishing Party 9.1.1 Research Program 3.1.1 Research Program Leader 4.1.1 Research Program Term 3.1.2 Research Sequence Pairs 3.4.1 Reserve Period 3.4.1 Reviewing Party 9.1.1 Rules 14.5.1 Second Program [...***...] 33 5.3 Taxes 6.3 Term 10.1.1 Third Party Claims 13.1 Third Party Obligations 3.4.1 Upfront Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)5.1 Zymeworks Preamble Zymeworks Development IP 7.1.1 Zymeworks Development IP Patent Rights 7.1.1 Zymeworks Indemnified Party 13.2 Zymeworks Milestone Event 5.5 Zymeworks Platform Improvements 7.1.1 Zymeworks Royalty Term 5.7.2 ____________________________ 32 Competitive Information – Financial Provisions. 33 Competitive Information – Financial Provisions.

Additional Definitions. The definition of each of the following capitalized terms have the respective meanings given to them is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b13D Group Section 10.08(a)(ii) 1974 Convention Section 13.01 Agreement Preamble Alternative Acquisition API Supply Section 6.03 Archemix Patent Rights Section 3.01(g) Auditor Section 7.07 Breaching Party Section 11.02(a) Clinical Supply Agreement 5.4(aSection 6.03 Co-Chairs Section 2.05 Co-Formulated Product Option Term Section 3.04(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xCode Section 3.10 Commercial Supply Agreement Section 6.03 Confidential Information Section 9.01 Controlling Party Section 4.09(f) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bDate Preamble Genentech Section 3.11 Indemnification Claim Notice Section 10.10(c)(i) Indemnified Party Proceeding 6.9(bSection 10.10(c)(i) Indemnifying Party Section 10.10(c)(i) Initial Development Plan Section 4.02 Initial Marketing Plan Section 5.04 Invalidity Claim Section 8.03(g) Issued Valid Claim Section 1.90 JCD/RS Section 2.02(a) JCS Section 2.04(a) JMS Section 2.03 JOC Section 2.01(a) Joint Collaboration IP Section 8.01(b)(iv) Joint Patent Rights Section 8.02(c) Legal Dispute Section 12.01 Lucentis License Agreement Section 3.11 Marketing Plan Section 5.04 Nektar Patent Rights Section 3.01(h) Non-Breaching Party Section 11.02(a) Non-Casting Vote Matter Section 2.08(d) Novartis Preamble Novartis Alternative Anti-PDGF Product Section 3.07(a) Novartis Casting Vote Matters Section 2.08(c)(ii) Novartis Collaboration IP Section 8.01(b)(iii) Novartis Indemnified Persons 6.9(aParties Section 10.10(a) Labor Agreements 3.20(aNovartis Patent Rights Section 8.02(a) Leased Real Property Leases 3.15(bOphthotech Preamble Ophthotech Anti-VEGF Co-Formulated Product Section 3.04(f)(iii) Marks 1.1(kkkOphthotech Alternative Anti-PDGF Product Section 3.06(a) Maximum Premium 6.9(bOphthotech Casting Vote Matters Section 2.08(c)(i) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iOphthotech Collaboration IP Section 8.01(b)(iii) New Plans 6.9(aOphthotech Indemnified Parties Section 10.10(b) Notice Ophthotech Patent Rights Section 8.02(b) Ophthotech Product Patent Rights Section 1.61 [**] Section [**] OSI IP Section 3.01(i) PEG Section 3.01(h)(i) Pending Valid Claim Section 1.90 Product Positioning and Branding Strategy Section 2.01(c)(ii) Promotional Materials Section 5.05 Requesting Party Section 4.09(f) Restricted Period 5.4(d)(ii)(3Section 10.08(b) Old Plans 6.9(aSevered Clause Section 13.03 Supply Agreement Section 6.03 Term Section 11.01 Third Party License Section 7.04(d) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)wet AMD Introduction Working Group Section 2.06

Additional Definitions. The following capitalized terms have the respective meanings given to them are defined in the respective Sections of this Agreement set forth opposite each of across from such term in the capitalized terms belowfollowing table: Additional Approval Condition 3.4(b) Aggregate Inventory Amount 3.3 Agreement Preamble Allocation Schedule 3.5 Alternative Acquisition Agreement 5.4(a7.9(c) Anti-Bribery Laws 3.22(cArrow Preamble Assumed Contracts 5.9 Assumed Liabilities 2.4 Balance Sheet Date 5.5 Business Employees 5.16(a) Articles Buyer Preamble Buyer Applications 7.14(a) Change of Merger 2.4(aRecommendation 7.9(c) Certificates 2.9(c)(iClaim Notice 8.4(a) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date Payment 3.2(a) Collection Period 7.23 Collections Deficiency 7.23 Collections Excess 7.23 Competing Business 7.2(a) Confidentiality Agreement 7.9(a) Current Prescription Volume 5.11 Data Converter 7.3(a) Eastern Preamble Employee Plans 5.16(b) Event of Loss 7.16(b) Excluded Assets 2.3 Excluded Contracts 2.3(b) Excluded Liabilities 2.5 Company Existing Worksite Pharmacies Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bFairness Opinion 5.22 Familymeds Preamble File-Transfer Amount 3.1(a) Company Leased Real Property 3.15(bFile-Transfer Inventory 2.1(b) Company Option 2.8(c)(iFile-Transfer Locations Preamble File-Transfer Records 2.1(a) Company Owned Real Property 3.15(aFMRX Preamble FMRX Proxy Statement 7.10(b) Company PSU 2.10(c)(iFMRX Recommendation 7.9(c) Company Recommendation 3.3(aFMRX Stockholder Approval 5.1(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company FMRX Stockholder Meeting 6.4(a7.10(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bIOU Prescriptions 7.5 Indemnified Event 8.6(b) Indemnified Party Proceeding 6.9(bPerson 8.4(a) Indemnified Persons 6.9(aIndemnitor 8.4(a) Labor Agreements 3.20(aIndemnity Agent 3.4 Indemnity Amount 3.2(d) Leased Real Property Leases 3.15(bIndemnity Escrow Account 3.2(d) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Indemnity Fund 3.4 Indemnity Termination Date 8.1(b) Trade Secrets 1.1(kkkIndependent Valuator 3.3(a) Transaction Matters 9.11(aInventory 2.2(c) Uncertificated Shares 2.9(c)(iiInventory Amount 3.3 Inventory Audit 3.3 Inventory Closing Date Payment 3.2(b) Union 3.20(aManagement Consulting Period 7.20(c) Vested Company PSU 2.10(c)(iNotice of Superior Proposal 7.9(c) Vested Company RSU 2.10(a)(iOperate Amount 3.1(c) Operate Location Pharmacies Preamble Payment Program 5.19(c)(i) Pending Proposal 7.9(c) (a) Personal Property 2.2(a) PHI 7.3(c) Power of Attorney 7.14(c) Purchase Price 3.1 Purchased Assets 2.2 Purchased File-Transfer Assets 2.1 Record Data 7.3(a) Records 2.2(b) Representatives 7.9(a) Revenue, SG&A and Balance Sheet Data 5.5 Revised Buyer Proposal 7.9(c) Rx Operations Data 5.5 Sellers Preamble Shortfall 3.2(c)(ii) Termination Date 10.1(e) Title Commitment 7.22 Third Party Distributor 7.4 Third Person Claim 8.4(a) Transferable Permits 7.14(a) Transferred Employee 7.1(b)

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) AHR Target 1.23 Alliance Manager 2.2.1 Anti-Bribery Laws 3.22(cPolicies 3.8.6 Antitrust Filings 4.4.2 Bankruptcy Code 7.5 Bankruptcy Event 11.4 Celgene Preamble Celgene Indemnitees 10.2 Chairperson 2.3.3 Collaboration 2.1 Collaboration Compound-Specific IP 8.2 Collaboration Effective Date Preamble Collaboration Material Transfer Agreement Collaboration Program Assets 3.7.1(a) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 4.3 Company Preamble Company Charter Amendment Certificate 2.1 Agreement 6.5.3 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Indemnitees 10.1 Cure Period 11.2.1 Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Protection Laws 1.61 Disclosing Party 8.1 Disputes 12.1 DOJ 4.4.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d13.10 EMA 1.77 Existing Confidentiality Agreement 8.10 FDA 1.77 Force Majeure 13.3 FTC 4.4.2 HIPAA 1.61 HSR Act 1.6 HSR Clearance Date 4.4.2 HSR Filing 4.4.2 Human Materials 3.8.3 Indemnitee 10.3 Indemnitor 10.3 Information Request 3.1.4 JRA Exception 7.6.1(b) ExJSC 2.3.1 Kynureninase Target 1.23 License Effective Date 4.4.2 Materials 3.7.1(b) Non-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Collaboration Compound-Specific IP 8.2 Officials 3.8.5 Opt-in 4.1 Opt-in Exercise Fee 6.2 Opt-in Exercise Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 4.2 Party or Parties Preamble Patents 1.1(kkkPatent Liaison 2.2.2 Payee Party 6.5.2(b) Payment Agent 2.9(a3.8.5 Paying Party 6.5.2 (b) Per Share Price 2.9(a)(iiiPHI 3.8.3 Providers 3.8.3 Qualified Scientist 3.2.2 Receiving Party 8.1 Review Period 3.1.4 Scientific Panel 3.2.2 SEC 8.4.1 (a) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Securities Regulators 8.6 Subcommittee 2.3.2 Subcontracting Essential Provisions 3.5

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: * Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission Definition Section Accounting Period 11.1 Acquired Party 20.3.7 Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) AntiAssets 10.8.3 Additional Review Period 3.2 [***] 4.1 Arbitral Tribunal 22.3 Assignee 19 [***] 1.5 Bankruptcy Code 21 Breaching Party 20.2.1 [***] 1.1 CMC 1.19 Continuation Election Notice 20.3.2 [***] 3.1 Decision Period 14.10 Deduction Cap 10.7 Development Plan 6.2 Disclosing Party 1.15 Escalation Notice 22.2 Excluded Patent Rights 1.55 Exclusive Right of First Negotiation 3.2 Expert Committee 10.6 [***] 1.1 [***] 16.1 GBT Invention 1.37 GBT Notice 3.1 Governing Law 22.1 Indemnified Losses 16.1 Indemnifying Party 16.3 Initial Review Period 3.1 Initiating Party 14.10 Insolvency Party 20.2.2 Joint Invention 1.37 [***] 3.1 NDA 22.1 Negotiation Period 3.2 Non-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) ExAcquired Party 20.3.7 Non-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Breaching Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) 20.2.1 Non-Insolvency Party 20.2.2 Patent Term Extensions 14.13 Peremptory Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble 20.2.1 Publishing Notice 18.4 Receiving Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover 1.15 Relative Commercial Value 10.5 [***] 3.3 [***] 3.2 Reverse Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) 3.2 * Confidential Information, indicated by [***], has been omitted from this filing and filed separately with the Securities and Exchange Commission Review Notice 3.1 [***] 16.2 [***] 3.1 Roche Invention 1.37 ROFN Exercise Notice 3.2 Settlement 14.10 SPCs 14.13 Strategic Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Revenues 10.8.1 Suit Notice 14.10 Term Sheet 3.2 Transfer 4.3 Valuation Firm 10.8.3

Additional Definitions. The following capitalized terms have the respective meanings given to them set forth in the respective corresponding Sections of this Agreement: ​ ​ ​ Action 18.3(c) Actual Damages Cap 19.2(i) Actual Passage Bio Receipt 8.2(b) Additional Batches 2.5.4, Exhibit C Arising IP Patents 15.7 Auditing Party 11.9 Audits 17.2(b) Batch Documentation 9.2(d) Batch Investigation 7.1(c) Batch Processing 7.1(a) Binding Orders Period 2.5.2, Exhibit C Binding Quarter or BQ 2.5.2, Exhibit C Catalent Arising IP 15.4 Catalent Indemnitee 18.7 Catalent Project Manager 9.1(b) Catalent Records 17.1(a) cGMP Manufacturing Runs 4.1 Chemistry Manufacturing and Control or CMC 11.1 Continuous Improvement Program 10.1(h) CIP 10.1 CPS Recitals Defective Batch 7.1(b) Delivery 4.6(b) Disclosing Party 14.3(a) ​ ​ ​ ​ ​ Disclosure Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b14.1 Extended Manufacturing Period 19.1(a) Failed Batch 7.1(b) FQ 2.5.1, Exhibit C Fiscal Year or FY 2.3.3, Exhibit C GMP Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) 14.2 Indemnified Party Proceeding 6.9(b18.8 Indemnifying Party 18.8 Initial Forecast 2.5.1, Exhibit C Initial Manufacturing Period 19.1(a) Indemnified Persons 6.9(aLOI Recitals Loss 18.6 Manufacturing Start Date 2.2, Exhibit C Supply Pricing 1.1, Exhibit C Maximum Annual Batches 2.4.1, Exhibit C Paragon 14.2 Passage Bio Approval 4.6(a) Labor Passage Bio Arising IP 15.5 Passage Bio Indemnitee 18.6 Passage Bio Supply Agreements 3.20(aRecitals Payment Schedule 4.7(a) Leased Real Property Leases 3.15(bPPI 2.3.2, Exhibit C Primary Cause 7.1(c) Marks 1.1(kkkProcess Performance Qualification or PPQ 4.1(a) Maximum Premium 6.9(bPPQ Completion Date 4.4 Receiving Party 14.3(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iRetained Copies 19.2(k) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bRolling Forecast 2.5.3, Exhibit C Scope of Work 4.1 Term 19.1 Terminating Event 7.1(a) Termination Date 8.1(b19.2(a) Trade Secrets 1.1(kkkTermination Fee 19.2(c)(i) Transaction Matters 9.11(a​ ​ ​ ​ ​ This Exhibit C establishes the Parties understanding as to (i) Uncertificated Shares 2.9(c)(iithe minimum annual ordering obligations of Passage Bio for the Manufacture of Batches of Passage Bio Products in the Dedicated Clean Room Suite, (ii) Union 3.20(athe fees that Passage Bio will pay to Catalent during the Term following the Readiness Determination for the Dedicated Clean Room Suite, and (iii) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(ithe establishment of procedures for the initial forecasting and rolling forecasts of Passage Bio’s ordering of Batches of the Passage Bio Products in the Dedicated Clean Room Suite. It is the intent of the Parties, that the minimum annual ordering obligations set forth in this Exhibit may be satisfied through the Manufacture of Batches under this Agreement, [*] (“Additional Manufacturing and Supply Agreements”).

Additional Definitions. The following capitalized table sets forth certain other defined terms have and the respective meanings given to them in the respective Sections of this Agreement set forth opposite each Section of the capitalized terms belowAgreement in which the meaning of each such term appears: Additional Approval Condition 3.4(bApproved Enterprise Status 34 SECTION 5.08 Assumed Liabilities 8 SECTION 2.03(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aAuthorizations 19 SECTION 3.09 Baseline Net Asset Value 10 SECTION 2.04(a)(i) Anti-Bribery Laws 3.22(cBusiness Intellectual Property 22 SECTION 3.16(g) Articles of Merger 2.4(aClaim 41 SECTION 9.04 Closing 13 SECTION 2.07(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company 13 SECTION 2.07(a) Closing Date Balance Sheet 11 SECTION 2.04(c) Closing Payment 10 SECTION 2.04(b)(i) COBRA 9 SECTION 2.03(b)(iv) Consents 19 SECTION 3.11 Direct Claim 40 SECTION 9.03(b) Disclosure Letter 1.4 Company Intellectual Property 3.17(bSchedule 13 ARTICLE III Dollars 7 SECTION 1.03 Enterprise Value 10 SECTION 2.04(a)(i) Company Leased Real Property 3.15(bEscrow Agent 10 SECTION 2.04(b)(ii) Company Option 2.8(c)(iEscrow Agreement 10 SECTION 2.04(b)(ii) Company Owned Real Property 3.15(aEscrow Amount 11 SECTION 2.04(b)(iii) Company PSU 2.10(c)(iEstimated Balance Sheet 10 SECTION 2.04(a)(i) Company Recommendation 3.3(aEVP Loan Repayment Amount 11 SECTION 2.04(b)(v) Company Recommendation Change 5.4(c)(iFinal Balance Sheet Adjustment 12 SECTION 2.04(d) Company RSU 2.10(a)(iFinal Balance Sheet Adjustment Escrow Amount 10 SECTION 2.04(b)(ii) Company SEC Reports 3.8(dGovernment Grants 29 SECTION 3.23(a) Company Securities 3.7(bIndemnifiable Losses 39 SECTION 9.01 Indemnity Basket 41 SECTION 9.06 Interim Balance Sheet 16 SECTION 3.05 Interim Financial Statements 17 SECTION 3.05 Interim Income Statement 17 SECTION 3.05 Israeli Employees 27 SECTION 3.17(i) Company Special Committee Recitals Company Stockholder Meeting 6.4(aManufacturing Documentation 20 SECTION 3.14 Net Asset Value 11 SECTION 2.04(c) Converted PSU Award 2.10(c)(iiNIS 7 SECTION 1.03 Non-competition Period 33 SECTION 5.05 Proposed Closing Date Net Assets Calculation 11 SECTION 2.04(c) Converted Restricted Share Award 2.10(bPurchase Price 10 SECTION 2.04(a) Converted RSU Award 2.10(a)(iiPurchased Assets 7 SECTION 2.01 Retained Assets 8 SECTION 2.02 Retained Liabilities 8 SECTION 2.03(b) Copyrights 1.1(kkkSeller Audited Financial Statements 16 SECTION 2.03(b) Covenant Exceptions 5.1(aSeller Databases 25 SECTION 3.16(p) Data Privacy/Security Requirements 3.17(gSeller Product 20 SECTION 3.16(a) Effect 1.1(xSeller Software 24 SECTION 3.16(l) Effective Time 2.4(bSeller’s Financial Statements 17 SECTION 3.05 Standard Form Agreement 21 SECTION 3.16(f) Electronic Delivery 9.13 Enforcement Expenses 8.3(dTerminated Employees 36 SECTION 6.02 Third Party Claim 40 SECTION 9.03(a) Ex-Im Laws 3.22(cTotal Cash Payment 10 SECTION 2.04(a)(i) Exchange Fund 2.9(bVAT 12 SECTION 2.05(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iVAT Request 12 SECTION 2.05(b)

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(bABI-H0731 Initial Development Plan 5.2(c) Accounting Firm 9.10(b)(i) Agreement Preamble Alternative Acquisition Agreement Payments 9.11(a) Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) Applicable Upstream License Provisions 2.8 AssemblyBio Preamble AssemblyBio Ancillary Trials Budget 5.5(c) AssemblyBio Indemnitee(s) 13.1 AssemblyBio Publication 11.1(d) AssemblyBio Veto Right 3.2(f)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) BeiGene Preamble BeiGene Collaboration Patent Rights 14.3(a) BeiGene Development Report 5.8 BeiGene Election 5.2(d)(ii) BeiGene Indemnitees 13.2 BeiGene Publication 11.1(c) BeiGene Veto Right 3.2(f)(ii) Breach Notification 15.2(c)(i) Claims 13.1 Clinical Supply Agreement 7.2(a) Commercial Supply Agreement 7.2(b) Commercialization Milestone Event 9.3 Commercialization Milestone Payment 9.3 Competing Product 2.6(a) Confidentiality Agreement 16.15 Continuing Technology Transfer 4.1 Development Cost Cap 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(xDevelopment Milestone Event 9.2 Development Milestone Payment 9.2 Disclosing Party 1.26 Dispute 16.6(a) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(dDate Preamble Enforceable Patent Rights 14.3(b) Ex-Im Laws 3.22(c) Exchange Fund 2.9(bTerritory Infringement 14.3(a) Excluded Arrangements 6.10(aClaim 16.6(e) FHWA 3.21(bExecutive Officers 3.2(f) Financing 6.5(aExisting Regulatory Materials 12.2(o) FMCSA 3.21(bExpert 16.7(c) Expert Dispute 16.7(a) Expert Resolution Notice 16.7(b) [* * *] 9.2 Global Brand Elements 8.4(c) Global Development Budget 5.2(a) Global Development Plan 5.2(a) Global Publication Strategy 11.1(a) ICH Guidelines 1.43 In-Licensed Patent Rights 2.8 Indemnified Party Proceeding 6.9(b13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Initiation 9.2 JAMS 16.6(a) Indemnified Persons 6.9(aJCC 3.3(b) Labor Agreements 3.20(aJDC 3.3(a) Leased Real Property Leases 3.15(bJGS Territory Extra Costs 5.4(c) Marks 1.1(kkkJGS Territory Extra Patients 5.4(c) Maximum Premium 6.9(bJMC 3.3(c) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iJoint COGM Improvements 7.2(d)(i) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(c)(ii) JSC 3.2(a) License 2.1 Losses 13.1 New Plans 6.9(aDevelopment Proposal 5.5(a) Notice Period 5.4(d)(ii)(3of Dispute 16.6(a) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Party/Parties Preamble Patents 1.1(kkkPatient Enrollment Guardrail 5.2(b) Payment Agent 2.9(aPharmacovigilance Agreement 6.4 Product Infringement 14.3(a) Per Share Price 2.9(a)(iiiProduct Marks 14.8 Public Official 12.7(d) Proxy Holder Recitals Proxy Statement 6.3(aPublication 11.1(d) Required Permits 3.20(cReceiving Party 1.26 Representatives 12.7(a) Restraint 7.1(b[* * *] [* * *] Review Period 11.1(c) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aRoyalty Term 9.6(b) Statutory Merger Stockholder Approval 3.4(aRules 16.6(a) Statutory Stockholder Approvals 3.4(aScheduled Patent Rights 12.2(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bSEC 11.4(c) Termination Date 8.1(bSecurities Regulators 11.4(c) Trade Secrets 1.1(kkkStandstill Period 16.1 Subcommittees 3.3(d) Transaction Matters Taxes 9.11(a) Uncertificated Shares 2.9(c)(iiTechnology Transfer 4.1 Term 15.1 Territory Clinical Trials 5.3(b) Union 3.20(aTerritory Development Budget 5.3(a) Vested Company PSU 2.10(c)(iTerritory Development Plan 5.3(a) Vested Company RSU 2.10(a)(i)Territory Only Case Budget 5.4(d) Territory-Related Clinical Trials 5.3(b) Territory-Specific Clinical Trials 5.3(b) Third Party License 14.5 Unilateral Development Activity 5.5(b) Upfront Payment 9.1

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Acquired Person 1.14 Active Immunotherapeutic Approaches 4.2.1 Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Celgene Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Celgene Acquired Competing Antibody 4.5.2 Celgene Exclusivity Term 4.5.1 Celgene Indemnitees 9.2 Celgene Proposed Terms 4.2.2 Celgene Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) 6.8.4 Celgene Third Party Payments 5.3.4 Combination Product 1.52 Competing Antibody 4.5.1 Competing Compound 4.1 Cure Period 10.2.1 Disclosing Party 7.1 Dispute 11.7.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d11.11 Effective Date Preamble EMA 1.68 Excluded Claim 11.7.3(d) ExExisting Regulatory Materials 2.2.1 FDA 1.68 [***] [***] Force Majeure 11.3 GAAP 1.1 Grant 4.2.2 Grant Notice 4.2.2 HIPAA 1.5 IFRS 1.1 Indemnitee 9.3 Indemnitor 9.3 Indirect Taxes 5.6.2(b) Insolvency Event 10.4 Joint IP 6.6.4 Joint Know-Im Laws 3.22(cHow 6.6.4 Joint Patent 6.6.4 Licensed Program Assets 2.4 Licensed Program Confidential Information 7.11 Licensed Program Inventory 2.3.4 Licensed Program Know-How 1.46(a) Exchange Fund 2.9(bLicensed Program Non-Specific IP 7.2 Licensed Program Patents 1.46(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Licensed Program Specific IP 7.2 Licensed Program U.S. License Agreement Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Master Collaboration Agreement Recitals MHLW 1.68 Negotiation Period 4.2.2 [***] [***] Notice Period 5.4(d)(ii)(34.2.2 Ongoing Clinical Trial 2.1.3(a) Old Plans 6.9(aOngoing Prothena Development Activities 2.1.3(c) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Liaison 6.7 Payee Party 5.6.2(b) Payment Agent 2.9(aPaying Party 5.6.2(b) Per Share Price 2.9(a)(iiiLicensed Product Annual Net Sales 5.3.1 Program Recitals Prothena Preamble Prothena Acquired Competing Compound 4.4 Prothena Indemnitees 9.1 Prothena Licensor 8.3.3 Prothena Ongoing Program Activities 2.1.3(d) Proxy Holder Recitals Proxy Statement 6.3(aProthena Reversion Antibodies 10.8.1 Publishing Party 7.8.1 Receiving Party 7.1 Regulatory Milestone Payment 5.4.1 Right of First Negotiation 4.2.2 Sales Milestone Payment 5.5.1 SEC 7.4.1(a) Required Permits 3.20(cSecurities Regulators 7.6 Tax Benefit 5.6.2(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Term 10.1.1 Transition Plan 2.3.6

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bAcquired Party 13.3(b) Acquirer 13.3(b) Acquisition 13.3(b) Administrator 11.3(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aTerm 10.1 AKA 1.3 Bankruptcy Laws 10.5(b) Anti-Bribery Laws 3.22(cBreaching Party 10.3 cGCP 1.3 cGMP 1.3 Claim 12.1 Commercialization Report 5.6 Cooperating Party 8.3(b) Articles of Merger 2.4(aCure Period 10.3 Development Event 6.2(a) Certificates 2.9(c)(iDevelopment Event Payment 6.2(a) Charter Amendment Development Plan 3.1 Development Report 3.5(b) Development Transition Plan 3.6 Disclosing Party 1.18 Event 6.2 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bFCA 1.3 FCPA 1.3 FFDCA 1.3 Inbound License 9.2(g) Company Leased Real Property 3.15(bIndemnifying Party 12.3(a) Company Option 2.8(c)(iIndemnitee 12.3(a) Company Owned Real Property 3.15(aInfringement Recovery 7.5(e) Company PSU 2.10(c)(iInsolvency Event 10.5(a) Company Recommendation 3.3(aJoint Inventions 7.1 Joint Patents 7.3(c) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting Losses 12.1 MacroGenics Preamble MacroGenics Indemnitee 12.1 MacroGenics Platform Inventions 7.1 Manufacturing Technology Transfer 4.1 Manufacturing Transition Plan 4.1 Millipore 6.4(a) Converted PSU Award 2.10(c)(iiMillipore License 6.4(a) Converted Restricted Share Award 2.10(bOfficials 9.4(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Package 5.3 Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkkPatent Extension 7.4 Patent Extensions 7.4 Payment 9.4(b) Platform Patent 7.5(d) Platform Patent Extension 7.4 Prior CDA 8.5 Provention Preamble Provention Common Stock 9.3 Provention Indemnitee 12.2 Provention License 2.1 Provention Series A Preferred Stock 9.3 Publishing Party 8.7 Qualified Consideration Agreement 1.71 R&D Technology Transfer 3.6 Receiving Party 1.18 Requesting Party 8.3(b) Reviewing Party 8.7 Rules 11.3(a) Sales Event 6.2(b) Sales Event Payment Agent 2.9(a6.2(b) Per Share Price 2.9(a)(iiiSecurities Act 9.2(k) Proxy Holder Recitals Proxy Statement 6.3(aSole Inventions 7.1 Terminating Party 10.3 Third Party Obligation 6.4(a) Required Permits 3.20(cThird Party Patent Challenge 7.7(b) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Transferred Materials 4.1 Transition Period 3.6 UKBA 1.3 Voluntary Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)10.2 Voting Debt 9.3 Warrant 6.1

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this Agreement set forth opposite each of the capitalized terms belowAgreement: Additional Approval Condition 3.4(b) Accused Party 9.5 ADC 1.19 Aggregate Annual Net Sales 8.3 Agreement Preamble Alternative Acquisition Alliance Manager 3.1 BLA 1.59 CAR 1.19 Cessation Period 13.4 Claims 11.1 CMCC 1.89 CMCC License Agreement 5.4(a1.89 Confidentiality Agreement 1.20 Development and Regulatory Milestone Event 8.2 Development and Regulatory Milestone Payment 8.2 Development Costs 4.2.1 Development Plan 4.2.1 Direct Cell Line License 2.9.2 Effective Date Preamble Enforcing Party 9.4.3 Executive Officers 14.1 Existing Agreements 10.2.11 GAAP 1.2 HBM Alpha Preamble HBM Alpha Indemnitees 11.2 HBM Alpha Inventions 9.1.3(b) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) ICC 14.2 IFRS 1.2 Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Infringement 9.4.1 Infringement Action 9.5 Joint Inventions 9.1.3(d) Indemnified Persons 6.9(aJSC 3.2.1 Losses 11.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Agreement 7.2 Mono Product 1.66 Negotiation Period 2.7.3 Other Product(s) Labor Agreements 3.20(a1.16 Party Preamble Patent Challenge 13.5 Pharmacovigilance Agreement 5.5 Product Materials 4.7 Publication 12.4.1 Remedial Action 5.6 Reversion License 13.7.1 Review Period 2.7.3 ROFN 2.7.1 ROFN Exercise Notice 2.7.3 ROFN Notice 2.7.2 ROFN Transaction 2.7.2 Royalty Term 8.4.2 Sales Milestone Event 8.3 Sales Milestone Payment 8.3 SEC 12.3.3 Securitization Transaction 15.6.2 Spruce Preamble Spruce Generated Data 9.1.1 Spruce Indemnitees 11.1 Spruce Inventions 9.1.3(c) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Step-In Rights 9.2.4 Subsequent Transaction 1.84 Subsequent Transaction Income Payment 8.6 Term 13.1 Third Party Acquiree 2.6.3 Third Party Acquiree Product 2.6.3 Third Party Acquiror Product 2.6.2 Third Party Acquisition 2.6.3 Third Party License 8.4.5 Transition Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)2.6.3 Unsolicited Offer 2.7.2 VAT 8.11.3 Withholding Action 8.11.2 Working Group 3.5

Additional Definitions. The Each of the following capitalized terms shall have the respective meanings given to them meaning described in the respective Sections corresponding Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bAcquiring Entities 9.7 Acquisition 9.7 Avanir Assumed Patent 9.2(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAvanir Indemnitees 11.1 Avanir Trademarks 9.6 [***] [***] Claims 11.1 Committee 3.4 Consultants Exhibit 4.5(b) AntiCost Sharing Commencement Date Exhibit 4.5(b) Current Clinical Studies and Activities 4.3(a) [***] [***] Debarred Person 10.3(l) Development Milestone 8.2(a) Development Plan 4.1(a) Development Plan Budget Exhibit 4.5(b) Device-Bribery Laws 3.22(cSpecific Regulatory Materials 5.4(b) Articles of Merger 2.4(a[***] [***] Escalation Notice 3.6 HSR Act 10.2(p) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bHSR Rules 10.2(p) Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Infringement 9.3(a) Indemnified Persons 6.9(aInfringer 9.3(a) Labor JAMS 14.3(b) Joint Development Committee / JDC 3.2(a) Joint Development Costs Exhibit 4.5(b) Joint Intellectual Property Committee / JIPC 3.3 Joint Steering Committee / JSC 3.1(a) Liabilities 11.1 OptiNose Indemnitees 11.2 OptiNose Style Guide 6.3 Patent Challenge 13.2(b) Product Launch Plan 6.2(a) Prosecution and Maintenance 9.2(c) Royalty 8.3(a) Royalty Report 8.3(b)(i) Royalty Term 8.3(d) Rules 14.3(b) Sales Milestone 8.2(b) Supply Agreement 7.4 Supply Transition Date 7.1 Supply Transition Period 2.1(b) Supply Transition Plan 7.1 Tax residence Certificate 8.4(b) Term 13.1 Third Party Agreements 3.20(a10.3(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Third Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Infringement Actions 9.4

Additional Definitions. The following capitalized terms have table identifies the respective meanings given to them location of definitions set forth in the respective various Sections of this the Agreement: Accused Party 9.5 Advaccine Preamble Advaccine Housemarks 9.6(b) Advaccine Indemnitees 11.1 Advaccine Inventions 9.1(d)(ii) Advaccine Product ▇▇▇▇ 9.6(a) Advaccine Sublicense Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b2.1(c) Agreement Preamble Alternative Acquisition Alliance Manager 3.1 Bankruptcy Laws 15.13 Claims 11.1 Clinical Manufacturing Technology Transfer Agreement 5.4(a7.1(c) Anti-Bribery Laws 3.22(cClinical Supply Agreement 7.1(a) Articles of Merger 2.4(aCombination Product 1.52 Commercialization Plan 6.2(a) Certificates 2.9(c)(iConfidentiality Agreement 1.19 Development Plan 4.3 Divestiture 2.5 Effective Date Preamble Enforcing Party 9.4(c) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Executive Officer 14.1 First Supplemental Development Plan 4.3 GAAP 1.1 IFRS 1.1 Indemnified Party Proceeding 6.9(b11.3 Indemnifying Party 11.3 Infringement 9.4(a) Indemnified Persons 6.9(aInfringement Action 9.5 Initial Development Plan 4.3 Inovio Preamble Inovio Device Commercial Supply Agreement 7.2(a) Labor Agreements 3.20(aInovio Indemnitees 11.2 Inovio Inventions 9.1(d)(i) Leased Real Property Leases 3.15(bInovio Partner 2.2 Insolvency Event 13.5 Insolvent Party 15.13 Joint Inventions 9.1(d)(iii) Marks 1.1(kkkJoint Steering Committee 3.2(a) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Losses 11.1 Non-Exclusive License Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(aNon-Insolvent Party 15.13 Other Products 1.52 Party Preamble PDF 15.12 Pharmacovigilance Agreement 5.8 Product Materials 4.7 Region 1.4 Remedial Action 5.9 Royalty Term 8.4(b) Statutory Merger Stockholder Approval 3.4(aSEC 12.3(c) Statutory Stockholder Approvals 3.4(aSecurities Regulators 12.2(c) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(bSIAC 14.2 SIAC Rules 14.2 Step-In Rights 9.2(d) Termination Date 8.1(bTax Withholding 8.9(b) Trade Secrets 1.1(kkkTerm 13.1 VAT 8.9(c) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)Working Group 3.5

Additional Definitions. The following capitalized table sets forth certain other defined terms have and the respective meanings given to them in the respective Sections of this Agreement set forth opposite each Section of the capitalized terms belowAgreement in which the meaning of each such term appears: Additional Approval Condition 3.4(bApproved Enterprise Status 34 SECTION 5.08 Assumed Liabilities 8 SECTION 2.03(a) Agreement Preamble Alternative Acquisition Agreement 5.4(aAuthorizations 19 SECTION 3.09 Baseline Net Asset Value 10 SECTION 2.04(a)(i) Anti-Bribery Laws 3.22(cBusiness Intellectual Property 22 SECTION 3.16(g) Articles of Merger 2.4(aClaim 41 SECTION 9.04 Closing 13 SECTION 2.07(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company 13 SECTION 2.07(a) Closing Date Balance Sheet 11 SECTION 2.04(c) Closing Payment 10 SECTION 2.04(b)(i) COBRA 9 SECTION 2.03(b)(iv) Consents 19 SECTION 3.11 Direct Claim 40 SECTION 9.03(b) Disclosure Letter 1.4 Company Intellectual Property 3.17(bSchedule 13 ARTICLE III Dollars 7 SECTION 1.03 Enterprise Value 10 SECTION 2.04(a)(i) Company Leased Real Property 3.15(bEscrow Agent 10 SECTION 2.04(b)(ii) Company Option 2.8(c)(iEscrow Agreement 10 SECTION 2.04(b)(ii) Company Owned Real Property 3.15(aEscrow Amount 11 SECTION 2.04(b)(iii) Company PSU 2.10(c)(iEstimated Balance Sheet 10 SECTION 2.04(a)(i) Company Recommendation 3.3(aEVP Loan Repayment Amount 11 SECTION 2.04(b)(v) Company Recommendation Change 5.4(c)(iFinal Balance Sheet Adjustment 12 SECTION 2.04(d) Company RSU 2.10(a)(iFinal Balance Sheet Adjustment Escrow Amount 10 SECTION 2.04(b)(ii) Company SEC Reports 3.8(dGovernment Grants 29 SECTION 3.23(a) Company Securities 3.7(bIndemnifiable Losses 39 SECTION 9.01 Indemnity Basket 41 SECTION 9.06 Interim Balance Sheet 16 SECTION 3.05 Interim Financial Statements 17 SECTION 3.05 Interim Income Statement 17 SECTION 3.05 Israeli Employees 27 SECTION 3.17(i) Company Special Committee Recitals Company Stockholder Meeting 6.4(aManufacturing Documentation 20 SECTION 3.14 Table of Contents Net Asset Value 11 SECTION 2.04(c) Converted PSU Award 2.10(c)(iiNIS 7 SECTION 1.03 Non-competition Period 33 SECTION 5.05 Proposed Closing Date Net Assets Calculation 11 SECTION 2.04(c) Converted Restricted Share Award 2.10(bPurchase Price 10 SECTION 2.04(a) Converted RSU Award 2.10(a)(iiPurchased Assets 7 SECTION 2.01 Retained Assets 8 SECTION 2.02 Retained Liabilities 8 SECTION 2.03(b) Copyrights 1.1(kkkSeller Audited Financial Statements 16 SECTION 2.03(b) Covenant Exceptions 5.1(aSeller Databases 25 SECTION 3.16(p) Data Privacy/Security Requirements 3.17(gSeller Product 20 SECTION 3.16(a) Effect 1.1(xSeller Software 24 SECTION 3.16(l) Effective Time 2.4(bSeller’s Financial Statements 17 SECTION 3.05 Standard Form Agreement 21 SECTION 3.16(f) Electronic Delivery 9.13 Enforcement Expenses 8.3(dTerminated Employees 36 SECTION 6.02 Third Party Claim 40 SECTION 9.03(a) Ex-Im Laws 3.22(cTotal Cash Payment 10 SECTION 2.04(a)(i) Exchange Fund 2.9(bVAT 12 SECTION 2.05(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(iVAT Request 12 SECTION 2.05(b)

Additional Definitions. The following capitalized terms have the respective meanings given to them in the respective Sections of this Agreement set forth opposite each of the capitalized terms below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(a) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a5.3(a) Certificates 2.9(c)(i2.10(c)(i) Charter Amendment Effective Time Closing 2.3 Closing 2.5 Closing Date 2.5 2.3 Company Preamble Company Charter Amendment Certificate 2.1 Board Recommendation 3.3(a) Company Board Recommendation Change 5.3(c)(i) Company Disclosure Letter 1.4 Company Intellectual Property 3.17(bOption Consideration 2.8(a) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(dPlans 6.9(b) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(aWarrant Consideration 2.9(a)(ii) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(iiComparable Plans 6.9(b) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(gDGCL Recitals Dissenting Company Shares 2.7(c)(i) Effect 1.1(x) Effective Time 2.4(b) 2.2 Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) 9.14 Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b2.10(b) Indemnified Persons 6.9(a6.8(a) International Employee Plans 3.19(a) Labor Agreements 3.20(a) Labor Entities 3.20(a) Lease 3.14(b) Leased Real Property Leases 3.15(b3.14(a) Marks 1.1(kkk) Maximum Annual Premium 6.9(b6.8(c) Merger Recitals Merger Acquisition Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a6.9(c) Notice Period 5.4(d)(ii)(35.3(d)(ii)(3) Old Plans 6.9(a6.9(c) Other Required Company Filing 6.3(a) Other Required Parent Filing 6.3(d) Owned Company Shares 2.9(a)(ii2.7(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) (a) Per Share Price 2.9(a)(iii2.7(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(aPersonal Information 3.17(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Requisite Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals 3.4 Surviving Corporation Recitals 2.1 Tail Policy 6.9(b6.8(c) Termination Date 8.1(b8.1(c) (b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i2.10(c)(ii)

Additional Definitions. The Each of the following capitalized terms shall have the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAlliance Manager 3.2 Angioblast Preamble Angioblast Competing Activities 2.4(b) Anti-Bribery Laws 3.22(cAngioblast Indemnitees 12.1 Angioblast Logos 10.2 BMF 4.6(c) Articles of Merger Cephalon Preamble Cephalon Competing Activities 2.4(a) Certificates 2.9(c)(iCephalon Indemnitees 12.2 CMC Information 4.6(c) Charter Amendment Co-Chair ¶3of Exhibit 3.1 Commercialization Plan 5.2 Committee 3.3 Competitive Product 2.4(c) Conditional Forecast 4.4(c) Costs 9.4(b) Cover 9.5(c) Defensive Action 9.4(a) Dispute 14.1 Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(bAction 9.3(b) Excluded Arrangements 6.10(aMarks ¶6(f) FHWA 3.21(bof Exhibit 13 Excluded Products ¶6(a) Financing 6.5(aof Exhibit 13 Excluded Region ¶7(a) FMCSA 3.21(bof Exhibit 13 Excluded Sub-Field ¶6(a) Indemnified of Exhibit 13 General Plan 4.2(a) Improvements 9.1(b) Indemnitee 12.3 Indemnitor 12.3 Infringing Product 9.3(b) Inventions 9.1(a) JAMS Rules 14.3(b)(ii) JMC 7.7 Joint Steering Committee 3.1 Joint Defense Agreement 9.4(a) Joint Interest Agreement 9.5(a) Joint Patent 9.2(b) JSC 3.1 Liabilities 12.1 Noticed Party Proceeding 6.9(b9.5(a) Indemnified Persons 6.9(aNoticing Party 9.5(a) Labor Agreements 3.20(aOther Dispute 14.3 Other Enforcement Action 9.3(c) Leased Real Property Leases 3.15(bOther Infringing Product 9.3(c) Marks 1.1(kkkParticipating Party 4.7 Patent Challenge 13.3(c) Maximum Premium 6.9(bPayee 6.6 Payor 6.6 Plan 3.4 Prior Confidentiality Agreement 1.18 Research Plan 4.1 Responsible Party 4.7 Senior Executives ¶5 of Exhibit 3.1 SFDA 1.56 Specific Angioblast Patent 9.2(a) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iSubcommittee ¶1 of Exhibit 3.1 Supply Agreement 7.1 Territory 1.60 Third Party Claim 12.1 Transfer Price ¶2(a) New Plans 6.9(aof Exhibit 6.3 Wind-down Period ¶5(b) of Exhibit 13 Withdrawal Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)¶6 of Exhibit 3.1

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(bDefined Term Section Audited Party §8.16(a) Agreement Auditing Party §8.16(a) AVEO Preamble Alternative Acquisition Agreement 5.4(aAVEO Control Assumption Date §14.6(a) AntiAVEO Indemnities §12.1 AVEO Group §3.2(b) Bankruptcy Code §13.3 Biogen Idec Preamble Biogen Idec Control Assumption Date §14.6(b) Biogen Idec ▇▇▇▇▇▇▇▇▇▇▇ §▇▇.▇ Breached Licensed Product §14.5(a) [**] §8.3(b) Collaboration Manager §4.5 Commercially Viable Indication §5.12(a) Competing Acquiror §13.1 Defined Term Section Competitive Infringement §9.6(a) Contract Manufacturer Notice §7.2 Control Assumption Option §13.1 Cost Payment §5.5 Cure Plan §14.3(b) Delivered Initial Development Plan §2.9 Development Plan Guidelines §4.8(a) Divestiture Period §13.1 Effective Date Preamble Event Milestone §8.4 Event Milestone Payment §8.4 Force Majeure Event §16.2 Funding Party §5.11(a) [**] §8.3(c) Indication Specific Royalty §5.13(a) ▇▇▇▇▇▇▇▇▇▇ §▇▇.▇ Initial Development Plan §2.9 Initial Release §10.3 Insolvency Control Assumption Option §13.3 Insolvency Event §13.3 JCT §6.2(a) JCT Chairperson §6.2(b) JDC §4.1 JDC Chairperson §4.2 M&A Control Assumption Option §13.1 M&A Event §3.9 Manufacturing Party §14.7 New Indication Existing Licensed Product §5.12(a) New Indication Funding Party §5.12(a) New Licensed Product §5.11(a) Non-Bribery Laws 3.22(cManufacturing Party §14.7 Non-performing Manufacturing Party §7.6 Notified Party §14.3(b) Articles of Merger 2.4(aNotifying Party §14.3(b) Certificates 2.9(c)(iOpt-in Indication §5.13(a) Charter Amendment Opt-in Effective Time Date §5.13(a) Opt-in New Indication Existing Licensed Product §5.13(a) Opt-in Notice §5.13(a) Opt-in Notice Date §5.13(a) Opting-out Party §5.11 Option §2.1 Option Exercise Date §2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses Exercise Fee §8.3(d) Ex-Im Laws 3.22(cOption Exercise Notice §2.3 Option Exercise Period §2.2 Defined Term Section Panel Identification §8.3(a) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Parties Preamble Party or Parties Preamble Patents 1.1(kkkPatent Expenses §9.5 Pre-Exercise Milestone §8.3 Pre-Exercise Milestone Payment §8.3 Product Opt-out Effective Date §5.11 Product Trademarks §9.9(b) Payment Agent 2.9(aPromotional Materials §6.4 Quarterly Cost Notice §5.5 Royalty Term §8.8 Royalty-paying Party §8.10 Section 5.11 Opt-out Effective Date §5.11(a) Per Share Price 2.9(a)(iiiSection 5.12 Opt-out Effective Date §5.12(a) Proxy Holder Recitals Proxy Statement 6.3(aSenior Representative §4.1 Supplemental Information §2.2 Supply Agreement §7.7 Tax/Taxes §8.11 Third Party Technology §3.6(a) Required Permits 3.20(cThird Party Technology Agreements §3.6(a) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)ARTICLE II.

Additional Definitions. The Each of the following capitalized terms have has the respective meanings given to them meaning described in the respective Sections corresponding section of this Agreement set forth opposite each of the capitalized terms indicated below: Table of Contents DEFINITION: SECTION: AAA 15.2.2 Acquired Third Party Development Program 9.11.2 (c) Acquired Third Party Druggable/LDD Target Development Program 9.11.2 (a) Acquired Third Party Undruggable Target Development Program 9.11.2 (b) Acquirer Activities 8.2.2 Additional Approval Condition 3.4(bCollaboration Undruggable Target Fee 9.6 Additional Target Chemistry Notification 2.8.2 (b) Agreement Preamble Alternative Acquisition Agreement 5.4(aAdditional Target Selection Fee 9.5 Additional Target Unblinding Notification 2.8.2 (a) AntiAlliance Manager 5.1 Antitrust Clearance Date 3.2 Audit Team 9.14.1 Bankruptcy Code 6.6 Biosimilar Product 9.10.3 (c) BMS Indemnified Parties 13.2.1 BMS Termination IP 14.5.4 [***] Milestone Payment 9.4 Collaboration Campaign Lesion(s) 1.1.19 Collaboration Druggable/LDD Target Resulting Compound 1.1.109 (a) Collaboration Term ROFN Period 7.1 Collaboration Undruggable Target Chemistry Period 2.9.1 (a) Collaboration Undruggable Target Resulting Compound 1.1.109 (b) Combination Product 1.1.85 Counteroffer Right 7.3.1 Cure Period 14.3.1 Disclosing Party 11.1 Dispute 15.1 DOJ 3.2 Electronic Delivery 15.14 Excluded Campaign Lesion(s) 1.1.19 Expert Schedule 5.2.6 (c) Final Data Package 2.5.6 (b) Firewalled Scientist 2.6.2 FTC 3.2 Generic Product 9.10.3 (c) [***] Milestone Payment 9.8 HSR Act 1.1.6 HSR/Antitrust Filing 3.2 Independently Validated Third Party Compound 9.11.2 (d) Internal BMS Gatekeeper 2.2.1 JSC 5.2.1 [***] Milestone Payment 9.7 Lone Target Campaign 2.5.7 (c) Material Receiving Party 2.12 Table of Contents DEFINITION: SECTION: Materials 2.12 Negotiation Period 7.2.1 Non-Bribery Laws 3.22(cIndependently Validated Third Party Compound 9.11.2 (e) Articles of Merger 2.4(aOption 2.7.1 (b) Certificates 2.9(c)(iOption Term 2.7.2 (c) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Overlapping Undruggable Target 2.6.1 (a) Post-Collaboration Term ROFN Period 7.1 Post-IND Third Party Compound 9.11.2 (g) Potential Target 2.5.1 (b) Pre-Existing Druggable/LDD Target Third Party Program 1.1.9 Pre-Existing Undruggable Target Third Party Program 1.1.14 (b) Pre-Option Campaign Lesion(s) 1.1.19 Primary Target Unblinding Notification 2.5.8 (a) Primary Target Unblinding Period 2.5.8 (a) Prioritized Overlapping Undruggable Target 2.6.1 (d) Purpose 2.12 Receiving Party 11.1 Redacted Version 11.3.2 Repare Collaboration Intellectual Property 3.17(b10.2.2 Repare Indemnified Parties 13.1.1 Resulting Compound/Product Collaboration IP 10.2.3 Reverted Optioned Target Third Party Compound 9.11.2 (f) Company Leased Real Right of First Negotiation 7.2.1 ROFN Transaction 7.1 Royalty Term 9.10.2 SEC 11.3.2 Secondary Target 2.5.7 (b) Secure Information Exchange 11.6.5 Selected Target 2.5.1 (d) Sole Collaboration Intellectual Property 3.15(b10.2.5 Tertiary Target 2.5.7 (c) Company Option 2.8(c)(iTerm 14.1 Third Party Gatekeeper Agreement 2.2.2 Third Party Required IP 9.10.3 (b) Company Owned Real Property 3.15(aTransferring Party 2.12 Unblinded Primary Campaign 2.7.2 (c)(i) Company PSU 2.10(c)(iUndruggable Campaign Lesion(s) Company Recommendation 3.3(a1.1.19 Undruggable Target Data Package 2.6.2 Undruggable Target Unblinding Notification 2.6.3 (a) Company Recommendation Change 5.4(c)(iUndruggable Target Unblinding Period 2.6.3 (a) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(b) Indemnified Party Proceeding 6.9(b) Indemnified Persons 6.9(a) Labor Agreements 3.20(a) Leased Real Property Leases 3.15(b) Marks 1.1(kkk) Maximum Premium 6.9(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(i) New Plans 6.9(a) Notice Period 5.4(d)(ii)(3) Old Plans 6.9(a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Unsolicited Offer 7.1 Upstream IP 9.12 Warrant Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(i)9.2 Table of Contents

Additional Definitions. The Each of the following capitalized terms have the respective meanings given to them definitions is set forth in the respective Sections Section of this Agreement set forth opposite each of the capitalized terms indicated below: Additional Approval Condition 3.4(b: (a) Abandoned Huadong Patents 7.3(c) (b) Abandoned Patents 7.3(a) (c) Adjusted Net Sales 6.5(a) Administrator 12.2(b)(i) Adverse Ruling 11.2 Agents 8.1 Agreement Preamble Alternative Acquisition Alliance Manager 3.3(e) (a) Arbitrators 12.2(b)(i) (a) Breaching Party 11.2 Claim 12.2(b)(i) CNS Product 6.3(a)(iv) Commencement Date 2.6(b) Commercialization Report 4.2 Confidential Information 8.2 Confidentiality Agreement 5.4(a8.2 Effective Date Preamble First Audit 6.7 Huadong Preamble Huadong [***] Notice 2.5(i) Anti-Bribery Laws 3.22(c) Articles of Merger 2.4(a) Certificates 2.9(c)(i) Charter Amendment Effective Time 2.3 Closing 2.5 Closing Date 2.5 Company Preamble Company Charter Amendment Certificate 2.1 Company Disclosure Letter 1.4 Company Intellectual Property 3.17(b) Company Leased Real Property 3.15(b) Company Option 2.8(c)(i) Company Owned Real Property 3.15(a) Company PSU 2.10(c)(i) Company Recommendation 3.3(a) Company Recommendation Change 5.4(c)(i) Company RSU 2.10(a)(i) Company SEC Reports 3.8(d) Company Securities 3.7(b) Company Special Committee Recitals Company Stockholder Meeting 6.4(a) Converted PSU Award 2.10(c)(ii) Converted Restricted Share Award 2.10(b) Converted RSU Award 2.10(a)(ii) Copyrights 1.1(kkk) Covenant Exceptions 5.1(a) Data Privacy/Security Requirements 3.17(g) Effect 1.1(x) Effective Time 2.4(b) Electronic Delivery 9.13 Enforcement Expenses 8.3(d) Ex-Im Laws 3.22(c) Exchange Fund 2.9(b) Excluded Arrangements 6.10(a) FHWA 3.21(b) Financing 6.5(a) FMCSA 3.21(bHuadong Parties 10.2 Huadong Sole Inventions 7.2(a) Indemnified Party Proceeding 6.9(b10.3(a) Indemnified Persons 6.9(aIndemnifying Party 10.3(a) Labor Agreements 3.20(aInfringement Claim 7.4(a) Leased Real Property Leases 3.15(bINN 7.9 JDC 3.3 JIPWG 7.1 Joint Inventions 7.2(b) Joint IP Working Group 7.1 Joint Patent Rights 7.3(b) Late Payment Notice 6.11 Manufacturing Technology Transfer Period 2.6(b) Material Breach 11.2 Material Breach Notice 11.2 MRCT Development Plan 3.6(a) MRCT Initiation Breach 11.2 Non-Breaching Party 11.2 Non-publishing Party 8.3 Other API 1.14 Paragraph IV Claim 7.10(a) Product Marks 1.1(kkk7.9 Publishing Party 8.3 Region 1.70 Remedial Action 5.3(d) Maximum Premium 6.9(bRoyalty Term 6.5(b) Merger Recitals Merger Sub Preamble Merger Sub Stockholder Approval 6.16 Net Debt 5.2(h)(iSafety Agreement 5.3(a)(i) New Plans 6.9(aSecond Audit 6.7 Sole Inventions 7.2(a) Notice Period 5.4(d)(ii)(3Standard Redaction 12.7 Term 11.1 Terminated Region 11.2 Third Party Claims 10.1 Third Party Licenses 6.5(d) Old Plans 6.9(aUSANC 7.9 (a) Owned Company Shares 2.9(a)(ii) Parent Preamble Party or Parties Preamble Patents 1.1(kkk) Payment Agent 2.9(a) Per Share Price 2.9(a)(iii) Proxy Holder Recitals Proxy Statement 6.3(a) Required Permits 3.20(c) Restraint 7.1(b) Rollover Agreement Recitals Rollover Shares Recitals Statutory Charter Amendment Stockholder Approvals 3.4(a) Statutory Merger Stockholder Approval 3.4(a) Statutory Stockholder Approvals 3.4(a) Support Agreement Recitals Surviving Corporation Recitals Tail Policy 6.9(b) Termination Date 8.1(b) Trade Secrets 1.1(kkk) Transaction Matters 9.11(a) Uncertificated Shares 2.9(c)(ii) Union 3.20(a) Vested Company PSU 2.10(c)(i) Vested Company RSU 2.10(a)(ivTv Preamble 10.1 vTv Sole Inventions 7.2(a)